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ABSTRACT 
Cutaneous immunity coordinates necessary protection of the host against exogenous insults, yet its 
deregulation can have profound pathogenic consequences which can lead to development of disease.  
Type-I interferons are a class of pro-inflammatory cytokines with fundamental roles in innate and 
adaptive immune responses. In the skin, they not only mount responses against pathogens and tumours, 
but also sustain re-epithelialisation following injury, and provide tonic signals for maintaining 
homeostatic balance. Importantly, they are also involved in the pathogenesis of a number of organ-
specific and systemic auto-immune diseases such as systemic lupus, type-I diabetes, and thyroid disease, 
and in the skin they are important drivers of psoriasis and discoid lupus. Exactly how perturbations of 
type-I interferons lead to cutaneous disease is still a hotly debated subject of research. 
Production of type-I interferons, in particular IFNβ, is achieved by all nucleated cells, yet small relative 
numbers of professional producers exist in the circulation and lymphoid organs, which produce many fold 
higher amounts of these inflammatory cytokines. Plasmacytoid dendritic cells (pDCs), though generally 
dispensable for many immune responses, are implicated in several type-I interferon-driven auto-immune 
diseases. Psoriasis, a TH1/TH17 disease with an important role for Tumour Necrosis Factor (TNF), is just 
such a disease. Intriguingly, treatment of psoriasis (or other diseases) with a class of biologics called anti-
TNFs is effective in most patients, but can also result in the development of novel psoriasiform lesions in 
about 2-5% of all treated individuals. This side-effect of anti-TNFs, called paradoxical psoriasis, has many 
similarities to classical psoriasis yet we know little of its pathogenesis. We find that paradoxical psoriasis 
lesions are characterised by uniform overexpression of type-I interferons with concurrent pDC 
accumulation. Intriguingly, TNF directly regulates production of type-I interferons through maturation of 
pDCs in vitro, and in pDCs recruited to the site of inflammation in a novel mouse model recapitulating 
paradoxical psoriasis. The resulting inflammation is type-I interferon-driven yet, unlike classical psoriasis, 
independent of T-cells and adaptive immunity. 
Rosacea is a common cutaneous disorder affecting the facial convexities, characterised by recurrent 
flares of disease, with apparent localised microbial infestation and aberrant expression of cathelicidin 
antimicrobial peptides. We find that specifically during acute flare-ups, type-I interferons are uniformly 
and selectively overexpressed. In addition, stabilised lesions display TH1/TH17 signatures and upregulated 
interferon-response gene expression suggesting previous interferon-bursts. Using a pre-clinical mouse 
model of rosacea, we find that type-I interferons are produced by pDCs and that they are responsible for 
the TH17-related cytokine expression. Interestingly, killing of rosacea-associated bacteria by cathelicidin 
antimicrobial peptides is sufficient to drive this pathogenic signature. 
Taken together, our observations indicate that pDCs drive a type-I interferon-dependent innate skin 
inflammation in distinct cutaneous manifestations. These can be triggered by cytokine imbalances, such 
as for paradoxical psoriasis, or bacterial infestation and overexpression of antimicrobial peptides, such as 
for rosacea, and prime downstream pathogenic innate immune responses. These findings re-centre 
attention towards a pathogenic role for pDC-derived type-I interferon, and provide a rationale for 
targeting this particular axis whilst leaving intact interferon production by other cells and protective 
immune responses. 
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RÉSUMÉ 
L’immunité cutanée est responsable de coordonner la protection de l’hôte contre des dommages 
exogènes, néanmoins sa dérégulation peut avoir des conséquences pathogéniques qui peuvent 
engendrer le développent de maladies. 
Les interférons de type 1 sont une classe de cytokines pro-inflammatoires avec plusieurs rôles dans 
l’immunité. Dans la peau, non seulement ils génèrent des réponses immunitaires contre pathogènes 
envahissants et tumeurs, mais ils garantissent la réépithélialisation suite aux lésions, et fournissent des 
signaux toniques pour maintenir la balance homéostatique. Surtout, ils jouent un rôle dans la 
pathogénèse de maladies auto-immunes ciblées à des organes et systémiques telles que le lupus 
systémique, le diabète de type 1, et la maladie thyroïdienne. Dans la peau, ce sont des facteurs 
importants dans le développement du psoriasis et du lupus discoïde. Le mécanisme par lequel ces 
perturbations des interférons de type 1 mènent à des maladies cutanées reste un sujet d’intense 
recherche. 
Toutes les cellules nucléés sont capables de produire des interférons de type 1, en particulier l’IFNβ, 
néanmoins une petite population professionnelle de cellules productrices existe dans la circulation et les 
organes lymphatiques, et peux produire une quantité plus importante de ces cytokines inflammatoires. Les 
cellules dendritiques plasmacytoïdes (pDCs), tandis qu’elles soient en général dispensables dans la génération 
de plusieurs réponses immunitaires, sont impliquées dans de nombreuses maladies auto-immunes menées par 
les interférons de type 1. Le psoriasis, une maladie TH1/TH17 avec un rôle important de la cytokine pro-
inflammatoire Tumour Necrosis Factor (TNF), est justement une maladie de ce type. De façon intrigante, le 
traitement du psoriasis (et d’autres maladies) avec une classe de biologiques appelés les anti-TNFs résulte 
dans un traitement efficace dans la majorité des patients, mais aussi dans le développement de nouvelles 
lésions psoriasiformes dans 2-5% d’individus traités. Cet effet secondaire des anti-TNFs, appelé psoriasis 
paradoxal, a plusieurs similarités avec le psoriasis classique mais peu est connu sur sa pathogénèse. Nous 
trouvons que les lésions de psoriasis paradoxal sont caractérisées par la surexpression uniforme des 
interférons de type 1 avec concomitante accumulation de pDCs. Nous décrivons que le TNF régule la 
production d’interférons via la maturation des pDCs tout aussi bien in vitro que des pDCs recrutées au site 
d’inflammation psoriasiforme dans un modèle murin. L’inflammation qui en découle est dirigée par les 
interférons de type 1 mais, en contraste avec le psoriasis classique, est indépendant des lymphocytes T 
et du système immunitaire adaptatif. 
La rosacée est une maladie commune des convexités du visage, et caractérisée par des poussées 
récurrentes de la maladie. Nous découvrons que spécifiquement pendant des poussées aigües de la 
maladie, les interférons de type 1 sont surexprimés de façon sélective et uniforme. Les lésions 
stabilisées, tout comme les lésions de poussée aigüe, sont caractérisées par des signatures TH1/TH17 ainsi 
que de surexpression de gènes de réponse à l’interféron, suggérant des précédentes flambées d’interféron. En 
utilisant un modèle préclinique murin de rosacée, nous décrivons que les interférons de type 1 sont produits 
par les pDCs et qu’elles sont responsables pour l’expression associée aux cytoquines TH17. De façon intrigante, 
le tuage de bactéries associées à la rosacée par les peptides antimicrobiens cathelicidin est suffisant pour 
engendrer cette signature. 
Mis ensembles, nos observations indiquent que les pDCs mènent une inflammation dépendant des interférons 
de type 1 dans distinctes manifestations dans la peau. Celles-ci peuvent être déclenchées par des déséquilibres 
cytokiniques, comme pour le psoriasis paradoxal, ou l’infestation microbienne et la surexpression de peptides 
antimicrobiens, comme pour la rosacée, et initier des réponses immunitaires innées pathogéniques. Ces 
observations recentrent l’attention vers un rôle pathogénique de l’interféron de type 1 produit par la pDC, et 
justifient le ciblage de cet axe en particulier qui laisserait ainsi intacte la production d’interférons provenant 
d’autres cellules, et l’induction de réponses immunitaires protectrices. 
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1. INTRODUCTION
The immune system of the skin is a complex network of cells mounting important protection of 
the host against exogenous insults, but it can also be at the root of a great number of human 
disorders. The following introduction aims at providing a broad overview of the cutaneous 
immune system and the functions it serves, as well as the aberrant responses which can be 
detrimental to the host and lead to the development of diseases of the skin and often beyond. 
1.1. THE INNATE AND ADAPTIVE IMMUNE SYSTEM IN THE SKIN 
The central dogma of the immune system describes two principal components. An innate 
immunity arm, which provides immediate, first-line of defence, but lacking pathogen 
specificity.1 An adaptive immunity arm which in contrast to innate immunity, provides high 
specificity for antigens found in pathogens, maintains long-lived “memory”, but requires time 
to be primed, typically five to six days.1 Making up the very first-line of defence against foreign 
insult are barrier sites such as the skin, and they provide separation from exogenous 
compounds and microorganisms, but also active protection.2 
1.1.1. THE SKIN, MORE THAN JUST BARRIER 
Physical barriers such as epithelial linings of respiratory, gastrointestinal, and genitourinary 
tracts, and the skin provide a protective separation between the host and exogenous insults. 
The skin plays a fundamental role in keeping microorganisms, chemicals, toxins, irritants and 
radiation at bay, yet it is becoming increasingly clear that this is but one facet of the largest 
organ of the human body. 
The skin is composed of an outer layer called epidermis, an inner compartment called 
dermis, and the innermost layer called hypodermis. Each has a diverse set of cell types and 
responsibilities that make for unique environments with distinct functions for the host. The 
epidermis is composed of keratinocytes, a cell type whose main function is to work in unison 
with neighbouring keratinocytes for a timely and continuous differentiation. Basal 
keratinocytes proliferate giving rise to daughter cells which form a stratified layer several cells 
thick, and which undergo continuous differentiation, progressively losing their status as living 
cells, and becoming an outer shell that makes up the corneal layer.  During homeostasis, this 
process has well defined timeliness averaging 4 weeks form initial proliferation from the basal 
membrane, up to final cornification. Acceleration of this process results in desquamation, 
whereas a delay can result in delayed and/or impaired wound healing.  Other cell types making 
up the epidermis are melanocytes and Langerhans cells, which are both dendritic and 
phagocytic in nature, and the latter is a proficient antigen-presenting cell. 
The dermis is found beneath the epidermis and is composed of fibroblasts, which form 
the connective layers; vascular epithelial cells, forming blood vessels which irrigate the 
surrounding tissues; macrophages, which act as sentinels for maintaining homeostasis; and 
mast cells which act as sensors for mechanical and chemical stresses. The papillary dermis 
makes up the intrafollicular spaces, intertwining with the rete ridges (papillae), and contains a 
web of blood capillaries that reach the lower layers of the epidermis. The reticular dermis  is the 
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 most ample skin segment, and forms the lower layer of the dermis, and is formed of dense 
collagenous, reticular fibres that give it its flexible, elastic and sturdy characteristics.  
The hypodermis, or superficial fascia, is mostly composed of adipocytes which store fat; 
epithelial cells forming the lymphatic and vascular vessels; and muscle cells forming a flat sheet 
of muscle in certain anatomical locations. Immune cells reside within the hypodermis, such as 
mast cells, macrophages, and T-cells, and contribute to skin homeostasis. 
The skin is a large organ. Widely accepted surface area values, based on anecdotal 
calculations of the surface area of skin, are of ca. 2m2. New interest on the microbial 
environment of the skin3 has led to a novel appreciation of the true size of skin. By taking into 
account skin appendages, which average to about 3mm deep and with 0.5mm diameter, with 
over 5x106 follicles, it is now estimated that the skin composes at least 25m 2 of surface area,4 
well over the previous estimates. The microbial flora is also known to reside in large numbers 
within skin appendages, as these naturally funnel microorganisms, making it an important area 
for host-microorganism interactions. In fact, it is now well-recognised that because skin is one 
large reservoir of microorganisms such as bacteria, fungi, and v iruses, it forms an important 
interface between the host and microbial flora. Interestingly, it is now argued that bacteria 
penetrate actively into the deeper layers of skin, through use of proteases,5 and therefore 
continuous innate antibacterial activity is required to impede skin infections. 
The epidermis forms a barrier against exogenous compounds and microorganisms, 
through a thick corneal layer and active renewal of keratinocyte layers. Among important 
innate host defence mechanisms produced by keratinocytes, are the antimicrobial peptides. 
These, usually low molecular weight, bactericidal, fungicidal and viricidal compounds can be 
produced by keratinocytes throughout differentiation and form a concentration gradient 
keeping exogenous microorganisms away from the deeper epidermal layers, and the dermis. 
Human Beta Defensins (HBD)-1, -2 and -3 are cysteine-rich cationic antimicrobial peptides. 
HBD1 is found constitutively expressed in keratinocytes with potent antimicrobial activity 
against Gram-negative bacteria. HBD2 and HBD3 are induced in keratinocytes upon bacterial 
challenge, but also by pro-inflammatory cytokines such as Interleukin-1 (IL-1) and Tumour 
Necrosis Factor (TNF). Cathelicidin antimicrobial peptides (CAMPs) such as LL-37 are also 
produced upon bacterial triggers and pro-inflammatory cytokines, including during skin injury.6 
Human cathelicidin antimicrobial protein 18 (hCAP18) is the precursor protein, which requires 
proteolitic processing by proteases for activation, and in skin by the serine protease kallikrein 5 
(KLK5)7,8. Further proteolitic processing of LL-37 can yield shorter peptides such as RK-31 and 
KS-30, which display increased antimicrobial activity, and interestingly these have been 
identified in human sweat and in sweat glands, in close proximity to skin appendages. 
Furthermore, antimicrobial peptides such as LL-37 are also potent chemoattractants for 
neutrophils, which themselves also produce β-defensins and cathelicidins, and are proficient 
antibacterial cells,9 thus further reinforcing antimicrobial activity. 
Skin cells need to initiate recruitment of more specialised cell types, both for mounting 
immunological responses against microorganisms, but also for proper wound healing. 
Keratinocytes are found to be able to release active IL-1α, but also to be able to produce pro-
IL-1β, in response to epidermal injury. These inflammatory mediators are thought to act in a 
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paracrine manner to initiate inflammatory and repair processes. They can also directly produce 
chemokines such as CCL17, which binds to CCR4 expressed by T-cells and DCs; CCL27, which 
binds to CCR10 expressed by CD8 T-cells; and CCL20, which binds CCR6 expressed by T-cells and 
in particular TH17 cells. They can secrete IL-7, an important growth factor for lymphocytes, 
suggesting a possible role in the survival and maintenance of recruited T- and B-lymphocytes.  
Fundamentally, the skin provides a protective barrier against insults from the outside world, 
but is also responsible for a complex cross-talk with the environment, and of orchestrating 
innate immunity for more specialised and rapid responses. 
1.1.2. INNATE IMMUNITY AGAINST EXOGENOUS INSULTS 
The innate immune system is at the first interface between host and invading pathogen upon 
barrier disruption. In the skin, this is initiated at keratinocytes which signal, repair-focused, 
inflammatory cascades which rely on rapid, innate immune responses (Figure 1). 
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Figure 1: Schematic representation of innate and adaptive immunity in skin. Upon skin 
barrier disruption, microbial patterns which provide danger signals trigger immediate mast 
cell degranulation and secretion of pro-inflammatory cytokines. Antimicrobial peptides are 
produced by resident cells and recruited neutrophils to control invading microorganisms 
and NETosis slows the microbial spread. Type-I interferons produced by recruited pDCs leads 
to induction of chemokines and priming of inflammatory cells. Recruited monocytes 
differentiate in either macrophages which resolve inflammation by engulfing dying and 
dead cells, or into Mo-DCs which capture antigens and prime adaptive immune responses in 
skin-draining lymph nodes.  Antigen-experienced T-cells can be polarised into TH1, TH2, or 
TH17 cells which are recruited to the site of inflammation for targeted immune responses. 
Macrophages promote a return to homeostasis and TRM cells populate the site of injury for 
future reactivation. IL: interleukin; AMP: antimicrobial peptide; pDC: plasmacytoid dendritic 
cell; IFN: interferon; MoDC: monocyte-derived dendritic cell; TH: helper T-cell; TNF: 
tumour necrosis factor; TRM: resident-memory T-cell. Schematic drawings modified and re-
used with permission from Nature Publishing Group.
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 Arguably, skin repair cascades are centred around the need to keep barrier breaches 
under control so that exogenous microorganisms remain on the outside. Mammals have 
evolved 13 known Toll-like receptors (TLRs) to sense a myriad of ligands found on exogenous 
organisms. Danger signals such as cell wall components of bacteria including Lipoteichoic acid 
(LTA; gram-positive bacteria) or Lipopolysaccharide (LPS; gram-negative bacteria), or 
unmethylated nucleic acids (NA) such as those contained in viruses and bacteria (including CpG 
motifs) to name a few, are recognised by TLRs and other sensors expressed on skin resident 
cell-types including keratinocytes and macrophages. TLR engagement (LTA through TLR2; LPS 
through TLR4; NA through TLR3, TLR7, TLR8, TLR9, STING-converging sensors,10 etc..) leads to 
production of pro-inflammatory mediators such as IL-1, TNF, chemokines including IL-8 
(CXCL1/15 in mouse), and antimicrobial peptides, which in unison work to prime and recruit 
neutrophils.  
Among first-responders are neutrophils, which are found in abundant numbers in the 
circulation, patrolling the periphery. Factors produced during danger sensing are released 
within the circulation, priming neutrophils, and chemotactic factors control neutrophil 
transmigration through endothelial walls. Primed neutrophils recognise and phagocytose 
microorganisms, which are then killed through reactive oxygen species and antimicrobial 
peptides from the fusion of granules with the phagosome. Of notable mention, neutrophils can 
also employ another method for rapidly hampering progression of bacteria within  the skin 
compartments, called neutrophil extracellular trap (NET).11,12 NETosis (the act of making NETs) 
culminates in the extrusion of nuclear and/or mitochondrial DNA through rapid 
decondensation of chromatin, and resulting in a landslide release of granule components. All in 
all, neutrophils are rapid responders at the site of barrier breaches and can both phagocytose 
target organisms, as well as create temporary barriers to slow down invasion from 
microorganisms. Correspondingly, neutropenic patients, either from inherited disorders or 
medically induced neutropenia (e.g. chemotherapy), have increased risk of infections from 
bacteria and fungi. Depending on the bacterial burden, this process can be lengthier thus 
leading to longer lasting recruitment of neutrophils, and the apparition of scars. 13 Once 
microbial control is achieved, dying neutrophils are cleared by macrophages. Historically, 
neutrophils have been considered as end-stage cells with limited metabolic and transcriptional 
capacity for de novo production of factors. This aspect of neutrophil biology has been revisited 
and compelling evidence has now accumulated as to the ability of neutrophils to produce 
cytokines and chemokines.14,15 There is increasing evidence that neutrophils are able to 
produce key chemokines for amplifying their own recruitment, but also to promote monocyte, 
DC, NK and T-cell recruitment. In recent, as yet unpublished observations, it is found that 
neutrophils are essential in the production of CXCL10 during skin inflammation, a chemokine 
known to bind CXCR3, and found to recruit plasmacytoid dendritic cells (pDCs) into inflamed 
skin.16,17 
Isaacs and Lindenmann (1957) first discovered that “viral interference”, the act of one 
virus interfering with the infectious capacity of another, was due to a soluble factor released by 
host cells, and not a component of the virus as previously hypothesised. 18 Years later, it was 
determined that one small proportion of cells in peripheral blood were the main producers of 
type-I interferon19,20 and the hunt for the principal interferon producing cell type led to the 
identification of the Natural IFN-producing cell (IPC),21,22 later called plasmacytoid dendritic 
14
cell. pDCs are a rare cell type, about 0.3% among leukocytes in peripheral blood, expressing 
CD123+ BDCA2+ BDCA4+ CD4+ CD11c- lineage- in humans, and PDCA1+ B220+ CD11cint Siglec-H+ in 
mice.23,24 They are virtually absent from human skin during homeostasis, but play an important, 
though seldom indispensable, role in protection from infection. pDCs are found to produce 10- 
to 100-fold more type-I interferon than other cell types, but also cytokines such as TNF and IL-
6, and chemokines such as CXCL10, IL-8 and CCL5. Specific bacterial and viral nucleic acid 
ligands which reach the endosomal TLRs -7 and -9, converge signalling onto MyD88, and trigger 
activation of IRF-7, inducing strong IFNα gene expression, and IRF-3, inducing mostly IFNβ 
(Figure 2). Importantly, pDCs express high constitutive levels of TLR7/925 as well as of IRF-7,26 
which makes them potent producers of type-I interferon. CpG-rich regions of DNA viral 
genomes, such as from herpes simplex virus (HSV) 1/2 and cytomegalovirus, activate TLR9;27–29 
whereas  single-stranded RNA (ssRNA) virus motifs, such as from influenza, arenavirus, or 
vesiculostomatitis virus activate TLR7.30–33 Type-I interferons can inhibit viral replication by 
induction of antiviral molecules,34,35 apoptosis of infected cells,36,37 and mounting antiviral 
innate and adaptive immune responses. They are activators of antiviral cytotoxicity  from 
natural killer (NK) cells and CD8 T-cells,38,39 and B-cell humoural responses.40–44 Yet, pDCs are 
not crucially required in mounting immune responses, as other cell types can compensate the 
production of type-I interferon leading to, albeit delayed, viral clearance.45 pDCs seem to play a 
role in skin injury, however, during early inflammatory responses,6,46 though the exact 
mechanism is unknown. 
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Figure 2: Microbial pattern recog-
nition by plasmacytoid dendritic 
cells. Endocytosed CpG-rich motifs 
from extruded bacterial DNA or viral 
DNA, or single-stranded RNA trigger 
endosmal TLR9 or TLR7 respectively. 
These signals converge onto adaptor 
molecule MyD88, which activates 
and causes translocation of IRF7 into 
the nucleus. IRF7 binds to the 
promoter sequences driving 
transcription of IFN alpha and 
beta genes resulting in 
production of type-I interferons. 
pDC: plasmacytoid dendritic cell; 
ssRNA: single-stranded RNA; vDNA: 
viral DNA; TLR: Toll-like receptor; 
IFN: interferon. Schematic 
drawings modified and re-used 
with permission from Nature 
Publishing Group.
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 Monocytes are large mononuclear cells with multiple known subpopulations. In mice 
there are two described subsets in mice, one Ly6Chi CCR2+, and one Ly6Clow CCR2- CX3CR1+,47 
whereas in humans three have been described, one CD14hi CD16- classical monocyte, one 
CD14+ CD16hi non-classical monocyte, and one CD14hi CD16+ intermediate subsets. Classical 
monocytes express preferentially CCR1 and CCR2, and are therefore recruited by CCL2 and 5. 
Non-classical monocytes express CX3C chemokine receptor 1 (CX3CR1), which is bound by 
fractalkine (CX3CL1). Intermediate monocytes express a combination of CCR1, 2, 5, 7, 9 and 
CX3CR1.48 Once recruited to the site of inflammation, monocytes differentiate into 
macrophages and dendritic cells, depending on the requirements of the inflammatory 
environment. It is known that macrophage colony stimulating factor (M-CSF) and IL-6 produced 
by fibroblasts during steady-state leads to preferential macrophage differentiation, which 
results in engulfment of dead and dying cells, and a return to homeostasis. However, in the 
inflamed tissue, pro-inflammatory cytokine TNF promotes differentiation into cells with 
dendritic morphology, expressing HLA-DRhi CD83+.49 Type-I interferons, in combination with 
granulocyte M-CSF (GM-CSF), can also lead to generation of CD25, CD40, CD80, CD86 co-
stimulatory molecule-bearing Mo-DCs which express CCR5 and 7, and can produce T-cell 
polarising cytokines such as IL-1β, IL-6, IL-23, TNF and IL-12 among others.50 Monocytes are 
recruited through chemokines CCL2, CCL5, CCL7, CCL12 and CX3CL1, the four former of which 
are type-I interferon inducible.51,52  
More recently, a novel cell type has been described called innate lymphoid cells. 53–57 
These cells have been subcategorised into group 1 (ILC1), group 2 (ILC2), and group 3 (ILC3) 
cells based on their cytokine and functional characteristics. Though lineage classification 
contradicts this, often oversimplified scheme,58 they are the innate immune’s system parallel of 
the adaptive’s immune system TH1, TH2, and TH17 T-cells. Although difficult to study due to 
their relatively low numbers, and them being negative for common lineage markers, they are 
found mostly in barrier surfaces including lung, gut and skin. Much like their adaptive 
counterparts and Natural Killer (NK) cells, ILC1s express transcription factors T-bet and 
Eomes,59 and depend on IL-12 for their function and production of IFNγ and TNF. ILC2 mediate 
type-2 inflammation for expulsion of helminths, express RORα and GATA-3, and produce IL-4, 
IL-5, and IL-13 in response to IL-17E and IL-33. ILC3s, which include lymphoid tissue inducer 
(LTi) cells, express RORγt and/or the aryl hydrocarbon receptor (AhR), and produce IL -17 and IL-
22 following stimulation.60 Typically, healthy human skin maintains mostly ILC2 populations61,62 
and are thought to switch to ILC3 or ILC1 depending on the environmental needs. 63 
In summary, skin barrier disruption leads to microorganism entry into  normally protected 
areas. This triggers sensing of danger signals by specialised receptors which leads to rapid 
secretion of pro-inflammatory factors by specific skin resident cells such as mast cells and 
keratinocytes. Paracrine signalling promotes production of antimicrobial peptides and rapid 
recruitment of neutrophils which provide specialised microbicidal activity and a temporary 
barrier function to slow microorganism spread. Neutrophils can also produce chemokines 
promoting recruitment of more specialised cell types such as pDCs, depending on the 
inflammatory needs. Finally, monocytes are recruited, in part in a type-I interferon-dependent 
manner, and differentiate according to the micro-environment resulting in a return to 
homeostasis. If the innate inflammatory response is not sufficient for controlling the invad ing 
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 pathogens, neutrophil infiltration is sustained, and more specialised cell types are called into 
action eliciting adaptive immune responses.  
1.1.3. SKIN ADAPTIVE IMMUNITY IN RESPONSE TO FOREIGN INVASION  
Adaptive immunity, though less flexible than innate immunity, provides targeted responses to 
invading pathogens when innate immunity is not sufficient, as well as swifter and more ordered 
responses and upon re-challenge. 
 A lot is known regarding T-cell responses in skin, thanks to extensive work performed 
using mouse models with primarily viral,64–68 and to a lesser extent parasitic,69 and bacterial,70 
infections. The current model supports that, upon first encounter with pathogens in the skin, 
danger signals recognised by keratinocytes and resident immune cells lead to activation of DCs.  
Local DCs migrate to draining lymph nodes where they present processed antigens from the 
pathogen to naïve T-cells. Through upregulation of co-stimulatory molecules CD80, CD83 and 
CD86, as well as HLA, they are able to activate T-cells by interacting with the T-cell receptor 
(TCR). Though not fully elucidated, type-I interferons and TNF play a role in maintenance of T-
cells within secondary lymphoid organs, thus increasing the chance of locating their cognate 
antigen.71 Thereafter, antigen-activated T-cells then express skin-homing molecules such as 
CCR6, CCR4, CCR10, and/or α1β1 integrin, cutaneous lymphocyte antigen (CLA) and other 
chemoattractant receptors which guide them to inflamed skin for entry into tissues. Depending 
on the polarising environment during T-cell receptor (TCR) engagement, as well as the local 
cytokine environment at the site of inflammation, T-cells can be driven towards T-helper 1 
(TH1), TH2, and/or TH17 responses which are appropriate for the encountered pathogen. 
Exposure to IL-12 induces predominant TH1 polarisation, with strong IFNγ responses which are 
particularly effective in response to viral and intracellular bacteria challenge. Cytokines such as 
thymic stromal lymphopoietin (TSLP), IL-25, and IL-33 lead to generation of TH2 cells which in 
turn produce cytokines such as IL-4, IL-5, and IL-13 which are effective against parasites. IL-23, 
IL-6, and IL-1β promote development of TH17 cells, whose signature cytokines include IL-17A, 
IL-17F, and the IL-10 family of cytokines IL-22 and IL-26. These are particularly suited for 
responses to extracellular bacteria. T-helper responses can then assist effector CD8 responses 
in the killing of pathogens, or of pathogen-infected cells. Type-I interferons contribute to T-cell 
mediated immunity at the interface between innate and adaptive immunity, both by priming 
and promoting DC antigen presentation, enhancing CD4 and CD8 T-cell responses,72,73 and 
contributing to their recruitment to sites of inflammation.74 Importantly, antigen presentation 
in the absence of danger signals results in the formation of immunosuppressive regulatory T -
cells (Treg) which produce IL-10 and may limit clonal expansion of antigen-specific T-cells during 
secondary immune reactions in the periphery. A similar mechanism is thought to take place in 
low immunogenic tumours of the skin, which mask pro-inflammatory cytokines, danger signals, 
and metabolic processes, thus priming dysfunctional, hyporesponsive, or immuno-regulatory T-
cell responses.75 
 B-cells are producers of antibodies, but can also produce cytokines. Though a lot is 
known about the role of adaptive B-cell immunity against systemic viral infections,76 less is 
known about the role of humoural adaptive immunity in skin. The most comprehensive 
evidence for a role B-cells in skin immunity comes from the skin manifestations in patients with 
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 clinical hypogammaglobulinemia and, more rarely, patients with hypogammaglobulinemia 
following therapies, such as with rituximab (anti-CD20).77,78 Most commonly, B-cell deficiencies 
resulting in poor antibody production lead to loss of control of commensal or dormant 
infections of the skin,79 including by bacteria Flexispira, Helicobacter, and Campulobacter,80–82 
and viruses such as herpes zoster.83 Like pDCs, B-cells express TLR-7 and TLR-9 making them 
direct targets of exogenous nucleic acids from microorganisms, especially viruses. Additionally, 
they also express TLR-4, allowing responses against bacterial patterns. TLRs -7 and -9 converge 
on MyD88, whereas TLR-4 signals through both MyD88 and TIR domain-containing adaptor-
inducing interferon-β (TRIF). Antigen recognition through the B-cell receptor (BCR) coupled 
with additional signals from helper T-cells, leads to activation of B-cells. It is well-described 
that B-cells rely on T-cell help for proper immunoglobulin production, particularly T follicular 
helper (TFH) cells. Activated T-cells can stimulate B-cells in a number of ways. They can 
stimulate contact-dependent mechanisms through CD40L-CD40 interactions,84,85 and inducible 
T-cell costimulator (ICOS)-ICOSL interactions86–88 which are essential for B-cell survival and 
proliferation. They stimulate immunoglobulin (Ig) class-switching, cell survival and plasma cell 
differentiation via soluble factors such as IL-4, IL-21, B-cell activating factor (BAFF), IL-17, and 
TGFβ89 among others, and chemoattraction via production of CXCL13 and binding to B-cell 
CXCR5 for recruitment to germinal centres.90 Other factors are important in antibody 
production, including type-I interferons and IL-6 which are produced by pDCs and lead to 
proliferation and more potent antibody production.44,91,92 Skin associated B-cell responses are 
thought to be achieved by CLA expression which guides them to cutaneous sites , though less is 
known about subsequent steps of B-cell homing. CXCR3 and CCR6 are highly expressed on B-
cell subsets, and its ligands are strongly expressed in skin upon inflammation. Whether they 
play a role in B-cell migration to the skin is unclear. 
 Both T-cell93,94 and B-cell76 mediated adaptive immunity depends on the generation of 
long-lived, central memory and sometimes tissue-resident, cells. Importantly, they are able to 
rapidly proliferate in response to secondary challenge. After resolution of an infection at a 
barrier tissue, circulating memory T-cells (also called central memory T-cells [TCM]) and resident 
memory T-cells (TRM) are generated. TCM have the ability to travel between lymphoid organs, 
circulation and tissues, whereas TRM retain tissue homing molecule expression leaving them 
anchored to tissues. Skin TRM also have the remarkable ability to colonize the rest of the skin 
surface. Effector memory T-cells can be heterogeneous in their polarisation, and produce all 
the prototypic cytokines associated with TH1, TH2 and TH17 cells. Memory B-cells are found 
adjacent to contracted germinal centres in lymph nodes and spleen and close to effector T FH 
cells, but also in the circulation. Because plasma cells are more stringently selected, memory B-
cells constitute the main pool for reactivation of humoural responses.  Little is known about 
tissue-resident B-cells. As opposed to T-cells, B-cells are found in very low numbers in 
homeostatic skin, yet display clonally restricted patterns, alluding to the possibility of these 
being memory B-cells resident within skin.95 
The adaptive immune system is engaged when innate immunity is insufficient for control of 
pathogens, and results in the formation of long-term memory for rapid and powerful responses 
upon re-challenge. Though little is known about skin associated B-cells, TRM cells are found in 
great numbers in human skin, patrolling the barrier tissue for antigens which may reactivate 
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 them. Tight regulation of TRM re-activation is important as inappropriate triggering of these 
cells can have pathogenic consequences. 
1.2. PATHOGENESIS AND TREATMENT OF PSORIASIS 
Inflammation in the skin is a finely choreographed set of immunological events that strive to 
maintain homeostatic balance. Yet, unbalanced responses can lead to a pathological outcome 
in predisposed individuals. Psoriasis as a disease, is just as perfect an example of an 
environmental trigger acting on a background of genetic susceptibility.  
Psoriasis is a chronic autoinflammatory disease of the skin and joints that has wide -
reaching systemic involvement. It is estimated to affect 2–3% of individuals worldwide, and can 
manifest as a broad spectrum of phenotypes including plaque-type, guttate, inverse, pustular, 
palmoplantar, and erythrodermic psoriases, which can sometimes occur, in combination, 
simultaneously in the same individual.96 Symptoms are shared between subtypes, and can 
include scaling and redness, itching and burning sensations, and soreness. Psoriasis follows a 
bimodal distribution with incidence peaking at [15-30] and [50-60] years of age. Overall, there 
is a cyclic evolution to the disease, with flaring for a variable period of time that can be up to 
months-long, followed by a phase of relative quiescence or even remission. It is well 
established that both the innate and adaptive immune systems play fundamental roles in 
disease, and complex interactions between keratinocytes, dendritic cells and T-cells lead to the 
pathogenesis of psoriasis. Importantly, psoriasis has one of the strongest genetic associations, 
with polygenic contributions. 
1.2.1. THE ROLE OF T-CELLS AND TH17/22 CYTOKINES IN DRIVING DISEASE 
T-cells are known to be key effectors in the pathogenesis of psoriasis. The first anecdotal 
evidence indicating T-cell involvement comes from unexpected observations that treatment 
with cyclosporine in patients under organ transplantation, which co-incidentally had active 
psoriasis, led to amelioration of disease. It is now well established that cyclosporine, a 
generalised immunomodulator of T-cells, is an effective treatment for psoriasis97–99. Over time, 
evidence stemming from genetic associations, pre-clinical studies, and successful therapy has 
accumulated, thus defining an instrumental role of T-cells in mediating disease. 
1.2.1.1. EVIDENCE FOR RECOGNITION OF SKIN-ASSOCIATED T-CELL ANTIGENS 
Genetically, psoriasis is mostly dominated by variations spanning the psoriasis susceptibility 
locus 1 (PSORS1) of the human leukocyte antigen-C (HLA-C) accounting for over 40% of 
detectable heritability100,101. This suggests a likely class-I to T-cell Receptor (TCR) interaction as 
a potential culprit to the disease with potential CD8 T-cell involvement. Furthermore, almost 
65% of patients with psoriasis are HLA-Cw*0602 positive, with younger age of onset and more 
severe clinical presentation than those that are negative.102  
 Histologically, psoriasis is characterised by acanthosis, which is a thickening of the 
epidermis due to hyperproliferation of keratinocytes; parakeratosis, which is a retention and 
accumulation of nuclei in the stratum corneum due to incomplete cornification and premature 
keratinocyte maturation; and increased vascularisation with dermal and epidermal immune cell 
infiltrates. The parakeratosis, acanthosis and increased vascularisation are the histological 
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 hallmarks that associate with typical psoriasis lesion signs of silvery, well -demarcated and 
raised, erythematous plaques. Importantly, CD4 T-cells are found infiltrating the upper dermis 
accompanied by dendritic cells, whereas CD8 T-cells mostly reside within the epidermis 
alongside keratinocytes. This spatial proximity of T-cells to the main affected cell types, 
including keratinocytes and vascular endothelial cells, supports a role for T -cells in the 
appearance of the psoriatic phenotype. In fact, T-cells are required for the development of 
psoriatic lesions and are already present in the skin,103 suggesting that these may be resident-
memory T-cells. Furthermore, expression of select integrins allows for CD8 T-cell entry within 
the epidermis and are required for full-blown development of psoriatic lesions.104 Moreover, T-
cells found in psoriasis lesions are largely monoclonal for CD8 and oligoclonal for CD4  
cells,105,106 suggesting that following recruitment, these cells expand in situ, potentially in 
response to a specific antigen. 
 Antigens proposed to elicit T-cell responses in psoriasis are argued to be self-antigens 
given the perpetuity and relapse of the disease. One theory suggests that immune responses 
against bacteria, such as streptococci, go awry and due to significant overlap between bacterial 
proteins and self-proteins there is an inappropriate response against self. This hypothesis of 
molecular mimicry is supported by several lines of evidence. One, streptococcal throat 
infections are known to re-activate or exacerbate ongoing psoriasis, guttate psoriasis in 
particular,107 suggesting the possibility of cross-reactive T-cells. Two, streptococcal M protein 
shares considerable structural homology with type-I keratins such as K17. Three, T-cells 
respond to M protein among other cell wall membrane components,108 as well as K17 and 
shared peptide sequences, including sequences predicted for HLA-Cw6 binding.109 These results 
remain controversial as others have failed to reproduce reactivity to M proteins, and rather 
find that other cell wall components are responsible for the observed result. 110,111 More recent 
reports identify auto-reactivity to different keratinocyte-associated proteins ezrin, maspin, 
hsp27, PRDX2, and K6,112 thus further lengthening the list of proteins liable to self-reactivity via 
molecular mimicry. Other antigens have also been proposed, in different cell types, including 
melanocyte-associated protein ADAMTSL5,113 and the antimicrobial peptide LL-37.114 The exact 
mechanism involved in the generation of T-cells that are not negatively selected for displaying 
intolerance to self, remain to be elucidated.  
Much work is needed to understand why only certain individuals develop auto-reactivity to 
self-antigens during what are likely to be canonical immunological responses to environmental 
cues. Other outstanding questions include why this auto-reactivity remains localised to specific 
areas, and what triggers dictate resolution and re-occurrence of psoriatic lesions. 
1.2.1.2. TNF GOVERNS THE INFLAMMATORY MILIEU IN PSORIASIS 
Tumour Necrosis Factor (TNF) is a pro-inflammatory cytokine with established roles in 
homeostatic functions as well as pathology. In the context of skin inflammation, it is well 
established that TNF plays a non-redundant role in psoriasis (Figure 3). 
In established chronic plaque psoriasis there are multiple sources of TNF, and the vast 
majority of cells can produce it. In the skin, at the site of inflammation, keratinocytes,115 
dendritic cells,116,117 macrophages,118 T-cells,119 and adipocytes120 are thought to be major 
contributors of TNF production, but by no means the only contributors. Keratinocytes, 
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especially basal keratinocytes, stain the most positive for TNF in chronic disease, like ly due to 
persistent priming from the pro-inflammatory environment. Dendritic cells are a well-known 
source of TNF during immune responses, and in psoriasis a subpopulation of DC-LAMP 
expressing, non-Langerhans, non-monocytic, Tip-DC (TNF and inducible nitric oxide synthase 
producing)-resembling dendritic cells provide continuous TNF production. Macrophages are 
widely regarded as bona fide TNF producers upon toll-like receptor ligation, and in psoriasis 
they contribute to clinically relevant amounts of TNF.118 T-cells have also been found to be 
important producers of TNF, in particular cytotoxic T-cells infiltrating the epidermis.119 
Adipocytes produce TNF, and increasing evidence suggests that obesity, a frequent co-
morbidity of psoriasis, influences severity of disease121 and this could be through contribution 
to TNF production. Likewise, the TNF receptors TNFR1 and TNFR2 are widely expressed across 
cell types, including both haematopoietic and stromal cells, thus making responses to TNF 
pleiotropic.  
Blockade of TNF is used as therapy for several inflammatory diseases of joints, bowel, 
and skin, as well as for the off-label treatment of more disparate, TNF-mediated, disorders. It 
has now become a gold-standard treatment for chronic plaque psoriasis. Treatment results in 
progressive regression of psoriasis lesions though time to response varies between patients 
and depending on starting psoriasis area and severity index (PASI). Histological amelioration 
precedes clinical response, with the former displaying visible differences as early as week 2, 
and the latter may take a mean time of about 12 weeks. In order to elucidate how TNF 
mediates cutaneous inflammation, histological and gene expression studies have been 
undertaken of regressing lesions over time.122–124 Among the first signs of amelioration, is the 
apparent diminution of the number of infiltrating dermal and epidermal T-cells, already by 
week 2 of treatment. This coincides with a reduction of proliferating Ki67 posi tive basal 
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Figure 3: Chronic plaque-type psoriasis is mediated 
by T-cells. Following TH17 polarisation, T-cells are 
dendritic cells, which maintain TH17 polarising environ-
ment for T-cells. Expression of α1β1 integrin allows for TRM? T-cell  entry within the epidermis where they produce
α1β1
IL-17, IL-22 and IFNγ. Pathogenic cytokines expressed at 
lesion sites cause epidermal hyperproliferation with loss 
of granular layer and parakeratosis, immune cell recruit-
T-cell
ment and in particular neutrophils leading to microab-
Epidermal scess formation, and expression of antimicrobial pep-
hyperproliferation tides which aggravate overall inammation. Biologic 
IL-23 CHRONIC targeting of IL-17, IL-23 or TNF leads to resolution of
psoriasis. Even following successful treatment of psoria-
sis, specic T- cell associated genes are found expressed at sites of resolved lesions, raising the possi-
bility that TRM are present and responsible for re-appearance of psoriatic lesions. TNF: tumour necro-
sis factor, TRM : resident-memory T-cell. Schematic drawings modied and re-used with permission 
from Nature Publishing Group.
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 keratinocytes. Select chemokines such as CCL20 involved in TH17 recruitment are drastically 
reduced by the first week of treatment. Concurrently, IL-17 levels are drastically reduced, 
whereas IFNγ and IL-22 drag behind and only return to normal by week 12. By week 4, DC 
numbers also start to diminish, and their maturation markers CD83, CD86, CD40, and activation 
markers HLA-DR and CD11c consistently drop. Interestingly, these follow similar kinetics as the 
reduction of IL-23 and IL-12 which start to return to basal levels by week 4. By week 12, 
epidermal hyperplasia is resolved, and concurrently keratinocyte differentiation returns to 
normal. All in all, TNF seems to control chemotaxis of TH17 cells, as well as activation of DCs 
which produce IL-23 and other cytokines involved in maintaining IL-17 production from T-cells. 
As T-cells start to exfiltrate, keratinocyte hyperproliferation comes to halt, followed by 
reduction of DC numbers. Finally, other pathogenic markers return to baseline levels as lesi ons 
are visibly resolved. These lines of evidence suggest that TNF controls IL -17 production in vivo. 
In summary, most cell types produce TNF in the inflammatory milieu of psoriasis lesions. 
Similarly, many others express the TNF receptor, suggesting that once established, disease can 
become self-driven by unrelenting TNF signalling, and proper regulation of TNF production is 
essential for a timely return to homeostasis. TNF has long been established to be a viable 
target for the treatment of several inflammatory and autoimmune diseases, including psoriasis. 
Currently, five anti-TNF agents exist, and have been both scientific and commercial successes, 
allowing treatment of millions of patients with TNF-mediated diseases. Yet, as mechanistic 
knowledge of the pathogenic pathways continues to expand, new targets are being unravelled 
and more success stories described. 
1.2.1.3. PSORIASIS IS MEDIATED BY T-CELL DERIVED TH17 CYTOKINES 
The role of T-cells and TNF is well established in the pathogenesis and maintenance of 
psoriasis, with abundant evidence from clinical observations, as well as proof-of-concept pre-
clinical studies. Yet, TNF is but one cytokine, and treatment efficacy is never of full -penetrance. 
TNF is a pervasive target in inflammation, but it is thought to be a chronic inflammation 
“umbrella” upstream signal. As such, downstream signals more specific to pathology must 
exist. 
Psoriasis has long been thought of as a type-1 (TH1) disease, due to the important levels 
of IFNγ found in lesions. TH1 differentiation, as discussed in more detail in earlier sections, does 
not critically depend on TNF in vitro. The addition of TNF does however further reinforce TH1 
polarisation, and stimulate increased production of IFNγ. Though IFNγ can play a fundamental 
role in skin inflammation,125 it has proven to be a less-than-optimal therapeutic target for the 
treatment of chronic plaque-type psoriasis in phase II dose-escalation trials, especially when 
compared to the gold-standard anti-TNFs. It is still unclear as to exactly why, despite such high 
levels of IFNγ, there is no fundamental role for the cytokine in the disease. One prevailing 
hypothesis suggests that IFNγ may play a role during the early pathogenesis of psoriasis, and 
that the high levels detected throughout chronicity are due to high numbers of inf iltrating T-
cells which will strongly produce the cytokine irrespectively of their polarising environment.  
More recently, focus has been shifted to TH17-related cytokines. Initially thought to 
specifically target IL-12, and thus inhibit TH1 polarisation, Ustekinumab is now an effective 
treatment for psoriasis.126,127 The antibody targets the shared p40 subunit of both IL-12 and IL-
22
 23, effectively blocking downstream signalling of both cytokines.  This serendipitous finding led 
to further work which pinpointed IL-17 and TH17 polarisation as a key inflammatory component 
of chronic psoriasis. Targeting IL-17 has recently become a major success as, within 5 years of 
phase trials, drugs targeting it have demonstrated tolerability and high efficacy, including for 
severe psoriasis with >75 PASI.128 Interestingly, another TH17 cytokine – IL-22 – with similar 
function on epithelial cells, and with promising pre-clinical data, has never passed a phase I 
trial (NCT00563524). It is not clear exactly why targeting IL-22 does not provide clinical efficacy, 
despite clear dependency for many murine models. Though more work is needed to elucidate 
this, it may be that IL-22 is regulated differently to IL-17, thus potentially allowing for 
compensation through other pathogenic pathways. In light of the discovery of IL -23 as an 
upstream cytokine of IL-17 and TH17-related cytokines, effort has been put into generating IL-
23–specific biologics which are now in phase trials and show greater efficacy as compared to 
anti-IL12/23.129,130  
Whereas TNF is not required for the in vitro differentiation of T-cells into TH17, several lines of 
evidence have pinpointed that TNF affects IL-17 signalling. For one, TNF has been 
demonstrated to work in synergy with IL-17 leading to more potent inflammatory 
outcomes.131,132 This has been found to be by both initiating transcription of gene transcripts 
stabilised by IL-17,133 but also through upregulation of IL-17R on keratinocytes.134 Additionally, 
in clinical responders to anti-TNF therapy, IL-17 expression in the skin is found to be dependent 
on TNF.124 This, coupled to compelling evidence from the successful IL-17 and IL-23 trials, really 
highlights the importance of TH17-mediated pathology in psoriasis. 
1.2.1.4. MOUNTING A TH17 RESPONSE IN THE SKIN 
Several types of T helper responses exist, and they are thought to play important roles in host 
defence at barrier sites. Whereas TH1 cells are important in antiviral
135 and intracellular 
bacterial defence,136 TH17 are particularly proficient in fighting extracellular bacterial and 
fungal pathogens.137 Exactly why there is a TH17 signature in the skin lesions of psoriasis, and 
whether there is a physiological reason for it, remains a subject of controversy. 
 The CD4 T-cell lineage 17 – termed TH17 – was discovered over 10 years ago,
138–140 and 
defines a third subset of T-cells based on cytokine requirement, pathway engagement, and 
transcription factor expression. Its main distinguishing factor is the production of IL-17, which 
has strong association with inflammatory diseases of the joints (rheumatoid arthrit is, 
ankylosing spondylitis, psoriatic arthritis) and an established role in psoriasis. With six 
members discovered to date (A through F), T-cells are the principal producers of IL-17A and IL-
17F. Differentiation requires principally cytokine stimulation from IL-23, and can be suppressed 
by type-I and type-II interferons, as well as IL-4,140 suggesting that TH17 cells live in competition 
with TH1 and TH2 cells. Additional cytokines have been identified to enhance TH17 function, 
including IL-6 and IL-1β,141,142 which are abundant and indiscriminately expressed at 
inflammation sites. Importantly, polarisation of naïve CD4 T-cells depends on IL-23 and 
inflammatory dendritic cells143 which provide co-stimulatory signals and TCR engagement, as 
well as IL-23 itself. Activating signals for DCs to induce TH17 polarisation include microbial 
stimuli (TLR2/1-ligands) as well as contact co-stimulation (CD40L).143 As TH17 are required for 
immunological responses to invading pathogens such as Candida albicans and Staphylococcus 
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 aureus,144 it is likely that more clues will be unveiled regarding the processes and stimuli for 
TH17 polarisation, and the events that lead to pathological TH17 polarisation. Transforming 
Growth Factor β (TGFβ) is also described to play an important role in differentiation of mouse 
naïve CD4s,142,145 though this remains controversial as in humans it inhibits differentiation in 
vitro,141,142,146 yet “natural” polarisation using inflammatory DCs required TGFβ .143 It is likely 
that several different pathways exist for generation of TH17, and our current paradigm of single 
cytokine and transcription factor characterisation may not explain heterogeneity within 
effector T-cells. Key surface markers distinguishing TH17 polarised cells include CCR6 and CCR4, 
which are required for homing to lymphoid tissues as well as certain tissue microenvironments 
with pro-inflammatory chemokines, particularly at barrier sites including skin and gut.  As such, 
a paradigm for skin TH17 responses is starting to take shape, whereby barrier disruption by 
certain triggers, likely microbial but potentially also environmental stresses, induces activation 
and migration of dendritic cells to lymphoid organs, where they present antigens and provide 
activating polarising signals to naïve T-cells. DC-mediated TH17-polarisation through IL-23, leads 
to CCR6 and CCR4 expression on T-cells, allowing them to be recruited to appropriate sites of 
inflammation where they are needed. The inflammatory milieu then maintains and enhances 
TH17 function through IL-1β, IL-6 and TGFβ production, supplied for by DCs and other 
inflammatory cells present. Production of IFNα, β, γ and/or IL-4, in response to the evolving 
inflammatory requirements dictated by the environment, inhibit IL-17 production, thus 
providing negative regulatory signals for TH17 responses. Depending on the magnitude of 
inflammation, T-cells can then reside in tissues becoming resident-memory T-cells, or 
recirculate in blood and lymphoid tissues, becoming long-lived central memory T-cells, with 
their phenotypic polarisation, and awaiting activating signals. 
The role of T-cells, and in particular TH17 cells which by definition are CD4 helper cells, and of 
the cytokine IL-17, is well established in psoriasis. Interestingly, there is evidence that CD8 T-
cells can also produce IL-17 (TC17), including in a pathogenic context.
147,148 It is still unclear 
whether CD8 T-cells, which in psoriasis are predominantly intraepidermal, can produce IL -17 
and whether they play a role in pathological outcome.  
1.2.2. TYPE-I INTERFERONS AND PLASMACYTOID DENDRITIC CELLS INITIATE PSORIASIS 
T-cells, TNF, and the IL-23/IL-17 axis are front and centre in established chronic plaque-type 
psoriasis, and they provide valuable targets for its treatment. Yet, for obvious reasons, very 
little is known about the initiating factors in the pathogenesis of the disease.  
Clinical signs of psoriasis appear, inevitably, once disease is well established. As such, 
studies on the mechanisms initiating disease are few, and rely on the use of in vivo models. The 
use of murine models over the years has shed light on several aspects of the disease, but this is 
confounded by wildly different genetic alterations and/or triggers, and relatively different 
fidelity to the human condition. Though several spontaneous models exist, few are bona-fide 
models of human psoriasis. Xenograft models, which involve the transplantation of human pre- 
or fully developed psoriatic plaques onto immunodeficient mice, are currently the closest 
models incorporating phenotypic, genetic, and immunopathogenic processes of psoriasis. 103,149  
Several landmark observations were made using this model. First, and foremost, 
engraftment of pre-psoriatic skin biopsies from patients with established chronic plaque-type 
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 psoriasis onto mice leads to spontaneous conversion of the graft into fully-fledged psoriasis. 
Through the mechanical stresses of transplantation, a series of events is set in motion that lead 
to localised expansion of T-cells already present in the skin, and characteristic histological signs 
start to become apparent culminating by 6 to 8 weeks post-transplantation. Resolved lesions of 
psoriasis maintain several T-cell signature genes,150 suggesting that even though their activity 
may be targeted with biologic therapy, they remain localised at continuously recurring 
developing lesion sites. These findings indicate that dormant, resident effector-memory T-cells 
(TREM) are found residing in the skin of patients of psoriasis, and await a trigger for reactivation 
and pathologic outcome.93,94 Second, blockade of T-cells, like for TNF, is sufficient to impede 
progression of the pathology, thus confirming the pathogenic role of T-cells. Third, dermal to 
epidermal transition of T-cells is responsible for the conversion from uninvolved to psoriatic 
skin.104 This T-cell migration takes place during phenotypic conversion of the lesion, but the 
initiating triggers of psoriasis and of T-cell re-activation were only starting to be elucidated. 
Plasmacytoid dendritic cells (pDCs) are the immune system ’s professional producers of 
type-I interferon. It was identified that early after transplantation, type-I interferon signatures 
were upregulated, preceding apparition of the phenotypic conversion. 151 Concurrently, 
psoriatic patients have detectable upregulation of downstream interferon-response genes 
along with prominent pDC infiltrates. Importantly, inhibition of either type-I interferon 
signalling or of pDCs leads to blockade of the psoriatic conversion in the xenotransplantation 
model, demonstrating a key role for early pDC-derived type-I interferon signalling in driving 
psoriasis.151 Furthermore, it was later found that antimicrobial peptides such as beta-defensins 
and cathelicidins are abnormally overexpressed in psoriasis and, through highly cationic 
charges, can bind to nucleic acids and mediate internalisation into pDCs. This allows nucleic 
acids to be able to reach and activate endosomal toll-like receptors 7 and 9,152,153 thus 
culminating in the production of high levels of type-I interferons. As for the trigger that elicits 
antimicrobial peptide expression in skin, mechanical injury is sufficient to induce antimicrobial 
peptides and this is followed by pDC recruitment and activation,6,46 thus providing a rationale 
for the Koebner phenomenon observed in psoriasis and a role for pDCs and type-I interferon in 
the initiation of psoriasis, but during skin homeostasis following injury (Figure 4). 
In summary, the xenotransplantation model has elucidated that an external, Koebner-like, 
trigger induces strong expression of antimicrobial peptides which potently activate pDCs to 
produce type-I interferon. Resident T-cells are activated and expand in situ, leading to 
transition into the epidermis via integrin expression. Although it remains to be elucidated what 
the exact role of type-I interferons is on T-cells in psoriasis, there is evidence that type-I 
interferons can upregulate specific integrins,154 and circumstantial evidence that viral infection 
leads to integrin upregulation in CD8 T-cells.155 Therefore, one may envisage that innate 
interferon production may stimulate the adaptive T-cell arm in the cascade of events that 
precede phenotypic conversion. It also remains to be determined whether this epidermal 
transition is mostly mediated by CD8 T-cells, and what their functional contribution is to 
psoriasis. 
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1.2.3. ANTI-TNFS AND RECENT ADVANCES IN BIOLOGIC THERAPY 
Though TNF is well-described to be required for homeostasis, including defence against 
pathogens, lymphoid-organ architecture, tissue repair, tumour control, and resolution of 
inflammation,156–158 it is also involved in many pathogenic processes. Psoriasis, and many other 
joint- and gut-related inflammatory conditions, have benefited immensely from targeting of 
TNF. Yet, given the complexity of TNF signalling, there have been counterintuitive, and 
sometimes contradictory, results from TNF blockade in the clinic (Figure 5). 
Currently, there are five TNF inhibitors – infliximab, etanercept, adalimumab, 
golimumab, and certolizumab pegol – which have successfully been used in the treatment of 
TNF-mediated diseases over the last two decades. Infliximab is a human-murine chimeric 
monoclonal IgG1 antibody, with a murine variable region and human constant domain , 
developed for pre-clinical testing as far back as 1993, and commercialised by Janssen Inc. 
(formerly Centocor Ortho Biotech) under the name Remicade. Etanercept is an engineered 
compound composed of the TNFR2 fused to a human IgG1 Fc domain, produced by Amgen and 
Pfizer. Adalimumab and Golimumab are fully human monoclonal antibodies, respectively 
Humira (AbbVie, Inc.) and Simponi (Janssen, Inc.). Certolizumab pegol is an Fab fragment of a 
humanised monoclonal antibody, and PEGylated for increased stability , produced by UCB 
Pharma SA under the name Cimzia. Indications are similar between the different compounds, 
and diseases treated include Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriatic 
arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, hidradenitis suppurativa, and 
chronic plaque-type psoriasis. Off-label use include the treatment of vasculitis and Behçet’s 
disease. 
Generally, anti-TNFs are considered more efficacious and safer than non-specific 
immunomodulators. Nevertheless, like most drugs, they too come with an array of possible 
adverse events, which can be quite disparate in nature. Among the most prevalent adverse 
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psoriatic phenotype. The precise mechanism by which pDC-derived IFN drives psoriasis remains to 
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BDCA2: blood dendritic cell antigen 2; IFN: interferon. Schematic drawings modified and re-used 
with permission from Nature Publishing Group. 
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effects of systemic TNF inhibition are opportunistic infections, lupus-like disease, sarcoidosis, 
demyelination, alopecia, vasculitis, vitiligo, and psoriasis or psoriasiform inflammation. The 
latter is also termed “paradoxical psoriasis” due to the apparent paradox of anti-TNF being an 
effective treatment for psoriasis, and able to induce it de novo in a small proportion of patients 
treated with the drugs. Interestingly, anti-TNFs are abnormally immunogenic as compared to 
other biologics, which is believed to contribute to progressive loss of efficacy of 
treatment.159,160 Moreover, the formation of self-reactive antibodies, mostly against DNA and 
nuclear components, is increased in patients under anti-TNF, which is thought to contribute to 
the increased incidence of lupus-like syndrome.161,162 Whether the two are linked remains to be 
elucidated. 
Anti-TNFs are highly efficacious in the treatment of many inflammatory diseases, and as 
such new strategies are being devised to reduce adverse effects and maintain long-term 
treatment efficacy. New compounds targeting TNFR1 now exist (ATROSAB,163 MDS5541,164 
TROS) and are being tested for their effectiveness. More recently, as patent restrictions on 
anti-TNFs are being lifted, anti-TNF biosimilars have started to be produced which carry much 
reduced costs. Infliximab biosimilar CT-P13 (Remsima, by Celltrion) has been tested in chronic 
plaque psoriasis with success, and is now approved.165 Interestingly, patients which develop 
anti-drug antibodies to anti-TNFs, and display reduced drug efficacy, when switched to CT-P13 
they also display reduced responsiveness to treatment. Concurrently, rates of induction of anti-
drug antibodies is similar between the two compounds.166,167 Together, these observations 
validate the almost indistinguishable nature between biosimilars and the reference products. 
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Riskier approaches are being undertaken in patients that exhibit secondary failure of response 
to TNF inhibitors, such as vaccination to TNF. Although there is variable efficacy using this 
approach, patients produce polyclonal antibodies specific for TNF and show a modest but 
correlated clinical response.168 Other approaches have been to use dual cytokine inhibition, or 
even dual-specificity (or bispecific) biologics. Though concurrent TNF and IL-1 inhibition have 
not yielded increased efficacy for the treatment of rheumatoid arthritis ,169 novel approaches 
are being undertaken such as the use of IL-17 and TNF bispecific antibodies.170 Due to the 
synergistic effect of TNF and IL-17 in inflammation, this may provide increased efficacy for 
patients with limited therapeutic responses to single cytokine inhibition. Other dual-inhibition 
methods, informed by experimental observations, may prove to be useful in the treatment of 
psoriasis.171 
Anti-TNF therapy is a powerful treatment option for a growing number of inflammatory 
conditions, several of which do not have alternative treatment options.  As for most drugs, 
undesired effects due to anti-TNF therapy exist, but with proper clinical evaluation and regular 
patient follow-ups these can be diminished. A few other side-effects of anti-TNFs do not display 
pre-treatment predicting power, and can lead to discontinuation of treatment. 
1.3. ANTI-TNF INDUCED PARADOXICAL PSORIASIS 
With more than 20 years of experience of the anti-TNF class of drug in the clinic,172,173 several 
side-effects have become apparent over time. Chronic TNF neutralisation, as expected, 
increases susceptibility to infections174,175 and there is evidence of increased chance of 
developing cancer,176 though this latter finding is disputed by more recent studies.177–179 Yet, 
there is no doubt about another significant but intriguing side-effect of anti-TNF therapy called 
paradoxical psoriasis, which has countless case-reports and is confirmed by several large-scale 
studies.180–188 
1.3.1. CLINICAL, EPIDEMIOLOGICAL AND HISTOLOGICAL CONSIDERATIONS 
Adverse events due to anti-TNF therapy occur most commonly on the skin, with 20 to 25% of 
patients developing one form or another of skin complication. Inflammatory, psoriasiform skin 
lesions are reported in about 0.6-5.3% of patients under anti-TNF therapy from a period of 
weeks to months after treatment start.181 Because histologically these lesions resemble 
psoriasis, these adverse manifestations are termed “paradoxical psoriasis” as anti-TNFs are 
widely used to successfully treat psoriasis.  
Paradoxical psoriasis can manifest irrespectively of the underlying disease being 
treated, and without association to personal or familial history of psoriasis. Eruptions occur 
frequently, but not exclusively, at sites of frequent koebnerisation such as the scalp (30%), skin 
folds (20%), palms and soles (20%), pubic region (15%), knees and elbows (5%), but also trunk 
(30%), arms and legs (40%), and face (40%).181,182 Clinical presentation can vary between 
patients, with plaque-type, guttate, and/or pustular features being observed like in classical 
psoriasis. Unlike classical psoriasis however, palmoplantar pustular psoriasis presentation rates 
(40%) are more frequent in paradoxical psoriasis.189 Mean time to incidence ranges between 30 
and 40 months, and cumulative incidence increases over time from 1% after the first year of 
treatment, up to 30% following 10 years. Psoriasiform lesions under anti-TNF can often lead to 
28
 discontinuation of treatment, depending on the severity and manageability of the adverse 
event. Reports differ, with overall estimates at between 20 and 40% of patients that develop 
psoriasiform lesions.190–192 New recommendations, however, suggest specific topical and 
eventually systemic treatments should be attempted before discontinuation, and that the 
percentage of patients discontinued from anti-TNF therapy may drop down to 5%-10%.181 
Strikingly, switching to a different anti-TNF leads to re-appearance of the skin lesions in 85% of 
individuals,189 really pointing to a class-effect of anti-TNF drugs. Incidence is a marginally higher 
in female patients (58%), and higher for Adalimumab (65%) as compared Infliximab and 
Etanercept, but this is argued to be inflated for Adalimumab as it is not a first -line anti-TNF. 
Often, patients are switched to Adalimumab following an adverse reaction to other anti-TNFs in 
the hope of reducing symptoms, and because of the high rate of reappearance or maintenance 
of paradoxical psoriasis this is overrepresented in second- and third-line anti-TNFs. Overall, it is 
recognised that the true prevalence and incidence is unknown and likely underreported, as 
case definition may vary between studies and diagnosis may not systematically be confirmed 
by a dermatologist. 
Histologically, paradoxical psoriasis is partly reminiscent of classical psoriasis on a few 
aspects. Typical features of psoriasis have been reported in psoriasis developing under anti -TNF 
treatment, including hyperplasia of the epidermis with elongation of rete ridges, diffuse 
parakeratosis, dermal perivascular infiltration, and where pustular les ions are observed, 
intraepidermal and subcorneal collection of neutrophils termed Munroe’s microabscesses. 
Many manifestations reveal a lichenoid and spongiotic inflammation, accompanied by focal 
necrotic keratinocytes.193,194 Treatment of paradoxical psoriasis differs depending on the 
severity of symptoms, with most cases treated with psoralen coupled with UVA, or UVB 
phototherapy, or steroids, or methotrexate, whilst maintaining current anti-TNF treatment. 
More severe cases are discontinued of anti-TNF therapy, but symptoms may persist beyond 
treatment cessation. In these cases, use of other biologics is sometimes warranted, usually 
with the goal of concurrently treating the underlying condition. Whereas antibiotics are 
normally used to treat cutaneous infections which arise from anti-TNF therapy in about 5% of 
patients,195 only few case reports exist of successful treatment of psoriasiform eruptions using 
doxycycline.196 Though the patient was treated with antibiotics because he had signs 
resembling reactive arthritis with skin involvement (Reiter’s), it is intriguing that  in patients 
with paradoxical psoriasis without apparent signs of infection, 25% have in fact bacterial 
infections superimposed on their lesions.182 Whether there is a link between microbial 
overgrowth and paradoxical psoriasis remains unclear, though often dry skin preceded 
psoriasiform eruptions, possibly suggesting that an impaired barrier might facilitate microbial 
entry. 
It is well described that a proportion of patients that undergo paradoxical psoriasis will 
experience exacerbation of their existing lesions.183 Remarkably, many patients with psoriasis 
treated with anti-TNF, but which subsequently develop de novo paradoxical psoriasis, usually 
see their underlying psoriasis improve.189 As to why certain patients develop de novo psoriasis-
like inflammation and simultaneously see an amelioration of their pre-existing psoriasis, is very 
much still unclear. This is all the more puzzling as paradoxical lesions present histologically 
identical to classical psoriasis. Many hypotheses have been postulated as to the pathological 
mechanisms of paradoxical psoriasis, several of which are reviewed hereafter. 
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 1.3.2. PUTATIVE GENETIC PREDISPOSITION 
Ground-breaking work has revealed strong genetic association for diseases such as psoriasis, 197 
arthritis,198 and inflammatory bowel disease (IBD).199 To date, no genome-wide association 
studies have been published demonstrating a genetic association between risk alleles and 
development of paradoxical psoriasis. Yet a few studies have aimed at identifying genetic 
association for paradoxical psoriasis with risk alleles from classical psoriasis and IBD.  
There is considerable genetic linkage between diseases where anti-TNF is used as a treatment, 
including Crohn’s disease and psoriasis. In one study, loci linked to both Crohn’s and psoriasis 
were screened in patients under anti-TNF which develop or not skin adverse events. Single 
Nucleotide Polymorphisms (SNPs) with association to development of skin lesions were linked 
to IL12B, COG6 and to a lesser extent IL23R and IL12RB2, among the 7 tested gene loci.182 In a 
different study, five SNPs linked with genes IL23R, FBXL19, CTLA4, SLC12A8, and TAP1 were 
found to be associated with development of paradoxical psoriasis.200 IL23R is by far the gene 
most confirmed by this type of study, with a third report showing association. 201 The fact that 
strong association exists with psoriasis may have been explanatory for a histologically similar 
type of skin pathology, yet it seems that paradoxical psoriasis associates with the protective 
allele of IL23R,200 as this variant reduces IL23-mediated TH17 signalling.
202 As to how this 
contributes to the development of paradoxical psoriasis is still unclear, but it seems to be 
related to a reduction of IL-23 signalling. Other genes are associated with T-cell function (CTLA4 
and TAP1), keratinocyte proliferation (SLC12A8), among other unknown functions.  
Much work needs to be done to determine genetic associations in patients that develop 
paradoxical psoriasis, as well as other cutaneous manifestations during anti-TNF therapy. This 
will shed light into the pathological mechanisms that may lead to better management of 
symptoms, as well as potential predictors of therapeutic outcome. 
1.3.3. MOLECULAR PATHWAYS INDUCED BY TNF BLOCKADE 
Several hypotheses have been put forth regarding the aetiology of paradoxical psoriasis. Chief 
among those is the hypothesis of cytokine imbalance, where loss of TNF leads to deregulation 
of other cytokines, with consequent pathogenic outcome.  
 Early observations from patients treated with anti-TNF led to the identification of 
detectable increases of anti-dsDNA antibody titers.203 Further studies confirmed this finding, 
and identified anti-nuclear antibodies (ANA) as well as anti-dsDNA antibodies with incidences 
of up to 76.7% and nearly 50% respectively.162,204,205 The role of type-I interferon in the 
establishment of autoimmunity, and of induction of autoantibodies was well -known and 
particularly apparent in patients receiving IFNα therapy for the treatment of chronic viral 
infections.206 As such, it was reasoned that anti-TNF could lead to deregulation of type-I 
interferons. Indeed, patients under anti-TNF therapy display increased interferon-response 
signatures in the circulation, which were absent before initiation of treatment. 207 In a proof-of-
concept approach, it was demonstrated that TNF governs plasmacytoid dendritic cell (pDC) 
maturation and cessation of IFNα production, as well as the generation of pDCs from 
progenitor cells. As described in a previous section, type-I interferon production by pDCs is an 
initiating early trigger for acute development of classical psoriasis.46,151,208 As such, it was found 
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 that type-I interferon signalling is in fact pronounced in lesions from paradoxical psoriasis. 209 
Though the exact pathological mechanism remains to be determined, this finding, coupled with 
increased infiltration and correlation with CXCR3+ cells, suggests a pathogenic role for type-I 
interferon signalling and activated T-cells in paradoxical psoriasis.  
 Other cytokines have been postulated to play a role in the development of paradoxical 
psoriasis, particularly in light of putative genetic predisposition(s). IL-12 and IL-23, two pro-
inflammatory cytokines related to TH1 and TH17/22 polarisation respectively, may be involved, 
but it is unclear how loss of TNF affects their regulation within the inflammatory milieu. 
Experiments performed using the CD4+ CD45RBhigh cell adoptive transfer set-up, indicate that 
TNF blockade leads to enhanced TH17 with decreased Treg responses, and a mildly exacerbated 
phenotype.210 Interestingly, in this skin inflammation model, there is little detectable TNF in 
skin lesions, suggesting that the effect of TNF is elsewhere. Seen as it is a T-cell mediated 
inflammatory model, it may be that TNF inhibition affects a finely-tuned balance of Treg-TH1-
TH2-TH17/22 pro-inflammatory cytokines, at distal sites, potentially lymphoid tissues. Another 
unexpected finding from this model, is that TNF is highly induced in the serum of mice treated 
with the anti-TNF, and that there is a sharp decrease of IL-12 and IL-23. This is hard to reconcile 
with the functional data demonstrating an amelioration of the phenotype upon IL12/23p40 
blockade. It is also unclear whether the exacerbation induced by TNF blockade goes through 
the IL12/23 axis. As such it may be that two independent pathways are at play, and the authors 
suggest a decrease in Foxp3+ T-cells and their capacity to produce IL-10 may be responsible for 
the aggravation upon TNF blockade. 
All in all, little is known about the molecular mechanism behind anti-TNF induced skin 
inflammation. Current knowledge points to type-I interferon signalling and IL12/23-mediated 
inflammation as a possible culprit, with concurrent loss of the anti -inflammatory cytokine IL-10, 
but there is little experimental evidence to support this. Furthermore, there is even fewer 
indication as to how exactly the crosstalk within these networks takes place.  
1.4. ROSACEA AND INNATE INFLAMMATION 
Rosacea is a chronic inflammatory disorder that selectively affects the facial convexities, 
including nose, cheeks, forehead and chin. Clinical and histological presentation can be 
different between patients, with the hallmark defining feature being non-transient centro-
facial redness. Differential diagnoses include Cutaneous Lupus Erythematosous, seborrheic 
dermatitis which can be concomitant and more rarely cutaneous sarcoidosis, all of which 
require careful clinical consideration. This poorly understood disease is highly debilitating 
causing profound emotional distress in affected patients. Currently there is only limited and 
transient efficacy of available treatments, and therefore there is a need for a deeper 
understanding of the pathological mechanisms in order to define treatment strategies with 
biological rationale. 
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 1.4.1. CLINICAL, EPIDEMIOLOGICAL AND HISTOLOGICAL CONSIDERATIONS 
Rosacea presents in the clinic as four distinct subtypes, which include erythematotelangiectatic 
(stage I), papulopustular (stage II), phymatous (stage III), and ocular (stage IV) subtypes. 
Reported incidence lies between 0.1% and 22%, and can vary between geographical locations, 
with highest frequency in persons of northern and western European descent, and lowest 
among African, Central and South American, and Asian individuals. Mean prevalence is 10%, 
with 14% of women and 5% of men affected. Frequencies from Swedish and Greek large series 
studies are in agreement, with stage I (70%) being more common than stage II (26%) and stage 
III (4%).211–213 Stage IV rosacea is concomitant with other subtypes in upwards of 4 of 5 cases.   
 Stage I erythematotelangiectatic rosacea presents as nontransient episodes of flushing 
with mostly central facial erythema that may involve also the neck, ears and upper chest, and 
may be accompanied by telangiectasias. Stage II papulopustular rosacea often encompasses 
the characteristics from stage I, with the addition of transient papules or pustules across the 
face. Both stage I and II rosacea are more commonly linked to female patients. Stage III 
phymatous rosacea is characterised by skin induration with irregular nodules and can be 
distributed along any facial sebaceous regions, with the nose as the predominantly affected 
site. Stage III rosacea affects more commonly male patients. Stage IV ocular rosacea is 
associated with bloodshot appearance with telangiectasias of eyelids, or with periocular 
erythema. 
 Despite the observations that stage II rosacea encompasses stage I attributes, that 
stage III rosacea occurs mostly in elderly following chronic inflammation from rosacea, and that 
sometimes all four stages may be present in patients, few scientific investigations have been 
conducted to elucidate progression between subtypes. Though this remains a controversial 
subject, there is new evidence suggesting that stage I precedes stages II and III, that stage II 
precedes stage III, and that the majority of patients developed cutaneous features before 
ocular stage IV symptoms.214 
Histopathological examinations of the different subtypes are disparate and usually nonspecific. 
Stage I classical features include dilated superficial blood vessels with perivascular 
inflammatory lymphohistiocytic and plasma cells. Papules and pustules from stage II also 
include neutrophil accumulation at hair follicles and beyond through to the mid-dermis. Stage 
III rosacea is characterised by sebaceous gland hyperplasia, accompanied by widespread 
fibrosis and dermal thickening. Histolopathological examinations are generally not required for 
a diagnosis of rosacea. In some cases, there is need to rule-out lupus, and generally only then 
are biopsies taken to determine whether there is Ig-deposition along the epidermal-dermal 
interface. Frequent histological observations include the presence of Demodex folliculorum 
mites in 50-90% of patients,215 with marked increased in the density of the mites ranging from 
5 to 30 mites per follicle, depending on sites investigated.216 Though their exact contribution to 
the disease is unclear, they are carriers of microorganisms such as Bacillus oleronius and 
Staphylococcus epidermidis in their hindgut, thus significantly increasing the bacterial load in 
the skin of patients. Additionally, they are a relatively efficacious treatment target, indicating a 
possible role for microorganisms in the disease. 
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 1.4.2. ROSACEA MANAGEMENT AND AVAILABLE TREATMENTS 
Rosacea management consists in reducing the exposure to environmental factors known to 
trigger flushes. Though no cure exists for rosacea, drugs are used to manage symptoms.  Among 
approved drugs for the treatment of rosacea, topical medications exist, which typically aim to 
reduce visible signs of the disease, and few systemic treatments are available, generally aiming 
at reducing the microbial burden. 
 Known triggers of rosacea exacerbation include ultraviolet (UV) light radiation, alcohol 
consumption, heat, ingestion of certain spices, and emotional stresses. 217,218 It is not entirely 
clear how these contribute to the disease, though it is hypothesised that all of these factors 
induce vasodilation, through a direct effect or neuromediators, rendering the erythema and 
telangiectasias apparent. The ensuing inflammatory exacerbation may lead to the worsening of 
existing papules and pustules. 
 Approved topical treatments for rosacea include formulations whose main component 
is sodium sulfacetamide, metronidazole, azelaic acid, or alpha-adrenergic agonists. Sodium 
sulfacetamide has considerable efficacy in reducing symptoms including facial erythema and 
inflammatory lesions,219,220 though the mechanism remains unknown and is generally regarded 
to be an unspecific anti-inflammatory effect. Other topical drugs with anti-inflammatory action 
are metronidazole and azelaic acid, which have reported efficacies in placebo-controlled 
trials,221,222 and are thought to reduce production of and inactivate reactive oxygen species 
(ROS).223,224 Additionally, topical alpha-adrenergic receptor agonists which cause blood vessel 
constriction by targeting superficial smooth muscles, have been found to reduce erythema 225 
and can be used in combination with anti-inflammatory agents. Recently, Ivermectin, an anti-
parasitic agent used in the treatment of demodicosis, has received approval for treatment of 
rosacea.226 Its main mode of action is thought to be through the reduction of the microbial 
burden.  
 The most efficacious systemic therapeutic options currently approved for rosacea are 
tetracycline drugs. These are potent antibiotics highly efficacious in the treatment of rosacea227 
and of other skin conditions such as acne.228 Because they carry undesirable side-effects such 
as selection of drug-resistant bacteria at high doses (100-200 mg doxycycline daily), they have 
been trialled at lower doses (40-50mg doxycycline daily) which avoid development of drug-
resistant microbes. They are argued to provide beneficial outcomes in patients through an anti-
inflammatory action that is independent of antibiotic effect, but it is unclear whether smaller 
doses affect the increased bacterial burden observed in rosacea patients. 
Currently, no approved treatments exist with a well-defined pathomechanistic rationale. These 
rather aim at reducing the inflammatory and microbial burden. Based on recent findings of the 
implication of the innate immune system, new emerging therapies are being tried in small scale 
pilot studies.  
1.4.3. ANTI-MICROBIAL PEPTIDES AND EMERGING THERAPIES 
Given the apparent role for antibiotics in the management of rosacea symptoms, it is likely that 
microorganisms, and thus by extension the innate immune system, are implicated in the 
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 pathogenesis of rosacea. Cathelicidin, along with its predominant serine protease responsible 
for its cleavage and activation, kallikrein 5 (KLK5), are found abundantly overexpressed in 
rosacea skin.7 In addition, cathelicidin fragments of various sizes have been described from 
patient skin, and several of these peptides can elicit inflammation macroscopically reminiscent 
of human rosacea when injected into mouse skin. But little is known as to the purpose of the 
different sized fragments, and how they may contribute to the inflammatory environment. 
 It is not entirely clear whether aberrant KLK5/cathelicidin expression comes as a final 
stage in the pathogenesis of rosacea, or whether it is an early trigger of the inflammatory 
cascade. From in vitro studies, cathelicidins have been shown to be inducible in keratinocytes 
by vitamin D,229 a factor borne from UV light exposure, linking a known trigger of rosacea such 
as UV light to cathelicidin-mediated inflammation. Upregulation of KLK5 in rosacea has been 
attributed to increased levels of TLR2, found overexpressed in rosacea, whose triggering via 
canonical TLR2 stimulation leads to KLK5 production and release from keratinocytes. 7,230 There 
are multiple potential triggers for TLR2 that are known to be present in rosacea, such as the 
gram-negative bacterium B.oleronius which produces gram-positive cell wall components, and 
Demodex mites carrying chitin which is a ligand for TLR2.215,231  
 Mast cells and Matrix Metalloproteinases (MMPs) have also been suggested to play a 
role in rosacea. KLK5 is first released as a pre-proenzyme and requires enzymatic processing for 
its activation in what is an intricate regulatory framework.232 One such enzyme identified to 
carry out proteolytic activation of KLK5 and that is found overexpressed in rosacea is MMP-9.233 
In fact, it is suggested that mast cells are important sources of MMP-9, and that they are 
needed for proteolytically activating KLK5 which in turn results in processed cathelicidins such 
as LL-37 being produced.234 The study goes further in suggesting that mast cells are responsible 
for the redness seen in rosacea as mast cell deficient KitW-sh mice do not develop the 
characteristic erythema seen upon intradermal injection of LL-37. In line with this finding, 
blockade of mast cell degranulation using systemic administration of cromolyn sodium also 
prevents development of redness. It is unclear what the contribution of neutrophils is, as they 
are also known producers of many MMPs such as MMP-9 as well as cathelicidin,235 but it is 
suggested that neutrophil chemoattraction to the site of LL-37 injection is impaired in mast cell 
deficient mice. 
KLK5 activity is positively regulated by MMP-mediated proteolitic activation, but its 
regulation goes beyond just positive signals. Protease inhibitors can also negatively modulate 
KLK5 activity, providing balancing signals for the timely termination of protease activity. 
Unabated KLK5 activity has been attributed as the defining cause of diseases involving skin 
barrier abnormalities. One such example is Netherton syndrome, a severe type of ichthyosis 
that affects skin, hair, and immune system, and presents as red scaly skin in newborns. 
Mutations in SPINK5 (serine protease inhibitor, Kazal-type 5) have been identified in families 
with Netherton’s, and these lead to null expression of the protein in patients  through 
premature stop codons.236 Incidentally, it was later discovered that the protein encoded by 
SPINK5, called Lympho-epithelial Kazal type inhibitor (Lekti), directly inhibits KLK5 and other 
serine proteases such as KLK7, trypsin, subtilisin A, plasmin, cathepsin G, and neutrophil 
elastase,237 and that this regulates physiological desquamation processes. Spink5-/- animals 
develop cutaneous inflammation with detachment of the stratum corneum from the granular 
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 layer via premature and unabated degradation of desmosomal cadherins, and importantly 
succumb to lethal dehydration few hours post-partum.238 KLK5 overexpression under the 
involucrin promoter leads to exfoliative erythroderma and scaling throughout the body only a 
few days after birth, reminiscent of Netherton’s hallmark features. 239 Importantly, loss of KLK5 
rescues the clinical and most histological presentation in Spink5-deficient animals,240 
suggesting a key role for KLK5 in skin inflammation, and highlighting the importance of tightly 
regulated networks of enzyme processing, and how imbalances inevitably lead to pathologic 
outcome.  
Cathelicidins, and by association upstream regulators KLK5 and Lekti, are involved in 
skin inflammation and the pathogenesis of rosacea. Many players have been identified with a 
potential involvement in the pathogenesis of rosacea, but given the lack of comprehensive in 
vivo investigations it is still unclear how they all fit together. It is not known whether 
KLK5/cathelicidin is an upstream trigger or downstream consequence of inflammation. 
Furthermore, though it is widely described that cathelicidins are potent pro-inflammatory 
alarmins,10,241,242 how they mediate pathogenic outcome in rosacea is still poorly understood.  
The most prominent hypothesis pertains to the induction of IL-8, CXCL1 and CXCL2 production 
from keratinocytes,234,243,244 or that LL-37 itself is able to bind CXCR2245 leading to strong 
neutrophil chemoattraction. This in turn leads to inflammation and to the characteristic 
papules and pustules found in stage II rosacea. Continuous recruitment of neutrophils and their 
activation in the inflammatory environment are thought to lead to collagen breakdown and loss 
of elasticity resulting in skin induration, a principal feature of stage III phymatous rosacea. As 
for the erythema and telangiectasias, prominent in stage I rosacea but present throughout, 
these are thought to be a direct effect of aberrantly processed forms of cathelicidins7 as LL-37 
is shown to lead to angiogenesis.246 This is controversial as it is disputed by recent findings 
suggesting that angiogenesis is a late, stage III feature of rosacea.217 
Based on the recently proposed pathomechanism of cathelicidin-mediated 
inflammation,7,229,230,247,248 emerging therapies have been proposed to inhibit aberrant 
processing of the antimicrobial peptides. Serine protease inhibitors exist in topical formulation , 
using ε-aminocaproic acid as the main active component, and are approved for the treatment 
of bleeding disorders.249 In a small 12-week long case series, there was significant improvement 
in the group receiving treatment as compared to placebo controls particularly in erythema. 250 
Concurrently, protease activity as measured from superficial skin sampling was significantly 
reduced. Mast cells have also been targeted in a different small-scale study using cromolyn,234 
a well-described mast cell stabiliser with unknown mode of action.251 The authors demonstrate 
a decrease in protease activity in a pre-clinical model and in patients treated with the 
compound, and mention efficacy in reduction of erythema. 
Despite a clearer understanding of the implication of the innate immune system in the 
pathogenesis of rosacea, we are only starting to scratch the surface when it comes to targeted 
therapies with an established pathomechanistic rationale.  
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2. AIMS OF THE STUDY
The following study aims at a elucidating the pathological mechanisms of paradoxical psoriasis 
induced by anti-TNF, based on observations that 1) paradoxical psoriasis has an increased 
interferon signature,209 2) TNF regulates pDC maturation and production of type-I 
interferons,207 and that 3) psoriasis is initiated by pDC-derived type-I interferon.252 
It aims to propose novel therapeutic approaches for rosacea based on a pathomechanistic 
rationale, and based on observations that 1) cathelicidin antimicrobial peptides are aberrantly 
expressed in rosacea lesions,7 2) cathelicidin LL-37 can potently activate pDCs to produce type-I 
interferons,152 and 3) that rosacea has a predominant innate inflammatory profile with a strong 
microbial contribution.247,253 
It aims at an understanding of the importance of the IL-23/TH17 axis in non-psoriasis skin 
diseases with a psoriasiform pattern of inflammation, such as for pityriasis rubra pilaris, based 
on observations that 1) PRP has considerable overlap with psoriasis, 254 2) can be treated with 
the IL-12/23 inhibitor ustekinumab.255 
Finally, it aims at elucidating the importance of epidermal CD8 T-cells in the development of 
psoriasis, based on observations that 1) psoriasis is a T-cell mediated disease that can be 
modelled using a xenotransplantation approach,103 2) conversion of non-lesional to lesional 
psoriasis involves expression of integrins that allow dermal to epidermal transition, 104 3) 
psoriasis has a strong genetic association to class I HLA-C molecules.100 
37

 3. RESULTS 
The following section is composed of two manuscripts which are recently submitted (Appendix 
1) or in preparation (Appendix 2), and two peer-reviewed manuscripts (Appendices 3 and 4).  
They are integrated in the thesis manuscript with for each a summary, an introduction, a 
description of thesis work involved and step-by-step approaches, and a discussion and outlook. 
Contributions for each manuscript are outlined at the end.  
 
Appendix 1 – TNF blockade induces a dysregulated type I IFN response without autoimmunity 
in paradoxical psoriasis  
Summary. TNF is an important target in the treatment of psoriasis yet, in a subset of patients, 
there is development of psoriasiform lesions resembling psoriasis due to anti -TNFs. 
Histopathologically, lesions have many similarities to classical psoriasis and expression of many 
innate and effector cytokines follow similar expression, with the exception of type-I interferons 
which are overexpressed in comparison to classical psoriasis, with striking infiltrates o f 
plasmacytoid dendritic cells (pDCs). In this work, we find that anti -TNF greatly potentiates and 
sustains IFNα production by pDCs in vitro with concurrent loss of maturation, and that pDCs are 
maintained in skin upon injury in vivo. This is reflected by marked overexpression of type-I 
interferons through loss of TNF-mediated maturation of pDCs. Importantly, mice treated with 
anti-TNF exhibit psoriasiform inflammation reminiscent of paradoxical psoriasis. Blockade of 
type-I interferons prior to induction of anti-TNF-driven inflammation leads to almost complete 
amelioration of the psoriasiform phenotype, pinpointing that the induction of type -I 
interferons is in fact pathogenic in this inflammatory context. Unlike classical psoriasis 
however, this inflammatory outcome is independent of T-cells and of adaptive immunity, 
indicating that anti-TNF triggers paradoxical psoriasis through the removal of an important 
brake on type-I interferon production by pDCs, and that this results in an unabated innate skin 
inflammation.   
Introduction. Biologic therapeutics targeting TNF – called anti-TNFs – have been an immense 
scientific and clinical advancement and revolutionized the treatment of many debilitating 
chronic inflammatory disorders, such as ankylosing spondylitis,  rheumatoid arthritis, psoriatic 
arthritis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa, or uveitis. To  date, 
more than 2.5 million patients have been treated with anti-TNFs and three different anti-TNF 
agents are currently among the top 10 best-selling drugs worldwide. With broad usage and 
increasing clinical experience, several side effects have become apparent. Surprisingly, anti-TNF 
treatment can induce new autoimmune diseases, including systemic lupus erythematosus and 
paradoxical psoriasis. These adverse events represent extremely important side effects in the  
treatment of major chronic autoimmune diseases as they potentially necessitate treatment 
cessation. The aims of the thesis work was to determine the pathogenic pathways involved in 
development of paradoxical psoriasis in order to further elucidate therapeutic options, and 
patient management. 
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 Description of thesis work and step-by-step approaches. The initial approach undertaken was 
to perform comparative gene expression analyses of genes involved in known skin 
inflammatory processes,256 using biopsies from paradoxical psoriasis lesions compared to 
chronic plaque psoriasis and healthy skin. By doing so, we identify type-I interferons 
significantly overexpressed as compared classical psoriasis, which indicated an interesting 
specificity of these cytokines for paradoxical psoriasis. To understand whether plasmacytoid 
dendritic cells (pDCs) may be involved in their production, we stained for specific markers in 
paradoxical psoriasis histology and found that they heavily infiltrate lesions, correlating with 
interferon expression. To determine whether pDCs are responsible for type-I interferon 
production in skin, we used an established tape-stripping model6 in mice genetically modified 
to express the diphtheria toxin-receptor specifically under the promoter of the Blood Dendritic 
Cell Antigen-2 (BDCA2) gene, essentially allowing the specific deletion of pDCs upon DT 
injection.38 Upon DT injection, type-I interferon expression in skin lesions was abrogated, 
indicating that in skin pDCs are responsible for the bulk of type-I interferon expression. 
Because it is known that TNF can be produced by a vast number of cells (both immune and 
epithelial cells) including pDCs, and because TNF-receptor 1 (TNFR1), which binds soluble TNF, 
is expressed in most cell types including pDCs, we wondered whether TNF blockade intrinsically 
could affect interferon-production by pDCs. Importantly, previous observations by others 
indicate that TNF negatively regulates interferon-production by pDCs, likely through induction 
of maturation.207 As postulated, stimulation with DNA/LL-37 complexes (10ug/mL and 50ug/mL 
pre-incubated for 15 minutes as determined previously152) or CpG-B (1uMm, as determined 
previously152), leads to rapid production of IFNα with subsequent maturation. The addition of 
TNF (100ng/mL, as defined previously207), leads to premature loss of  IFNα producing capacity, 
paralleled by increased maturation. Conversely the addition of anti-TNF (1ug/mL of infliximab, 
adalimumab or certolizumab pegol as determined by log-dilutions on pDC cultures using 
infliximab) leads to sustained production of IFNα and reduction of maturation marker 
expression, as expected. This defines a model whereby TNF negatively regulates IFNα 
production, an effect that is intrinsic in pDCs, as gene expression profiles of stimulated pDCs 
reveal rapid expression of IFNA2, followed by replacement by TNF. To determine whether these 
observations hold in vivo, we took advantage of a skin injury model which is known to induce 
pDC infiltration peaking at around 24h post injury.6 For in vivo use, we calculated the murine 
equivalent of the anti-TNF to be used, with the following formula (used for pre-clinical to 
clinical translation) 
                                    
        
       
 
where the Animal (murine) Km = 3, the Human Km = 37, and this equation can be re-
interpreted as 
  
                                    
       
        
 
or 
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We find that mice treated with anti-TNF have pDCs in lesions displaying lower expression of 
maturation markers, and their numbers are maintained for much longer as compared to control 
mice reflecting accumulation of pDCs in paradoxical psoriasis lesions. Blockade of IFNAR 
signalling leads to much reduced pDC infiltration suggesting that sustained production of type -I 
interferons by pDCs maintain pDC infiltration in skin lesions. This is reflected by the increase in 
expression of Cxcl9, Cxcl10, and Cxcl11 during anti-TNF treatment, which we believe participate 
in the recruitment of pDCs in skin, and their abrogation during IFNAR-blockade, suggesting that 
interferon-induced chemokine expression causes pDC maintenance in skin lesions. Importantly, 
histological analyses reveal that there is clear epidermal thickening, with focal sites of 
parakeratosis, as in histology from paradoxical psoriasis lesions, accompanied by hallmark signs 
of psoriasiform inflammation including basal keratinocyte hyperproliferation and loss of 
terminal differentiation of keratinocytes of the granular layer demonstrated by confocal 
microscopy of Ki67 and involucrin (expressed on undifferentiated keratinocytes) and loricrin 
(expressed in fully differentiated keratinocytes). Remarkably, IFNAR-blockade leads to an 
almost complete rescue of the observed epidermal thickening highlighting that the abnormal 
increase in type-I interferons locally leads to the paradoxical psoriasis outcome. Because a 
similar pathway involving pDC activation and type-I interferon production is involved in driving 
T-cell dependent inflammation in classical psoriasis, we wondered whether a similar 
mechanism may take place. Yet depletion of conventional T-cells expressing TCRαβ (using anti-
TCRβ depletion prior to induction of the model, amount determined for complete depletion in 
injured skin) does not affect the phenotype in any apparent way. In mice, several pre-clinical 
models pinpoint unconventional γδ-T-cells as important effectors in driving psoriasiform 
inflammation.257–261 Because there is no clear consensus on whether γδ-T-cells can be 
successfully targeted through antibody-mediated depletion,262 we opted for the use of mice 
lacking recombination-activating gene 2 (Rag2-/-), thus lacking all T-cells (and B-cells). We 
reasoned that, in light of previous results targeting conventional T-cells, should there be an 
amelioration of the phenotype that this may be due to either lack of unconventional γδ-T-cells, 
or the lack of humoural immunity. This did not warrant further investigation, as the phenotype 
was recapitulated entirely in mice lacking an adaptive immune system, suggesting that neither 
conventional nor unconventional (nor humoural immunity) is required for the development of 
anti-TNF-induced paradoxical psoriasis inflammation. Classical psoriasis is well-known to be 
mediated by T-cells, in particular intraepidermal CD8 T-cells. Indeed, CD8 T-cells are heavily 
infiltrating the dermis and epidermis of classical psoriasis, in sharp contrast to paradoxical 
psoriasis where only few can be found in the epidermis, further supporting the lack of a role for 
T-cells in paradoxical psoriasis. 
Discussion and outlook. In summary, this work pinpoints an innate skin inflammation pathway, 
linked to cytokine deregulation and loss of the TNF-mediated break on type-I interferon 
production by pDCs. It highlights a role for the pDC–interferon axis in the pathogenesis of 
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paradoxical psoriasis, and pinpoints a major difference with classical psoriasis despite similar 
histopathological presentation. The pre-clinical determination of the pathogenic role of the 
pDC–interferon axis raises the possibility for targeting this pathway in patients that develop 
paradoxical psoriasis. This may be of further interest in patients which have an underlying 
moderate/severe psoriasis that is ameliorated with anti-TNF (but that subsequently develop 
paradoxical psoriasis) and thus cannot be treated with anti-TNFs. Thus switching them to 
biologics targeting the pDC–interferon axis would treat paradoxical psoriasis and prevent new 
flares of classical psoriasis, as these are thought to be initiated by the same pathogenic axis. 
Currently, there are several anti-IFNα and anti-IFNAR biologics which have been found to be 
effective in other interferon-driven diseases,263,264 have passed safety and tolerability trials, 
and are currently in Phase III trials (anifrolumab, AstraZeneca [MedImmune]; sifalimumab, 
AstraZeneca [MedImmune] discontinued due to superior efficacy of anifrolumab). Importantly, 
there are several biologics targeting pDCs and their capacity to produce type-I interferons upon 
TLR-ligation,265 which again demonstrated efficacy in small case studies and are currently in 
either Phase I (MEDI7734 anti-ILT7, AstraZeneca [MedImmune]) or Phase II trials (BIIB059 anti-
BDCA2, Biogen). The latter group of biologics may be more versatile in the treatment of 
diseases driven by a specific pDC–interferon axis, whilst leaving immunity by stromal and other 
non-pDC cells unscathed. 
Contributions to Appendix 1 – TNF blockade induces a dysregulated type I IFN response 
without autoimmunity in paradoxical psoriasis 
Figure 3f – figure, plus repetitions 
Figure 3g – figure 
Figure 3h – figure 
Figure 4a – repetitions (x4) 
Figure 4b – repetitions (x4) 
Figure 4c – repetitions (x4) 
Figure 4d – figure, plus repetitions 
Figure 4e – figure, plus repetitions 
Figure 5 – figure, plus repetitions 
Figure 6a – figure, plus repetitions 
Figure 6b – figure, plus repetitions 
Figure 6c – figure, plus repetitions 
Supplementary Figure 1a – figure, plus repetitions 
Supplementary Figure 1b – figure, plus repetitions 
Supplementary Figure 2 – repetitions (x6) 
Supplementary Figure 3 – figure, plus repetitions 
Supplementary Figure 5 – figure, plus repetitions 
Supplementary Figure 6 – figure 
Supplementary Figure 7 – figure, plus repetitions 
Critical appraisal of the manuscript, and redaction of parts of the Methods section. 
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 Appendix 2 – Rosacea-associated bacteria activate plasmacytoid dendritic cell-derived type-I 
interferon driving flare-ups of disease 
Summary. Rosacea is a debilitating skin inflammatory disorder affecting the facial convexities, 
characterised by repeated flare-ups of disease. There is clinical and molecular evidence for a 
progression in rosacea, and this may be linked to the repeated inflammation cycles during 
flare-ups. Cathelicidin antimicrobial peptides have been known to be implicated in the 
pathogenesis of rosacea, particularly through differential processing of active peptides by its 
serine protease kallikrein 5. Yet little is known about the pathological mechanisms behind 
cathelicidin-mediated inflammation. Recently, there has been renewed interest on the role of 
the innate immune system in driving inflammatory cascades in rosacea. In this work, we find 
that rosacea lesions present TH1/TH17 genes and related signatures, with no TH2 expression in 
comparison to healthy skin. Importantly, we report that, specifically during flare-ups of 
rosacea, type-I interferons are uniformly and selectively overexpressed as compared to 
stabilised lesions. We determine that plasmacytoid dendritic cells (pDCs) are required for this 
production using a pre-clinical model, and that targeting them or the type-I interferon 
signalling pathway leads to loss of several TH17-polarising pro-inflammatory genes and IL22, 
but not TH1/TH2-related cytokines. This induction of interferons is dependent on the surface 
commensal bacteria, as topical antibiotic treatment leads to loss of the type-I interferon 
signature, and commensal bacteria such as Bacillus oleronius, which are found infesting rosacea 
lesions, are sufficient to drive this pathogenic signature. Importantly, B.oleronius is exquisitely 
sensitive to killing by cathelicidin antimicrobial peptides, much more than other commensal 
and non-commensal bacteria tested, providing evidence that their killing may be the trigger for 
pDC-derived type-I interferon-driven flare-ups of rosacea. 
Introduction. Rosacea is an inflammatory condition affecting the facial convexities and 
characterised by recurring flare-ups of disease. Microbial dysbiosis is a defining feature of rosacea, 
with apparent infestation with Demodex folliculorum as a diagnostic criterion in the vast majority of 
cases. These commensal mites flourish in hair follicles deep in the dermis of rosacea and are the 
base of deep granulomatous formations. Bacillus oleronius has been identified as the principal 
bacterium harboured by D.folliculorum, and is thought to be continuously released. This reservoir for 
bacteria has been suggested to be the reason for the relative inefficacy of long-term antibiotics in 
the treatment of rosacea, and as such anti-mite insecticides are also used in the clinic. Though 
several disease management strategies are available, little is known about the pathological 
mechanisms of flare-ups of disease. Microbe-associated molecular patterns are well described to 
induce antimicrobial peptides for controlling foreign agents. Cathelicidin antimicrobial peptide has 
been identified as one such antimicrobial agent induced in keratinocytes downstream of TLR2, and 
needing proteolitic processing for activation. Cathelicidin has been found overexpressed in rosacea 
and its enzyme processing by kallikrein 5 (KLK5) has been pinpointed as an important component of 
the disease. LL-37 has been shown to be able to bind bacterial as well as human DNA, to allow its 
condensation and thus to be able to activate endosomal toll-like receptors- (TLR-) 7 and 9 in 
plasmacytoid dendritic cells (pDCs). Notably, stimulation of pDCs with these indissociable complexes 
leads to production of vast amounts of type-I interferons which have been implicated in the 
pathogenesis of other inflammatory skin diseases such as psoriasis.  
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 Description of thesis work and step-by-step approaches. Previously, we had observed that 
type-I interferon-response genes such as MX1 were upregulated in established stabilised 
lesions of rosacea, yet intriguingly could not find type-I interferons expressed. We reasoned 
that this may be indicative of a previous interferon burst long after type-I interferon genes may 
have died down. We collected samples taken from patients with rosacea during active flare-ups 
of disease, and to our astonishment found that they all had massive upregulation of the type -I 
interferon genes, compared to both healthy skin and stabilised lesions, along with co ncurrent 
overexpression of response genes. Importantly, all other genes showed similar expression 
between flare-ups and stabilised lesions, suggesting that the abnormality in the “life-cycle” of 
flare-up/stabilisation are selectively type-I interferons. This was with the remarkable exception 
of TNF which was marginally but significantly upregulated in stabilised lesions compared to 
flare-ups, and could be a parallel of TNF regulation of type-I interferons. Staining of pDCs in 
lesions revealed large infiltrates of cells, which were quantified with the aid of image analysis 
tools for unbiased counting of total infiltrating cells (defined by their round nuclei), and the 
manual counting of plasma-like cells with round nuclei and positive staining. The percentage of 
cells correlated closely with type-I interferon expression, which may indicate that 1) pDCs 
produce type-I interferons and thus transcript levels reflect pDC infiltration, or 2) that pDC 
infiltration results from type-I interferon expression, as type-I interferons are known strong 
inducers of chemokines. To determine whether either (or both) of these hypotheses is true, we 
turned to an in vivo system. Previously, work by others indicated that cathelicidin antimicrobial 
peptide injection in skin leads to inflammation and erythema with many features resembling 
rosacea (more important of which, the aberrant presence of cathelicidins), 7 we wondered 
whether cathelicidins could be directly responsible for induction of type-I interferons, and 
whether they could be produced by pDCs. We consistently found that induction of type -I 
interferons increased over time as compared to injection of the vehicle (saline) and these were 
closely paralleled by pDC infiltration, reproducing the human observations. Remarkably, prior 
depletion of pDCs using antibodies specifically directed to them, or performing these 
experiments in mice genetically modified for selective depletion of pDCs using diphtheria toxin 
(hBDCA2-DTR), lead to complete abolishing of IFNα genes, and marked significant reduction of 
IFNβ. Similarly, interferon-response genes were severely reduced, though not completely 
abolished as compared to type-I interferon signalling blockade. This indicated clearly that pDCs 
are the major contributors to type-I interferon production in skin in the context of rosacea. 
Strikingly, pDC infiltration was also abolished upon type-I interferon blockade, indicating that 
type-I interferons produced by pDCs lead to further pDC recruitment. Thus, both hypotheses 
are true, pDCs are the producers of type-I interferons and type-I interferon leads to pDC 
recruitment. This latter finding was further confirmed in the paradoxical psoriasis mouse model 
whereby IFNAR-blockade leads to almost complete abolishing of pDC infiltration, in the tape-
stripping skin injury model where baseline infiltration of pDCs is abolished, and in intradermal 
injections of type-I interferons which lead to marked pDC infiltration. This is suggestive that 
pDCs produce type-I interferons but continuous stimulation is required for sustained interferon 
expression and pDC accumulation. This observation led us to hypothesise that type-I 
interferons are responsible for chemokines to be expressed at the site of skin inflammation. A s 
rosacea is well-described to be highly expressing in several families of chemokines, 266 we tested 
the most highly expressed chemokines in this pre-clinical model of rosacea, and found that 
select chemokines of the CXCR3 and CCR2/5 families were strongly dependent on type-I 
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 interferons and pDCs. Intriguingly, TH17-related and polarising pro-inflammatory cytokines, as 
well as IL22, were significantly dependent on type-I interferons, but not TH1 nor TH2 genes. 
Given the clear microbial dysbiosis in rosacea, and because pDCs are strongly activated by 
microbial CpG-rich DNA, we wondered whether the commensal bacteria might play a role in 
the induction of the pathogenic pDC-derived type-I interferon-driven pathway. Topical 
antibiotic treatment reduces growth of skin surface bacteria from 50-150 CFU/cm2 of swab area 
down to nil. Importantly, the induction of type-I interferons upon cathelicidin injection was 
clearly dependent on this microbial load at concentrations below 200uM of LL -37. Intriguingly, 
concentrations in excess of 250uM could induce type-I interferons independently of microbial 
presence, suggesting that potential massive host cell killing could also be a driver of 
cathelicidin-mediated inflammation. In vitro, skin commensal bacteria such as 
Propionibacterium acnes, Staphylococcus epidermidis, and Bacillus oleronius, were more 
susceptible to cathelicidin-mediated killing compared to non-skin associated, and generally 
non-commensal bacteria such Escherichia coli, Pseudomonas aeruginosa, and Klebsiella 
pneumoniae. Remarkably, B.oleronius is far more sensitive to killing by cathelicidins. Pre-
incubation of heat-killed B.oleronius with cathelicidin peptides and stimulation of pDCs in vitro 
leads to potent production of IFNα. Similarly, in vivo injection of B.oleronius pre-incubated with LL-
37, for the same concentration of LL-37, leads to substantially increased type-I interferon expression. 
It is important to note that B.oleronius at CFUs in excess of 100 (determined after overnight culture 
in blood agar, 37°C) per injection can, by itself, be stimulatory of type-I interferons over time. Finally, 
pre-treatment of skin with antibiotics (which abolishes the LL-37 [100uM] mediated induction of 
type-I interferons) and injection of heat-killed B.oleronius pre-incubated with LL-37 restores the 
type-I interferon induction, indicating that cathelicidin-mediated killing of commensal bacteria is 
sufficient for the induction of the type-I interferon signature.  
Discussion and outlook. Our findings point to the importance of pDC-derived type-I interferon 
production during flare-ups of rosacea, and raise the possibility of using it as a therapeutic target to 
prevent one of the hallmark signs of the disease. Like for paradoxical psoriasis, targeting of the type-I 
interferon pathway, or pDCs directly, are a feasible and foreseeable option for the treatment of 
rosacea flares, and could essentially hamper the progression of the disease (see Discussion and 
Outlook for Appendix 1). Our data indicate that an understanding of the factors that govern 
microbial infestation in rosacea might lead to better prevention and management of the disease. 
Importantly, we don’t know how the demodex mite may contribute to the disease flare-ups. Though 
we think that it acts as a reservoir for the bacterium, it’s still not clear why it is not controlled in 
patients with the disease. Unfortunately, culturing is difficult and it does not take well in wild-type 
mice. Interestingly, strains deficient in adaptive immunity, in particular TH2 responses, were more 
susceptible to spontaneous demodicosis with mouse-specific commensal mites. It’s unclear whether 
this is reflected by heightened TH1/TH17 responses without TH2 signatures in lesions of rosacea, and 
whether type-I interferon in response to bacterial triggers might play a direct role in this. For now 
there is a controversial link between the two, with reports suggesting that type-I interferons are 
required for TH2 responses via priming of DCs,
267,268 whereas other reports suggest that they restrict 
TH2 immunity through regulation of ILC2.
269 Though currently unclear whether IL17 plays a 
pathogenic role in rosacea, this is currently being investigated in an open-labelled phase 1b 
trial using secukinumab in an estimated 24 patients (trial NCT03079531). It would be 
interesting to see whether inhibition of IL17 may lead to more directed anti -parasitic TH2 
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 responses which could lead to control of mite infestation. Additionally, more work is needed to 
elucidate the link between environmental and intrinsic triggers of flare-ups and type-I interferons. 
We show that commensal bacteria can trigger type-I interferon-driven flare-ups of rosacea, but we 
don’t know how these may be related to environmental triggers such as UV light exposure and 
alcohol consumption, or emotional stress and the autonomic nervous system. Whether these 
influence stress or killing of the mites, thus leading to massive release of bacteria and initiation of 
the cascade, is unclear. 
 
Contributions to Appendix 2 – Rosacea-associated bacteria activate plasmacytoid dendritic 
cell-derived type-I interferon driving flare-ups of disease 
Writing of the manuscript. 
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 Appendix 3 – Interleukin 23-helper T cell 17 axis as a treatment target for pityriasis rubra 
pilaris 
Summary. Pityriasis rubra pilaris (PRP) is a sporadic chronic inflammatory skin disease whose 
major differential diagnosis is psoriasis. Therefore, many treatments for psoriasis are used for 
the treatment of PRP solely on their resemblance, and not on empirical evidence. In this work, 
we examined the expression of inflammatory cytokines in three patients that develop PRP and 
identify a notable TH1/TH17 signature, with upregulation of both IL12B and IL23A. Given the 
effectiveness of ustekinumab, an anti-IL12/23 monoclonal antibody, for the treatment of 
moderate-to-severe psoriasis, we treated one severe PRP case that did not show signs of 
spontaneous remission. Like for psoriasis, there was a clear amelioration four weeks after a 
single infusion and a return to homeostasis after 16 weeks. Intriguingly, TH17 cytokines IL17A 
and IL17F were quickly diminished due to the treatment, but not the TH1 cytokine IFNG, thus 
providing evidence that blockade of IL23 may be of interest in PRP rather than IL12.  
Introduction. Pityriasis rubra pilaris is a rare inflammatory skin disorder which often appears 
sporadically. Histopathologically, there is remarkable similarity with psoriasis, with apparent 
branny scale, orange-red erythema, palmoplantar keratoderma, and histological features such 
as epidermal thickening, immune cell infiltration, and parakeratosis. There’s a particular 
urgency, in particular for erythrodermic PRP, for efficacious and fast-acting treatments. 
Similarities between psoriasis and PRP warrant a better understanding of the pathomechanistic 
pathways involved in PRP. One particularly effective treatment option for moderate -to-severe 
psoriasis are biologics targeting the TNF-IL23-IL17 axis. There are several case reports of 
successful treatment of PRP with anti-TNFs,270,271 and sporadic cases with anti-IL12/23 but with 
no pathomechanistic rationale.255 As such, we wondered whether patients with PRP had a 
particular cytokine signature that may warrant anti-IL12/23 therapy, and which pathway (be it 
IL12-TH1, or IL23-TH17) is likely to play a role. 
Description of thesis work and step-by-step approaches. Samples were collected from lesions 
of three patients with PRP, and gene expression analyses performed of notable innate and 
adaptive TH1, TH2, and TH17 inflammatory cytokines. One patient displayed particularly 
recalcitrant disease, and based on inflammatory TH1/TH17 cytokine profiles was given 
subcutaneous anti-IL12/23 along same dosages given to patients with severe psoriasis. Lesional 
skin samples were taken for gene expression analyses, at weeks 4 and 28 post treatment 
initiation. Concurrent with marked and rapid amelioration, TH17 cytokines IL17A and IL17F 
were abolished first by week 4, and to some extent IL22, with IFNG and TNF lagging behind the 
phenotypic and histological changes due to therapy. 
Discussion and outlook. This study gives evidence that a similar IL23-TH17 axis exists between 
psoriasis and PRP, and points to an immunopathological rationale for targeting IL23 in the 
treatment of refractory PRP. However, there is need for further validation of the pathway with 
large scale studies. Importantly, there are striking differences between PRP and psoriasis, 
including follicular hyperkeratosis, orange-red waxy keratoderma, and absence of neutrophils. 
Thus, further work is needed to clarify pathologic mechanisms and effector cell types that 
mediate this effect, and whether T-cells play a role in PRP. 
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 Contributions to Appendix 3 – Interleukin 23-helper T cell 17 axis as a treatment target for 
pityriasis rubra pilaris. 
Figure 1c – figure 
Figure 2 – figure 
Figure 3b – data from figure 
Critical appraisal of the manuscript, and redaction of parts of the Methods section.  
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 Appendix 4 – Targeting CD8+ T cells prevents psoriasis development 
Summary. Psoriasis is a T-cell mediated disease,103 and it is well-described that effector 
cytokines IL17A, IL22 and IFNγ produced by CD4+ T-helper cells actively contribute to disease. 
We know that T-cells require expression of integrin α1β1 for dermal to epidermal transition and 
that it can be targeted to prevent development of psoriasis.104 Yet, epidermal T-cells are mostly 
CD8+ T-cells, and their role in the pathogenesis of psoriasis has not been fully elucidated. Here, 
we find that CD8+ T-cells can be targeted for the treatment of psoriasis, as epidermal expansion 
of CD8+ T-cells closely mirrors psoriasiform inflammation and epidermal hyperproliferation, 
along with pronounced production of IL17A as compared to dermal T-cells.   
Introduction. T-cells have long been known to be involved in the pathogenesis of psoriasis, 
with large dermal and epidermal infiltrates. Importantly, targeting IL23, and downstream T -cell 
derived cytokine IL17A, have proven to be effective treatment options for even the most 
difficult cases. As these cytokines are historically known to be produced efficiently by CD4 + T-
helper cells, they have been regarded as the key effector cell type mediating pathology. There 
is substantial evidence, however, that CD8+ T-cells can produce pro-inflammatory cytokines 
including IL17A.272 Being present mostly in the epidermis, CD8+ T-cells may recognise antigens 
via MHC class I, which in psoriasis carry one of the strongest susceptibility allele – HLACw6.273 
Therefore, we wondered whether CD8+ T-cells might participate, or even be required for the 
development of psoriasis.  
Description of thesis work and step-by-step approaches. Samples were taken from engrafted 
mice treated with anti-TNF (infliximab) as a positive control, anti-CD8 depleting antibody (M-
T807), or isotype treated mice, and histology assessed. CD8+ T-cell depletion stopped the 
spontaneous development of the psoriasiform phenotype, similarly to anti-TNF treatment. 
Discussion and outlook. The advancement of biologic therapies targeting cytokines have 
brought conclusive and definitive evidence that T-cells, and the IL23-IL17A axis are key drivers 
for chronic plaque psoriasis. Historically, CD4+ T-helper cells are known to produce large 
amounts of cytokines, and provide “help” for immune responses, whereas CD8 + T-cells are 
known to perform a cytotoxic function. Therefore, one may indeed postulate that CD4+ T-
helper cells are key effector cells in the pathogenesis of psoriasis, as they respond to IL23 and 
produce large amounts of IL17A. Our data demonstrate that CD8+ T-cells, are key drivers of the 
development of psoriasis. Moreover, the high association between psoriasis and mutations in 
the class I molecule HLACw6 may be suggestive that their epidermal localization is important in 
the recognition of antigens involved in the disease. Ideally, the specific depletion of these cells 
or their cognate antigen or trigger may lead to a permanent cure for the disease.  
Contributions to Appendix 4 – Targeting CD8+ T cells prevents psoriasis development 
Figure 2g – figure (histology) 
Critical appraisal of the manuscript. 
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 4. DISCUSSION AND PERSPECTIVES 
Type-I interferon is well-known to be essentially necessary for the cell-intrinsic antiviral and 
antibacterial effects,274 though newer evidence points to a balancing act of interferons and 
highlights another cell-intrinsic effect that has instead detrimental potential to the host. 275–279 
Type-I interferon is also important the proper priming of immune antiviral72,74 and anti-
tumoural280–283 responses, yet this has been also found to have profound detrimental effects in 
autoimmune, adaptive immunity-driven diseases such as psoriasis46,151–153,208 and systemic 
lupus.284–287 In work outlined in Appendices 1 and 2, we describe a detrimental effect of type -I 
interferons in driving cutaneous inflammation via pDCs, one of which is through a mechanism 
related to cytokine imbalance, and the other through commensal bacteria initiated pathogenic 
responses. 
In this section, major differences between adaptive immunity-driven versus innate immunity-
driven pathology initiated by type-I interferons are outlined. Furthermore, therapeutic 
intervention on the type-I interferon pathway may not be a viable target, as immune-mediated 
pathology due to cytokine imbalances may be more commonplace than previously appreciated, 
as taught by lessons from anti-TNF biologics. Importantly, selective inhibition of cell-specific 
production of cytokines may be the future approach for the treatment of diseases. Finally, the 
possible upstream triggers and downstream targets of type-I interferon will be discussed in 
light of these findings. 
4.1. TYPE-I INTERFERON AT THE CROSSROADS OF PATHOGENIC INNATE AND ADAPTIVE IMMUNITY 
The inter-regulation between TNF and type-I interferon has long been appreciated207 and 
compelling evidence indicates that TNF blockade is associated to type-I interferon expression in 
paradoxical psoriasis.209 In work performed herein, we find that pDCs are responsible for in situ 
uniform overexpression of type-I interferons upon anti-TNF induced paradoxical psoriasis, and 
also for a cutaneous disease, rosacea. Using a novel mouse model, we describe an 
inflammatory mechanism for paradoxical psoriasis which, unlike classical psoriasis, is 
independent of T-cells and adaptive immunity. 
 It is unclear exactly how type-I interferon initiates chronic plaque-type psoriasis. It is 
thought that type-I and type-II interferons play a priming role during initial phases, before 
establishment of chronic disease, as neither anti-IFNα nor anti-IFNγ treatments demonstrated 
increased effectiveness for therapy of plaque-type psoriasis.288,289 The role of early priming may 
be in the generation of pathogenic T-cells in secondary lymphoid organs. This is evidenced by 
the role of interferons in driving adaptive T-cell responses, both against viruses and tumours, 
and that mechanistically they can both upregulate co-stimulatory molecules and HLA 
expression on APCs, and maintain T-cells within DC compartments for increased interaction and 
potential recognition of cognate antigen. Once pathogenic T-cells are established and become 
skin resident at lesion sites, type-I interferon may act to maintain them in an effector state and 
expanding. Dendritic cell activation by type-I interferons in situ is also likely to influence T-cell 
activity, as it is known to drive maturation of DCs. Additionally,  evidence from viral infection 
models points to a direct effect on T-cells as well. Antigen-specific CD8 and CD4 T cells use 
IFNAR signalling for clonal expansion.72,73 LCMV-specific, antigen-experienced T-cells from  
ifnar-/- mice adoptively transferred into recipient, LCMV infected mice either fail to expand 
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Figure 6: Anti-TNF induced paradoxical psoriasis model. In classical psoriasis, skin injury 
(Koebner phenomenon) ellicits pDC-derived type-I interferon production, which drives 
activation of skin T-cells. Dendritic cells produce copious amounts of TNF, thus inhibiting 
pDCs and type-I interferon production, and sustain a TNF-driven inammatory environment. 
This maintains IL-23 production and TH17 cytokines from T-cells, giving rise to pathological 
outcome. In contrast, in paradoxical psoriasis, anti-TNF therapy blocks TNF, thus raising inhibi-
tion from pDCs and leading to unabated production of type-I interferon. This in turn drives a 
T-cell independent innate inflammation resembling classical psoriasis but without 
relapses. Schematic drawings modified and re-used with permission from Nature 
Publishing Group.
Classical psoriasis
Paradoxical psoriasis
(CD8 T-cells <1%), or their expansion is severely impaired (CD4 T-cells <10%). This is proposed 
to be mediated by poor survival of daughter cells upon antigen recognition. Thus one may 
envisage that in psoriasis, at the site of inflammation, TRM may require type-I interferons for 
clonal expansion during the initiation of response, but once plaques are established, pre -
existing and expanded (self)-antigen experienced T-cells can mediate pathology without the 
need for type-I interferon.  
This role of type-I interferon on adaptive immunity which drives skin inflammation is in 
stark contrast with our observations on paradoxical psoriasis. Whereas in  classical psoriasis the 
pDC-IFN axis is acting on T-cells, in paradoxical psoriasis inflammation is entirely independent 
of T-cells and the adaptive immunity branch, as evidenced by sustained inflammation in rag2-/- 
and mice depleted of αβ-T-cells and CD3 cells (not shown). As such, a new model is starting to 
emerge whereby the pDC-IFN axis is no longer inhibited by TNF and can stimulate the innate 
immune system generating pathological outcome in the skin (Figure 6).  
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 Though the precise mechanisms of type-I interferon-driven innate skin inflammation remain to 
be determined, one might envisage anti-IFNα therapy in difficult-to-treat paradoxical psoriasis 
where anti-TNF discontinuation is either not an option or not sufficient to reverse the 
cutaneous manifestation. Yet, as from lessons learned from anti-TNF therapy, type-I interferon 
inhibition may lead to a domino effect-type of imbalances of other cytokines. 
4.2. UNDESIRED EFFECTS OF TYPE-I INTERFERON BLOCKADE AND OF CYTOKINE IMBALANCE 
Targeting of the type-I interferon pathway in the clinic is now coming to fruition after many 
years of research in pathogenic mechanisms of interferon-driven diseases. Systemic Lupus 
Erythematosous (SLE) is just one such disease which has the potential to benef it greatly from 
targeting of the type-I interferon pathway.290 
SLE is a disease which for almost a century was thought to be restricted to skin, hence 
the clinical designation “lupus erythematosous”. Later the systemic aspect of the disease was 
discovered, and the disease called SLE. Though all organs are usually affected in SLE (skin, 
heart, lungs, kidneys, joints, and nervous system), discoid lupus affects skin specifically. Skin 
manifestations in lupus, both systemic and discoid, frequently (but not exclusively) involve the 
famous butterfly (malar) pattern rash reminiscent of rosacea. Indeed, one differential diagnosis 
of rosacea is often lupus, as systemic inflammation needs to be ruled out.  Similarities between 
lupus and rosacea are many (skin location, female incidence bias, and now type-I 
interferon291,292) though it is not known whether they share common pathogenic pathways, and 
one major difference is the presence of autoimmunity driven by T- and B-cells in SLE. 
 New compounds which target specifically IFNα cytokines263 or the type-I interferon 
receptor264 have been developed and recently trialled in lupus. Medium-scale phase IIb trials 
have recently been published revealing significant efficacy at up to 52-weeks of treatment, and 
interestingly stratification by interferon-response expression levels reveals even greater 
efficacy. All patients that displayed amelioration had marked resolution of skin rashes.  For 
lupus trials this is remarkable, particularly in patients without severe nephri tis where other 
biologics to date have either failed to achieve efficacy endpoints or have been aborted because 
of an unfavourable balance between benefits versus adverse events.293,294 
 Both interferon-targeting trials reported statistically significant incidence of infections 
with Herpes zoster (5.9% vs 0.9% and 6.9% vs 2%) or influenza, in a dose-dependent manner. 
Antiviral therapy resolved the infections in all patients. Few other adverse effects have been 
reported over the 52-week trials, without difference with placebo-controlled groups. It remains 
to be established whether longer duration treatment increases viral susceptibility further, and 
whether this treatment will have higher rates of malignancies.  
Total blockade of type-I interferon signalling has been proven successful in the treatment of 
lupus and a role for this pathway in the pathogenesis of the disease is proven clinically. Longer 
duration studies may reveal more serious complications which may take years to fully develop. 
As such, another strategy is likely to be sought, one that targets the pathway straight at its 
pathogenic source. 
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 4.3. TYPE-I INTERFERON PRODUCTION BY PDCS AS A DRUGGABLE TARGET 
Type-I interferon is an important pro-inflammatory cytokine that plays a fundamental role in 
viral and tumour defence as demonstrated by mouse studies. As such, strategies seeking to  
target only the pathogenic type-I interferon component are likely to be sought. One such 
approach may be to target pDCs specifically, as they are rarely critically required for mounting 
of immune responses. In contrast they have often been implicated as directly necessary in the 
pathogenesis of several disease models.  
The search for pDC-specific cell surface markers to study the, at the time, recently 
discovered cell type led to the identification of the blood dendritic cell antigen -2 (BDCA2),295 a 
C-type lectin receptor (CLR) which coincidentally negatively regulates pDCs when engaged. 
CLRs are part of the family of pattern recognition receptors (PPRs) such as TLRs, Nod -like 
receptors (NLRs) and retinoic acid-inducible gene 1 (RIG-1), and interact with pathogen-
associated molecular patterns (PAMPs) for their recognition. CLRs are mostly expressed by DCs, 
and function by interacting with mannose, fucose and glucan carbohydrates found on 
pathogens (mannose on viruses, fungi and mycobacteria; fucose on certain bacteria and 
helminths; and glucans on mycobacteria and fungi).296,297 Triggering of CLRs results in the 
internalisation and processing of pathogens for degradation and antigen presentation. It also 
results in modulation of signalling pathways and of other PPRs such as TLRs. 
 BDCA2 is expressed specifically on pDCs, is found to interact with immunoreceptor 
tyrosine-based activation motif (ITAM)-containing Fc receptor γ-chain (FcRγ). Other receptors 
that pair with FcRγ are found to activate Nuclear Factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) signalling and transcription of downstream targets. Ligation of BDCA2 
on pDCs does not induce NF-κB activation or cytokine production, instead it abolishes TLR-
mediated activation and production of type-I interferons.298,299 It is still not clear whether other 
pathways may be triggered by BDCA2 ligation, as some propose engagement of BCR-like 
signalling in pDCs, or what exactly the natural ligands of BDCA2 do on pDCs and how in vivo 
triggering of BDCA2 may modulate lack thereof natural ligation. Nonetheless, there is recent 
interest on targeting BDCA2 for the inhibition type-I interferon pathway, as new antibodies are 
being produced and tested,300 and others tested in small scale human proof-of-concept 
studies.265 As these studies show good drug tolerability, more are bound to follow in the near 
future with potential for phase trials. 
In our recent study, we find that directly targeting pDCs yields a similar beneficial effect as 
targeting the type-I interferon pathway. Other recent work highlights the pathogenic impact of 
pDC-derived type-I interferon in response to viral infection.301 Therefore, this strategy has 
potential for clinical relevance. Another approach may be to target the pathogenic trigger 
upstream of type-I interferon and pDC activation.  
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Figure 7: Plasmacytoid dendritic cell-derived type-I interferon drives flares of rosacea. In our 
proposed model, we identify type-I interferons selectively produced during flare-ups of rosacea. We 
find that cathelicidins induce pDC-derived type-I interferons which drive a TH17-polarising cytokine 
environment and IL-22 at the site of inflammation, along with select CXCR3 and CCR1/5-binding 
chemokine expression. The resulting effector responses are known to induce further cathelicidins  
and exacerbate inflammation resulting in further activation of pDCs and leading to a recurring 
feedback loop of interferon production. Intriguingly, we find that Bacillus oleronius, a commensal 
bacterium that resides deep within the hair follicles, is exquisitely sensitive to cathelicidin peptides 
specifically identi-fied in rosacea. Furthermore cathelicidin peptide-mediated killing of the bacterium 
lead to potent activation of pDCs for production of type-I interferons. Protection of B.oleronius in the 
gut of Demodex folliculorum may provide it with a perfect breeding environment away from immune 
responses, thus remaining a continuous trigger in rosacea. D.folliculorum: Demodex folliculorum; 
B.oleronius: Bacillus oleronius; CAMP: Cathelicidin-antimicrobial peptide; TLR2: Toll-like receptor 2; 
pDC: plasmacytoid dendritic cell; IFNα: interferon alpha; NK: Natural killer cell; IL: interleukin. 
Schematic drawings modified and re-used with permission from Nature Publishing Group. 
4.4. UPSTREAM PATHOGENIC TRIGGERS OF TYPE-I INTERFERONS IN SKIN DISEASE 
Upstream activation of type-I interferon production is induced by PAMP-recognition. Viruses, 
bacteria, fungi, and parasites are all activators of the pathway, but self -nucleic acids are also 
known to be triggers.152,153  
In the context of rosacea (Figure 7), we find that commensal bacteria are critically 
required and sufficient for cathelicidin-initiated, pDC-driven inflammation. This is in line with 
the use of topical and systemic antibiotics and anti-parasitic drugs. This strategy poses several 
issues, as indiscriminately targeting of the microflora, particularly in the gut, can be 
detrimental to the host in the long run. Interestingly, low-dose non-antimicrobial 
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 administration of tetracycline drugs (40mg/day) also show efficacy. 302 These dosages have been 
proven to be non-antimicrobial in vitro and to act directly on the immune system via inhibition 
of mitochondria, though the effect on bacteria in vivo, over the course of treatment, has never 
been assessed. The metabolic state of microbiota and the metabolites produced have recently 
been the subject of keen interest by the community. In studies involving drug-resistant 
bacteria, it was found that inducing metabolic activity in bacteria led to loss of resistance to 
antibiotics.303,304 As such, it is unclear whether low-dose tetracyclines may have an effect on 
bacteria specifically in inflammatory lesions which are metabolically active. Unsurprisingly, the 
total metabolome in the gut of the host is affected by antibiotic treatments,305,306 leading to 
increased susceptibility to infection.307 It remains to be determined whether metabolites 
produced by bacteria may be affected by low-dose antibiotic treatments, and whether this may 
have a downstream inflammation-modulating consequence. 
For paradoxical psoriasis (Figure 6), we know that there is a cell-intrinsic effect on pDCs 
which causes increased pathogenic type-I interferon production. It is not known whether in 
paradoxical psoriasis TNF blockade may also play in concert with type-I interferon275 in 
maintaining a pro-bacterial environment which drives an even further enhanced type-I 
interferon production. Moreover, this may influence downstream inflammation and contribute 
directly to type-I interferon-driven pathology in paradoxical psoriasis. Increased rates of 
superinfection in lesions of paradoxical psoriasis182 may reflect this, though it is unclear 
whether it affects the inflammatory environment and how. Furthermore, it is unclear whether 
the virome, fungiome, and parasitome may also play a role. 
Understanding of upstream activators of the pathogenic pathway in rosacea and paradoxical 
psoriasis may elucidate targets for therapeutic intervention. Another approach, which has been 
successful for the treatment of psoriasis, is to target downstream effectors.   
4.5. DOWNSTREAM INNATE MEDIATORS OF TYPE-I INTERFERON-DRIVEN SKIN INFLAMMATION 
Currently, the treatment of psoriasis relies on targeting of the TNF-IL23-TH17 axis. Targeting of 
the TH1 or TH22 component of psoriasis has not yielded particular efficacy. Other diseases, 
which have considerable clinical and molecular similarities, may also benefit from similar 
treatment strategies. 
 Pityriasis rubra pilaris (PRP) is a rare skin disorder of unknown aetiology that causes 
orange scaly patches with well-defined borders and may affect the entire body. Each case is 
unique, and no specific or consistently effective therapy exists.  We find that targeting of the IL-
12/23 cytokines leads to pronounced amelioration of the condition, and loss of IL -17 
expression. Intriguingly, IFNγ and TNF stabilisation lags behind the amelioration, suggesting 
that IL-23/TH17 (and not IL-12/TH1) is specifically targeted (Appendix 3).
308 We find that, like 
psoriasis and PRP, rosacea and paradoxical psoriasis have an important  TH1 and TH17 
component, with clear upregulation of IL-17, IL-22, IL-23, IL-12, and IFNγ. Targeting IL-23/TH17 
is effective for a surprising number of skin, but also joint and gut-associated, diseases and thus 
may be worth exploring for rosacea and paradoxical psoriasis. This is especially interesting in 
light of a conserved pathogenic role for the type-I interferon pathway, but also given 
overexpression of TH1/TH17- (but not TH2)-associated cytokines.
291,309,310 Using pre-clinical 
models of disease, such as the paradoxical psoriasis model, or the rosacea-reminiscent KLK5-
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 mediated spontaneous inflammation genetic model, could provide important clues as to the 
potential efficacy of treatment via targeting of downstream cytokines which are pathogenic in 
other skin disorders. 
Ongoing work will elucidate whether, during innate inflammation such as for paradoxical 
psoriasis, type-I interferon acts upstream of an IL-23/TH17-related axis that may be targeted as 
in psoriasis. 
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 5. APPENDICES 
Five appendices are attached to this thesis. 
Appendix 1 – TNF blockade induces a dysregulated type I IFN response without autoimmunity 
in paradoxical psoriasis 
Appendix 2 – Rosacea-associated bacteria activate plasmacytoid dendritic cell-derived type-I 
interferon driving flare-ups of disease 
Appendix 3 – Interleukin 23-helper T cell 17 axis as a treatment target for pityriasis rubra 
pilaris 
Appendix 4 – Targeting CD8+ T cells prevents psoriasis development 
Appendix 5 – Table of licence numbers for permissions to re-use and modify material from 
Nature Publishing Group  
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ABSTRACT 18 
Although anti-Tumour necrosis factor (TNF) agents are highly effective in the treatment of 19 
psoriasis, 2-5% of treated patients develop psoriasis-like skin lesions called paradoxical psoriasis. 20 
The pathogenesis of this side effect and its distinction from classical psoriasis remain unknown. 21 
Here, we show  that skin lesions from patients with paradoxical psoriasis are characterized by a 22 
selective overexpression of type I interferons, dermal accumulation of plasmacytoid dendritic 23 
cells (pDC), and reduced T cell numbers, when compared to classical psoriasis. Anti-TNF 24 
treatment prolongs type I interferon production by pDCs through inhibition of their maturation. 25 
The resulting type I interferon overexpression is responsible for the skin phenotype of 26 
paradoxical psoriasis, which, unlike classical psoriasis, is independent of T cells. These findings 27 
indicate that paradoxical psoriasis represents an ongoing overactive innate inflammatory process, 28 
driven by pDC-derived type I interferon that does not lead to T cell autoimmunity.  29 
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INTRODUCTION 30 
Tumour necrosis factor (TNF) is a homotrimeric cytokine produced by immune and epithelial 31 
cells in response to infection or tissue injury1,2. TNF exerts potent pro-inflammatory functions via 32 
activation of immune cells and vascular endothelial cells2-4. Increased TNF expression levels can 33 
be found at sites of inflammation in many autoimmune diseases, such as rheumatoid arthritis, 34 
Crohn's disease, or psoriasis5-7. TNF blockade is highly efficacious and has become the 35 
benchmark in management of these diseases8-11. As such, more than two million patients have 36 
been treated with TNF blockers.  37 
Nevertheless, TNF blockade as a therapeutic option has its limitations. Long-term TNF 38 
neutralization increases susceptibility to infections and skin cancer12,13. Another common side 39 
effect of TNF blockade is the development of inflammatory skin lesions, which resemble 40 
psoriasis and are observed in 2-5% of patients receiving anti-TNF therapy14-18. These skin 41 
manifestations are called “paradoxical psoriasis”, as TNF blockade is usually highly efficacious 42 
in psoriasis treatment. Notably, this side effect even occurs in patients undergoing successful 43 
psoriasis treatment with anti-TNFs. More severe cases necessitate interruption or complete 44 
cessation of anti-TNF therapy and, for several diseases, no equivalent alternative treatments exist. 45 
Therefore, understanding the pathogenic mechanism underlying paradoxical psoriasis, and its 46 
distinctions from classical psoriasis, remains a critical issue for the future design of successful 47 
therapeutic and preventive measures.  48 
Classical psoriasis is a chronic, autoimmune skin disease mediated by T cells19-21. Evidence for a 49 
pathogenic role of T cells stems from the following observations: first, T cell targeted therapies 50 
including cyclosporine (inhibition of calcineurin in activated T cells), DAB-IL-2 (interleukin-51 
2 receptor-specific fusion toxin)22, and inhibitors of T cell costimulation, including alefacept23, 52 
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efalizumab24, and CTLA-4-Ig25, are efficacious in psoriasis treatment; second, HLA-Cw6 53 
represents the strongest genetic risk variant associated with psoriasis26; third, clinically-relevant 54 
xenotransplant models of psoriasis are dependent on T cells27-29; and, finally, lesional T cells are 55 
oligoclonal and recognize epidermal autoantigens30-34. These pathogenic T cells mediate the 56 
chronic and relapsing course of psoriasis and define it as an autoimmune disease.  57 
Autoimmune T cell responses in psoriasis are initiated by a subset of dendritic cells called 58 
plasmacytoid dendritic cells (pDCs), which infiltrate pre-psoriatic skin and are activated to 59 
produce type I interferons (IFN)35. pDC-derived type I IFNs unleash the autoimmune response by 60 
promoting activation and maturation of conventional DCs (cDCs) that stimulate expansion of 61 
autoreactive T cells. These autoreactive T cells – in particular CD8+ T cells – migrate into the 62 
epidermis, where they recognize keratinocyte autoantigens and induce keratinocyte 63 
hyperproliferation28,36. Whether paradoxical psoriasis follows a similar pathomechanism remains 64 
unknown. 65 
Here, we show that paradoxical psoriasis induced by anti-TNF is characterized by an exaggerated 66 
type I IFN response, which does not lead to T cell autoimmunity. Anti-TNF antibodies directly 67 
increase the capacity of pDCs to produce type I IFNs, by inhibiting their maturation. The 68 
exaggerated type I IFN response induced by anti-TNF treatments is sufficient to trigger a 69 
psoriatic skin phenotype. However, in contrast to classical psoriasis, type I IFN fails to induce 70 
cDC maturation and the subsequent activation of autoimmune T cells that is required for a 71 
chronic-relapsing disease course. Thus, paradoxical psoriasis is a side effect of an anti-TNF 72 
treatment stemming from an overactive, but self-limiting innate inflammation driven by pDC-73 
derived type I IFN.  74 
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RESULTS 75 
Clinical characterisation of paradoxical psoriasis 76 
We analyzed 25 paradoxical psoriasis patients as summarized in Supplementary Table 1. Mean 77 
age of the patients was 44.8 years (range 15 to 73 years). Mean duration of anti-TNF treatment 78 
until onset of paradoxical psoriasis was 9.5 months (range 3 weeks to 5 years). Anti-TNF therapy 79 
indications include Crohn’s disease (n=6), psoriasis and/or psoriatic arthritis (n=8), ankylosing 80 
spondylitis (n=8), rheumatoid arthritis (n=1), as well as SAPHO (n=1) and juvenile rheumatoid 81 
arthritis (n=1). Patients were treated with the anti-TNF antibodies infliximab (n=10), adalimumab 82 
(n=10), certolizumab (n=1), and golimumab (n=2), and the TNF-receptor fusion protein 83 
etanercept (n=2). Anti-TNF-induced paradoxical psoriasis appeared independent of the 84 
underlying diseases or the type of anti-TNF agent used (SupplementarySupplementary Table 1). 85 
Paradoxical psoriasis regressed in all patients when anti-TNF therapy was discontinued, but 86 
relapsed or persisted in 7 of 11 cases (64%) when anti-TNF treatment resumed. These relapses 87 
occurred despite switching to another anti-TNF agent. Importantly, no relapses were seen upon 88 
discontinuation of anti-TNF treatment, which suggests that paradoxical psoriasis does not 89 
represent de-novo psoriasis. The clinical presentation showed great variations reminiscent of 90 
classical psoriasis in its clinical forms (plaque-type, guttate, pustular) or particular sites of 91 
involvement (palmoplantar, scalp, skin folds) (Figure 1 and Table 1). However, we also observed 92 
some clinical particularities of paradoxical psoriasis, including a higher frequency of 93 
palmoplantar involvement as compared to classical psoriasis (80% versus 2-19% 37,38) and severe 94 
noncicatricial alopecia, in numerous cases with scalp involvement (Figure 1). Histopathology of 95 
paradoxical psoriasis showed a large spectrum with three identifiable patterns: an eczematiform 96 
spongiotic pattern, a psoriasis-like pattern (with different amounts of intraepidermal or 97 
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subcorneal neutrophilic infiltration), and a lichenoid pattern with focal interface dermatitis 98 
(Figure 1). However, these patterns were usually overlapping, presented at variable degrees in 99 
most cases, and did not correlate to the clinical presentations. These findings suggest that 100 
paradoxical psoriasis is a transient side effect induced by TNF blockade independent of treatment 101 
type (class effect) with diverse clinical and histological presentations resembling psoriasis. 102 
 103 
High IFN expression and PDC numbers in paradoxical psoriasis 104 
We analyzed mRNA expression levels of selected innate cytokines involved in the pathogenesis 105 
of psoriasis to identify expression patterns unique to paradoxical psoriasis. We observed no 106 
significant difference in the expression levels of TNF, IL23A, IL12A, IL36G, IL8 (CXCL8), IL6, 107 
and IL1B when comparing skin lesions from paradoxical psoriasis with classical psoriasis (Fig. 108 
2a). In contrast, type I IFNs IFNA2 and IFNB1 expression was greatly increased in paradoxical 109 
psoriasis relative to chronic plaque psoriasis (Fig. 2a). Importantly, high levels of type I IFN 110 
expression were observed in all samples, despite the variability in clinical and histological 111 
presentation. Thus, uniform high levels of type I IFN expression in lesional skin characterize 112 
anti-TNF-induced paradoxical psoriasis. Interestingly, adaptive T cell derived cytokines IL17A, 113 
IL17F, IL17C, IL26, IFNG, IL4, and IL10 show comparable levels in skin biopsies from 114 
paradoxical and classical psoriasis (Fig. 2b). However, we found significantly increased IL22 115 
expression in paradoxical psoriasis, which correlated significantly with the increased type I IFN 116 
expression (IFNA2 r=0.567, p<0.005; IFNB1 r=0.474, p=0.017; calculated by Spearman’s rank-117 
correlation).  118 
IFNs are preferentially expressed by pDCs, or natural type I IFN-producing cells. They can 119 
produce 50-100-fold more type I IFNs than any other cell type. We therefore investigated 120 
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whether pDCs are present in paradoxical psoriasis skin lesions by staining paraffin-embedded 121 
sections with CD123 (IL3RA). CD123+ lymphoid cells in skin represent bona-fide pDCs35, as 122 
demonstrated by co-staining with BDCA2 (CLEC4C) in selected cryo-samples of paradoxical 123 
psoriasis (Fig. 3b). pDCs were absent in normal skin from healthy volunteers. However, 124 
confirming previous studies 39, we found large numbers of pDCs in paradoxical psoriasis skin 125 
lesions (Fig. 3a). This increase was significantly greater than the number of pDCs found in 126 
classical plaque psoriasis (Fig. 3c). Expression of both IFNA2 (Fig. 3d) and IFNB1 127 
(Supplementary Figure 1) significantly correlated with pDCs quantity, suggesting that they 128 
represent the principal source of type I IFN. Notably, pDC accumulation coincides with elevated 129 
type I IFN expression at a uniform rate regardless of the clinical or histological phenotype in 130 
paradoxical psoriasis. 131 
 132 
Anti-TNF enhances IFN by inhibiting PDC maturation 133 
Given the increased IFNA2 expression in anti-TNF-induced paradoxical psoriasis, we 134 
investigated whether TNF blockade would enhance IFN-α production by pDCs directly.  As 135 
LL37 complexed with DNA has been shown to activate pDCs in psoriasis40,41, and because 136 
CAMP mRNA expression (corresponding to LL37) in paradoxical psoriasis was comparable to 137 
psoriasis (Supplementary Figure 2), we used LL37/DNA complexes as stimulus to activate 138 
enriched human peripheral blood pDCs in the presence or absence of anti-TNF antibodies. TNF 139 
blockade significantly enhanced IFN-α production by stimulated pDCs measured 48 hours after 140 
stimulation (Fig. 3e,f). This was direct effect of TNF blockade and not mediated by Fc-receptors 141 
as shown by a similar IFN-α increase when using certolizumab, a Fc-free Fab-fragment of a 142 
monoclonal antibody, but not an irrelevant human IgG antibody (Supplementary. Figure 3a,b). 143 
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Furthermore, addition of recombinant TNF to the culture strongly suppressed IFN-α production 144 
by activated pDCs (Fig. 3f) indicating that TNF controls IFN-α production by pDCs. To gain 145 
further insights into the mechanisms by which TNF controls IFN-α production, we performed 146 
time course analyses of cytokine expression in activated pDCs. IFNA2 expression occurred early, 147 
peaking at 24 hours, whereas TNF expression increased at later time points (48 hours and 72 148 
hours after stimulation) and coincided with the decrease of IFNA2 expression (Fig. 3g). Anti-149 
TNF antibodies did not affect early IFNA2 expression but markedly increased its levels at 48 150 
hours and 72 hours, indicating that TNF blockade prolongs the ability of pDC to produce type I 151 
IFNs (Fig. 3h and SupplementarySupplementary Figure 4). Moreover, addition of recombinant 152 
TNF to the culture shortened IFNA2 expression by pDCs (Fig 3h). Together these data show that 153 
IFN-α precedes TNF expression and suggest that TNF replaces IFN-α by inhibiting its 154 
expression. Because TNF drives pDC differentiation into mature DCs which lose their ability to 155 
produce IFN-α42, we hypothesized that anti-TNF would prolong type I IFN production of 156 
activated pDC by inhibiting their maturation. Indeed, anti-TNF significantly decreased 157 
maturation of pDCs as shown by reduced surface expression of HLA-DR (CD74) 48 hours after 158 
activation (Suppl Figure 5a,b). Anti-TNFs also reduced expression of costimulatory molecules 159 
CD80 and CD86, as well as maturation marker CD83, on activated pDCs 160 
(SupplementarySupplementary Figure 5c-g). Addition of recombinant TNF, which suppressed 161 
IFN-α production by pDCs, strongly upregulated expression of CD80, CD86, and CD83 162 
(SupplementarySupplementary Figure 5c-g). These data suggest that TNF controls the duration 163 
of IFN-α production by promoting differentiation of pDCs into mature DCs. Consequently, TNF 164 
blockade inhibits pDC maturation and prolongs their ability to produce IFN-α, providing an 165 
explanation for high levels of type I IFN in anti-TNF induced paradoxical psoriasis. 166 
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 167 
ANTI-TNF INCREASES IFN AND PDC NUMBERS IN THE SKIN 168 
Next, we studied whether anti-TNFs are sufficient to increase type I IFN production in-vivo 169 
utilizing a skin injury mouse model. In this mouse model, repetitive tape stripping leads to a 170 
short-lived pDC infiltration into injured skin, peaking at 24 hours and declining at 48 hours (Fig. 171 
4a)43. Anti-TNF treatment promoted significant increased and sustained pDC infiltration (Fig. 4a, 172 
b), which paralleled prolonged type I IFN expression (Fig. 4c). Importantly, pDC depletion 173 
largely abrogated this type I IFN expression, which confirmed in-vivo that pDCs are the principal 174 
source of type I IFNs following TNF blockade (Supplementary Figure 6). Similar to the human 175 
in-vitro data, TNF blockade in-vivo significantly inhibited pDC maturation as shown by a 176 
decreased expression of Cd80 and Cd86 (Fig. 4d). Interestingly, blocking type I IFN-signaling by 177 
an anti-type I IFN-receptor (anti-IFNAR) antibody significantly reduced the numbers of pDCs 178 
infiltrating injured skin (Fig. 4e). As CXCR3-ligands CXCL9, CXCL10, and CXCL11 are 179 
induced by type I IFNs and mediate pDC migration into the skin44,45, we analyzed their 180 
expression in our mouse model. Indeed, we found a significant, type I IFN-dependent 181 
overexpression of Cxcl10 and Cxcl11 in the skin of anti-TNF treated mice at 24, 48, and 72 182 
hours, as anti-IFNAR treatment completely abrogated their expression (Supplementary Figure 7). 183 
These data show that type I IFN production sustains skin infiltration of pDCs and suggest an 184 
amplification loop in which type I IFN produced by pDC promotes additional pDC infiltration 185 
into the skin. These data demonstrate that blocking TNF decreases pDC maturation and enhances 186 
type I IFN production by pDCs to amplify their skin infiltration. 187 
 188 
Anti-TNF promotes paradoxical psoriasis via IFN 189 
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Transient type I IFN production by pDCs promotes wound healing43, whereas sustained 190 
expression may initiate classical psoriasis development35,46. Because anti-TNF treatment in wild-191 
type mice increases pDC accumulation and type I IFN production in the skin, we determined 192 
whether it also induced a psoriasis-like phenotype. Indeed, 6-7 days after tape stripping, the 193 
epidermis of anti-TNF treated mice showed typical hallmarks of psoriasis including acanthosis, 194 
parakeratosis, and a focal loss of the granular layer. In addition, we observed basal and 195 
suprabasal Ki67 expression indicative of keratinocyte hyperproliferation and involucrin 196 
expression throughout the entire epidermis suggesting abnormal keratinocyte differentiation (Fig. 197 
5a-d). In contrast, the epidermis of control mice was similar to untreated skin showing minimal 198 
Ki67-positive keratinocytes and involucrin expression within the upper epidermal layers (Fig. 5a-199 
d). We then treated mice with anti-IFNAR antibodies to determine if enhanced type I IFN 200 
induced the psoriatic phenotype. Inhibition of type I IFN-signaling decreased the anti-TNF-201 
induced psoriatic phenotype to levels indistinguishable from control mice (Fig. 5e,f). Together, 202 
these data indicate that anti-TNF induces a psoriatic phenotype through enhanced and sustained 203 
type I IFN production by pDCs. These data provide a mechanism that underlies paradoxical 204 
psoriasis.  205 
 206 
Development of paradoxical psoriasis is T cell-independent 207 
Type I IFN production by pDCs triggers classical psoriasis35 through activation of conventional 208 
DCs (cDC) and expansion of autoimmune T cells. These pathogenic T cells are direct triggers of 209 
epidermal hyperproliferation and their persistence in the skin and circulation of psoriasis patients 210 
are responsible for chronicity and the recurrent disease course19-21. Because paradoxical psoriasis 211 
does not represent true psoriasis as it never relapses upon cessation of anti-TNF (Supplementary 212 
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Table 1), we next asked whether T cells play a role in paradoxical psoriasis. We depleted 213 
conventional T cells in our paradoxical psoriasis mouse model using anti-TCR-beta antibody 214 
administration. T-cell depleted mice treated with anti-TNF developed a psoriasis-like phenotype 215 
with increased acanthosis that was similar to non-depleted control mice treated with anti-TNF 216 
(Fig. 6a,b). Because unconventional T cells such as γ/δ-T cells have been implicated in the 217 
development of psoriasiform skin inflammation in mouse models47, we treated Rag2-/- mice, 218 
which are deficient of both conventional α/β-T cells and γ/δ-T cells, with anti-TNF. Similar to 219 
wild type mice, anti-TNF treated Rag2-/- mice developed a psoriatic phenotype with significantly 220 
increased epidermal thickness (Fig. 6a,c). These data indicate that neither conventional T cells, 221 
nor γ/δ-T cells are required for the type I IFN-driven keratinocyte hyperproliferation. To 222 
investigate the role of T cells in human paradoxical psoriasis, we quantified CD8+ T cells 223 
infiltrating the epidermis, which represent the pathogenic T cell subpopulation in psoriasis28,36. 224 
Compared to the large numbers of CD8 T cells present in the epidermis of classical psoriasis 225 
(n=11), a significantly lower number of CD8+ T cells was present in the epidermis of paradoxical 226 
psoriasis (n=16) (Fig. 6d-f). CD8+ T cells were completely absent in normal skin of healthy 227 
donors (n=5). Because mature cDCs in psoriatic skin represent the key stimulators of pathogenic 228 
CD8+ T cells to migrate into the epidermis, we next quantified mature cDCs in skin samples 229 
using the maturation marker LAMP3. We found a significantly increased number of LAMP3+ 230 
cDCs in the skin of classical psoriasis as compared to skin from healthy donors (Fig. 6g). In 231 
contrast, there were significantly fewer LAMP3+ cDCs in paradoxical psoriasis suggesting a lack 232 
of cDC maturation despite the increase type I IFN expression (Fig. 6g-i). Taken together, these 233 
data suggest that paradoxical psoriasis represents an overactive type I IFN-driven innate 234 
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inflammation that does not lead to cDC maturation with consequent T cell-mediated autoimmune 235 
response as in classical psoriasis.  236 
237 
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DISCUSSION 238 
This study identifies the pathophysiological mechanism underlying anti-TNF-induced 239 
paradoxical psoriasis. By comparing skin lesions of paradoxical psoriasis with classical psoriasis, 240 
we found a selective and uniform increase of type I IFN expression along with a marked dermal 241 
accumulation of pDCs. Using in-vitro and in-vivo models, we then demonstrated that anti-TNFs 242 
directly prolong the ability of pDCs to produce type I IFN. The resulting overexpression of type I 243 
IFNs is sufficient to drive the development of the psoriatic skin phenotype observed in 244 
paradoxical psoriasis, which, in contrast to classical psoriasis, is independent of T cells.  245 
A link between anti-TNFs and increased type I IFN expression has been suggested by previous 246 
findings that anti-TNF therapy induces a type I IFN signature in blood of juvenile arthritis 247 
patients48 and can exacerbate lupus, a well-known type I IFN-driven autoimmune disease49,50. 248 
Using a combination of in-vitro and in-vivo studies, we now unravel the mechanism by which 249 
this occurs: TNF temporally controls and limits type I IFN expression by pDCs, and this effect 250 
can be reversed by anti-TNFs. Upon stimulation of pDCs, type I IFN production occurs first and 251 
is subsequently relayed by TNF production, which drives pDC maturation into DCs that lose the 252 
ability to produce type I IFNs51. Therefore, by promoting pDC maturation, TNF directly controls 253 
and limits the duration of type I IFN production by pDCs. On the other hand, blocking of TNF 254 
activity by anti-TNFs decreases pDC maturation and thereby prolongs the ability of pDC to 255 
produce type I IFN. Together our findings suggest a yin-yang model in which there is a temporal 256 
equilibrium between early type I IFN and late TNF expression48 that is shifted by TNF blockade 257 
towards a prolonged and excessive type I IFN response. 258 
Our study shows, that the type I IFN overproduction in paradoxical psoriasis is required for the 259 
development of a psoriatic skin phenotype. This finding raises questions about the differences 260 
Appendix 1 - TNF blockade induces type I IFN
without autoimmunity in paradoxical psoriasis
73
14 
 
between paradoxical psoriasis and classical psoriasis, which is also driven by an early type I IFN 261 
production by pDCs35. Our data show that, unlike classical psoriasis, which is a T cell-mediated 262 
autoimmune disease, development of paradoxical psoriasis is independent of T cells. Therefore, 263 
both paradoxical psoriasis and classical psoriasis are triggered by pDCs and type I IFN, but only 264 
classical psoriasis develops into a T cell-mediated relapsing autoimmune disease. In contrast, 265 
paradoxical psoriasis fails to elicit an adaptive immune response and remains fixed in an ongoing 266 
pDC-driven innate immune response. These findings explain why there is no disease memory in 267 
paradoxical psoriasis while classical psoriasis is characterized by T cell-mediated recurrent flare-268 
ups. There are two possible explanations for the lack of T-cell autoimmunity in paradoxical 269 
psoriasis. In classical psoriasis, the type I IFN response is rapidly replaced by increasing levels of 270 
TNF, which is critical for the maturation of cDCs that stimulate T cells46. In the context of 271 
paradoxical psoriasis, TNF blockade inhibits the induction of mature cDC and subsequent T cell 272 
activation, while magnifying type I IFN-driven innate inflammation. Another possibility is that 273 
paradoxical psoriasis patients lack genetic risk variants that drive and regulate T cell 274 
autoimmunity. In fact, variants involving T cell activation and Th17 differentiation including 275 
IL23A, IL23R, IL12B, HLACw6, RUNX3, STAT3, and TRAF3IP2 genes have been identified in 276 
classical psoriasis52,53.  277 
The mechanisms by which type I IFNs promote the psoriatic skin phenotype are currently 278 
unclear. Type I IFN itself does not induce keratinocyte proliferation nor is it responsible for the 279 
altered differentiation54. Most likely, type I IFN activates immune cells releasing cytokines that 280 
drive the development of a psoriatic phenotype. One possible link between type I IFN and 281 
keratinocyte hyperproliferation is IL22, which induces epidermal remodeling by promoting 282 
proliferation of keratinocytes55,56. Indeed, type I IFN drives IL22 expression, as absence of type I 283 
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IFN-signaling completely abrogates induction of IL22 expression in skin43. Accordingly, IL22 is 284 
selectively upregulated in paradoxical psoriasis and significantly correlates with type I IFN 285 
expression. The cellular source of IL22 remains unclear. Because T cells do not play a role in 286 
paradoxical psoriasis, potential candidates include innate lymphoid cells (ILC3), NK cells57, mast 287 
cells58, and neutrophils59, which have all been reported to express IL22. 288 
In addition to increased type I IFN expression, higher numbers of skin pDCs are observed in 289 
paradoxical psoriasis as compared to classical psoriasis. The increased pDC numbers is not a 290 
direct anti-TNF effect, but rather dependent on the type I IFN overexpression induced by TNF 291 
blockade. Although the exact mechanisms by which type I IFN drives pDC infiltration in 292 
paradoxical psoriasis remains to be elucidated, CXCR3-ligands induced by type I IFNs may 293 
prolong the recruitment of pDCs into the skin in a self-amplifying loop44.  294 
Our study also identifies a new mouse model for the induction of a psoriasiform skin phenotype 295 
with acanthosis, basal keratinocyte hyperproliferation, and altered epidermal differentiation. This 296 
model displays the following three key features of human paradoxical psoriasis, which are clearly 297 
distinct from classical psoriasis. First, the psoriatic phenotype in this model is induced and not 298 
blocked by anti-TNFs; second, like in paradoxical psoriasis, the phenotype in this model is T cell 299 
independent, whereas classical psoriasis is a T cell mediated disease; and finally, the model 300 
shows sustained type I IFN expression, which is in line with the persistent type I IFN expression 301 
in the skin of paradoxical psoriasis but not classical psoriasis.  An intriguing question is why anti-302 
TNF is able to induce a psoriatic phenotype in wild-type mice and enhance type I IFN production 303 
by pDCs from blood of healthy donors, but only 2-5% of anti-TNF treated patients develop 304 
paradoxical psoriasis. The future identification of specific genetic variants potentially involving 305 
pDC activation and/or type I IFN-signaling may provide an explanation for an increased 306 
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susceptibility of these individuals to develop paradoxical psoriasis in the context of anti-TNF 307 
treatment. 308 
In conclusion, this study identifies the relevance of the temporal equilibrium of TNF and type I 309 
IFN (TNF-IFN yin-yang) in the pathogenesis of paradoxical psoriasis. While TNF controls type I 310 
IFN under steady-state conditions, anti-TNF treatment may tip the balance towards type I IFN 311 
ultimately driving the psoriatic phenotype in paradoxical psoriasis. In contrast to classical 312 
psoriasis, paradoxical psoriasis fails to turn into a T cell-mediated autoimmune disease with a 313 
relapsing course but remains a drug-related side effect in which inflammation perpetuates in self-314 
amplifying innate immune response. These findings provide the basis for the design of new 315 
strategies targeting pDCs and type I IFN for the treatment and prevention of paradoxical 316 
psoriasis.  317 
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METHODS 318 
CLINICAL DATA 319 
This study was performed in accordance with the guidelines of the Declaration of Helsinki and 320 
was approved by the local ethics committee (Ethics Committee Vaud, swissethics). Clinical data 321 
of 25 patients with paradoxical psoriasis were collected at the Department of Dermatology, 322 
University Hospital CHUV, Lausanne (n=16) and the Department of Dermatology, University 323 
Hospital of Zurich (n=9) between 2011 and 2013. Paradoxical psoriasis was defined as newly 324 
appearing psoriasiform skin lesions under anti-TNF therapy despite response to treatment. 325 
Skin biopsies 326 
Skin biopsies were taken from patients with paradoxical psoriasis or untreated classical plaque 327 
psoriasis after written informed consent was obtained. Human samples were fixed using 4% 328 
paraformaldehyde for immunohistochemistry (samples available from all 25 patients) or snap-329 
frozen and stored at -80ºC for RT-PCR (cryomaterial available from 14 out of the 25 patients). 330 
Paraffin-embedded skin sections were deparaffinized, stained with anti-CD123 (BD 331 
Pharmingen), anti-LAMP3 (Sino Biological, 10527-RP02-50), or anti-CD8 (DAKO, C8/144B), 332 
and visualized using standard horseradish peroxidase-technique. For quantitative RT-PCR, cDNA 333 
was synthesized using Superscript II reverse transcriptase (Invitrogen) and relative Gene 334 
expression was quantified using specific Taqman probes (Life technologies, Supplementary 335 
Table 2) and expressed as 2-CT using GAPDH as endogenous control. 336 
For immunofluorescence analyses of mouse tissue, cryopreserved skin samples were stained with 337 
anti-involucrin (Covance, PRB-140C-200, 1/400) or anti-Ki-67 (eBiosciences, SolA15, 1/1000) 338 
followed by labeled secondary antibody. For flow-cytometry analysis, mouse skin was digested 339 
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with Dispase (Sigma-Aldrich) and collagenase (Invitrogen) and stained with anti-B220 FITC (BD 340 
Pharmingen, RA3-6B2, 1/400), anti-CD45 PerCp-Cy5.5, (BD Pharmingen, 30-F11, 1/400), anti-341 
CD11c PE, (eBioscience, N418, 1/800), and anti-PDCA1 APC (Biolegend, 927, 1/400), anti-342 
CD80 PE (BD Pharmingen, 16-10A1, 1/800) or anti-CD86 PE (BD Pharmingen, GL1, 1/800). 343 
For flow-cytometry analyses of human pDCs, antibodies used include anti-CD123 APC 344 
(Biolegend, 6H6, 1/400), anti-BDCA2 PE (Miltenyi, AC144, 1/400), anti-BDCA4 APC 345 
(Miltenyi, REA-380, 1/400) anti-CD80 PE (BD Pharmingen, 16-10A1, 1/800), anti-CD83 FITC 346 
(eBioscience, HB15e, 1/400), anti-HLADR (BD Pharmingen, G46-6, 1/400). Assessors were 347 
blinded for all histological quantifications. 348 
CELL CULTURE EXPERIMENTS 349 
Plasmacytoid DCs (pDCs) were purified from peripheral blood mononuclear cells obtained from 350 
blood buffy coats of healthy donors by Ficoll separation followed by enrichment using a CD304 351 
Microbeads kit (Miltenyi Biotech). pDCs were cultured in RPMI 1640 + GlutaMAX (Gibco) 352 
supplemented with 10% FBS and 1% penicillin/streptomycin and stimulated with 10µg/ml 353 
human DNA (Biochain) complexed with 50µg/ml LL-37 (Proteogenix) with or without 1µg/ml 354 
anti-TNF antibodies (Adalimumab, Humira®), or 100ng/ml recombinant human TNF (RnD). 355 
After 48 hours of culture, interferon (IFN)-α was measured in cell-free supernatants by ELISA 356 
(Mabtech). 357 
MOUSE MODELS 358 
All animal experiments were performed according to institutional guidelines and Swiss federal 359 
and cantonal laws on animal protection. Ethical approval was obtained for all described 360 
experimentation according to regulations by the Federal Food Safety and Veterinary Office 361 
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(FSVO). Animals were maintained and bred in pathogen-free facilities. Age- (8-10 weeks old) 362 
and sex-matched mice were used for all experiments. Female wild type Balb/c mice were 363 
purchased from Jackson Laboratory, hBDCA2-DTR (hCLEC4C-DTR) mice were bred at our 364 
facility. Skin injury was performed as previously described43. Briefly, mice were anaesthetized 365 
and their lower backs shaved using clippers, and then depilated using the commercially available 366 
Veet® cream. After cream removal with a paper tissue, 10 gentle strokes of commercially 367 
available tape (ScotchTM, 3M) were applied to the lower back. Dosage of antibodies applied was 368 
deduced from therapeutic use in humans and injected intraperitoneally as follows: 1500µg of 369 
anti-TNF (Infliximab, Remicade®) at days -1 and 0; 200µg of anti-TCRβ (BioXCell, h57-597) at 370 
days -2, 0, 2, and 4; 250µg of anti-IFNAR (BioXCell, MAR1-5A3) at days -1, 0, 1, and 3. We 371 
used Remicade because it was previously shown to efficiently block both human and mouse 372 
TNF60. However, as a positive control, we used a mouse-specific anti-TNF antibody 373 
(Supplementary Figure 8). As a negative control, we used an irrelevant human IgG antibody 374 
(Supplementary Figure 8). Effective blockade of type I IFN-signalling by the anti-IFNAR 375 
antibody is demonstrated by the absence of type I IFN-response genes at day 7 after mechanical 376 
injury (Supplementary Figure 9). For pDC-depletion experiments, 120ng of diphtheria toxin was 377 
injected intraperitoneally into hBDCA2-DTR mice at day -1. At indicated time points, injured 378 
skin was excised for histology, flow cytometry, and gene expression analysis. 379 
STATISTICS  380 
Unpaired non parametric Mann-Whitney U test was used for analysis of human gene expression 381 
and histological analysis. To investigate an association between pDCs and type I IFN gene 382 
expression, the Spearman’s rank-correlation coefficient was calculated. For preclinical mouse 383 
data, Student’s t-test was used to perform statistical analyses. All testing was two-sided, and a p 384 
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value of less than 0.05 was considered to indicate statistical significance. All analyses were 385 
performed with GraphPad Prism 6.0. 386 
 387 
DATA AVAILABILITY  388 
All relevant data are available from the corresponding authors upon reasonable request. 389 
 390 
391 
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Figure 1 
a Patient 1 
b Patient 2 
c Patient 3 
Fig. 1. Clinical and histological presentation of paradoxical psoriasis induced by anti-TNF. (a-c) Photographs of 
cutaneous lesions and corresponding histopathology of three individual patients presenting paradoxical psoriasis. (a) Patient 
1 with small erythemato-squamous plaques disseminated over the entire body resembling guttate psoriasis and palmoplantar 
psoriasis-like lesions. Histology with a classical psoriasis pattern with acanthosis, papillomatosis, parakeratosis, and loss of 
the granular layer, but with spongiosis. (b) Patient 2 with partially crusted, eczematiform lesions on her legs and trunk, 
palmoplantar psoriasis-like lesions, and severe scalp involvement. Histology with acanthosis, papillomatosis, also in addition 
to spongiosis and minimal interface dermatitis. (c) Patient 3 with small erythematous plaques and pustules. Non-cicatricial 
alopecia on the site of scalp involvement. Histology with acanthosis, papillomatosis, and spongiosis. Scale bars represent 
100μm. Clinical signs and histopathology of the patients shown are representative of the patient population in this study.
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Fig. 4. Anti-TNF increases plasmacytoid dendritic cell infiltration and type I interferon production in vivo. (a) 
Plasmacytoid dendritic cell (pDC) numbers infiltrating the skin upon mechanical injury of the back of mice treated with 
or without anti-TNF. pDCs quantified by flow cytometry at indicated time points. (b) One representative contour plot 
for each group at indicated time points. (c) Total skin mRNA expression of the type I interferons Ifna6 and Ifnb1 upon 
mechanical injury of mice treated with or without anti-TNF at indicated time points. (d) Expression of co-stimulatory 
molecules Cd80 and Cd86 on skin infiltrating pDCs 48 hours after mechanical skin injury of mice treated with or 
without anti-TNF. (e) Percentage of pDCs infiltrating the skin of mice upon mechanical injury in the presence or 
absence of anti-TNF and/or anti-IFNAR antibodies. Experiment depicted in (a, c) is representative for at least 3 
independent experiments using at least 3 mice per group. Bar charts in (d) show mean values plus S.E.M. of 6 mice, with 
pDCs from skin of 2 mice pooled for each data point; one representative contour plot for each group (2 mice pooled) is 
depicted in the right panel (d). All statistical analyses were performed with unpaired Student’s t-test. 
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Fig. 6. Induction of paradoxical psoriasis is independent of conventional T cells. (a) Quantification of acanthosis 
7 days after mechanical injury of wild type mice, wild type mice treated with anti-TCRβ antibody, and Rag2-/- mice, 
all of which were treated with or without anti-TNF antibody. (b) Representative HE-staining of skin 7 days after 
mechanical injury of mice treated with anti-TCRβ antibody alone or anti-TCRβ and anti-TNF antibodies combined. 
(c) Representative HE-staining of skin 7 days after mechanical injury of Rag2-/- mice treated with or without anti-
TNF antibody.  (d) Number of epidermal CD8+ T cells per high-power field in skin lesions of patients with classical 
psoriasis and paradoxical psoriasis. (e,f) Representative CD8-staining of paradoxical psoriasis (e) and classical 
psoriasis (f). (g) Number of dermal LAMP3+ cells per high-power field in skin of healthy donors as well as in skin 
lesions of patients with classical psoriasis and paradoxical psoriasis. (h,i) Representative LAMP3-staining of 
paradoxical psoriasis (h) and classical psoriasis (i). Experiment depicted (in a-c) is representative for 2 independent 
experiments. Bar charts in (a) show mean values plus S.E.M. of 5 mice each group. Dashed line in (b,c,e,f,h,i) 
represents border between epidermis above and dermis below. Arrows point at intraepidermal CD8+ T cells in 
paradoxical psoriasis (e) or dermal LAMP3+ cells (h) respectively. Scale bars represent 100μm in (b,c,e,f,h,i). All 
statistical analyses were performed with unpaired Student’s t-test. anti-TCRβ = anti-T cell receptor beta chain-
antibody. 
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Supplementary Figure 1: Correlation of plasmacytoid dendritic cells and IFNβ. 
Correlation of numbers of CD123-positive plasmacytoid dendritic cells with gene 
expression of IFNB1 in skin lesions of paradoxical psoriasis. Dots represent individual 
patient. For statistical analysis, the Spearman’s rank-correlation coefficient was 
calculated. pDCs = plasmacytoid dendritic cells. 
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Supplementary Figure 2: CAMP expression in classical and paradoxical psoriasis. 
mRNA expression analysis of CAMP (LL37) relative to GAPDH in skin lesions of 
paradoxical psoriasis compared to classical plaque psoriasis. Dots represent individual 
patient and horizontal bar denotes the median value. Data shown as mRNA expression 
level relative to mean expression in classical psoriasis (mean value for classical psoriasis 
was set at 1). Statistical analysis was performed with unpaired non parametric Mann-
Whitney U test. CAMP = cathelicidin antimicrobial peptide.  
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Supplementary Figure 3: Promotion of IFN-α by different anti-TNF antibodies. IFN-α 
produced by plasmacytoid dendritic cells isolated from healthy volunteers, 48 hours upon 
stimulation with DNA-LL37 complexes with or without (a) anti-TNF agents – either a 
monoclonal antibody (adalimumab) or a FC-free antigen-binding fragment (Fab’) of a 
monoclonal antibody (certolizumab pegol) or (b) an irrelevant human IgG antibody or a 
monoclonal anti-TNF antibody (adalimumab). Data depicts one representative experiment 
of five (a) or three (b) independent experiments with cells from different healthy volunteers 
for each experiment. ADA = adalimumab (Humira®), CZP = certolizumab pegol (Cimzia®). 
Error bars in represent S.D. of duplicate wells.  
LL37/DNA 
- - ADA CZP 
IF
N
-α
 (
pg
/m
l) 
0
1000
2000
3000
IF
N
-α
 (
pg
/m
l) 
LL37/DNA 
- - IgG ADA 
a 
b 
Appendix 1 - TNF blockade induces type I IFN
without autoimmunity in paradoxical psoriasis37
97
01000
2000
3000
Supplementary Figure 4: Extended IFN-α production promoted by anti-TNF. IFN-α 
produced by plasmacytoid dendritic cells isolated from healthy volunteers and kept in 
culture for 6 hours, 24 hours or 48 hours respectively, upon stimulation with DNA-LL37 
complexes either with anti-TNF antibodies or addition of TNF. Data depicts one 
representative of three independent experiments with cells from three different healthy 
individuals.  
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Supplementary Figure 5: Inhibition of plasmacytoid dendritic cell-maturation by anti-TNF. HLA -DR  
(CD 74) expression  on plasmacytoid  dendritic cells  isolated  from peripheral  blood of healthy volunteers  48 hours  
upon activation with DNA -LL 37 complexes  with (black  line) or without anti-TNF  antibodies  (gray  shaded  area),  
with (black  line) or without TNF  (a,  b). Expression  of co-stimulatory molecules  CD 80 (c,  d) and CD 86 (e) as  well 
as  maturation marker  CD 83 (f,  g) on plasmacytoid  dendritic cells  isolated  from healthy volunteers  48 hours  after 
stimulation with 1μM CpGB  in the presence  or absence  of anti-TNF  or TNF .  Experiments  depicted in (a, c, and 
f) are  represent ative for at least  5 independent experiments,  each  with blood from dierent healthy volunteers .
Statistical  analyses  were performed with paired Student’s  t-test. gMFI  = geometric  mean  uorescence  intensity,  
FSC  = forward scatter .
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Supplementary Figure 6: Plasmacytoid dendritic cell-dependent type I interferon overexpression. 
Gene expression of the type I interferons Ifna6 and Ifnb1 in anti-TNF-treated mice in uninjured skin and 
upon mechanical injury in the presence or absence of plasmacytoid dendritic cells. The mean ± SEM is 
given and represent data from three mice. Experiment depicted is representative for at least 2 
independent experiments. Statistical analyses were performed with unpaired Student’s t-test. pDC = 
plasmacytoid dendritic cells. 
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Supplementary Figure 8: Similar skin phenotype induced by anti-murine anti-TNF. 
Quantification of epidermal thickening (acanthosis) in mice treated with PBS, irrelevant 
human IgG antibody, the anti-TNF antibody infliximab (Remicade), or an anti-mouse 
anti-TNF antibody 7 days after mechanical injury by tape stripping. Statistical analyses 
were performed with unpaired Student’s t-test. PBS = phosphate buffered saline, hu-IgG 
= irrelevant human IgG antibody, INX = infliximab, anti-mTNF = anti-murine anti-TNF 
antibody, n.s. = not significant 
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One Sentence Summary: Flare-ups of rosacea are driven by type-I interferon production by 
pDCs which can be triggered by commensal bacteria, thus providing novel therapeutic targets. 
Abstract: Rosacea is a chronic skin inflammatory disease characterised by recurrent flare-ups, 
but it is unclear how they are induced. Microbial pattern recognition is thought to trigger flare-
ups, and is known to induce potent innate antimicrobial responses. Cathelicidin antimicrobial 
peptides have been identified in rosacea, and are aberrantly processed by Kallikrein 5 proteases 
leading to potent pro-inflammatory responses. Mature cathelicidin LL-37 is known to activate 
plasmacytoid dendritic cells (pDCs) to produce large amounts of type-I interferons (IFN-I) via 
internalisation of exogenous nucleic acids. We find overexpression of IFN-I specifically during 
flare-ups of rosacea, with concomitant pDC infiltration. TH1, TH17 and TH22 signature genes are 
elevated across the entire cohort, irrespective of active flare or stabilised lesions. Using an 
intradermal injection model of rosacea, we find that pDCs are the major producers of IFN-I and 
that, as with blockade of IFN-I, there is a substantial reduction of TH17-related cytokines and a 
loss of IL22. Moreover, we find that Bacillus oleronius, a bacterium-associated and infesting 
lesions of rosacea, is most sensitive to cathelicidin-mediated killing and a potent activator of 
pDCs and IFN-I production both in vitro and in vivo, suggesting that it may be a trigger of IFN-I 
driven flare-ups of rosacea. Furthermore, we find that commensal skin bacteria are required for 
induction of type-I interferons in situ, and that cathelicidin-killed B.oleronius is sufficient to 
drive type-I interferon expression. Among rosacea-associated cathelicidins, we find that FR-29 is 
more potent than LL-37 for nucleic acid binding, internalisation into pDCs and bacterial killing, 
leading to more potent IFN-I production both in vitro and in vivo. Our observations indicate that 
aberrant processing of cathelicidins can result in microbial-dependent, pDC-driven flare-ups of 
rosacea. 
Appendix 2 - Commensal bacteria activate
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Introduction 
Rosacea is an inflammatory condition affecting the facial convexities and characterised 
by recurring flare-ups. Microbial dysbiosis is a defining feature of rosacea, with apparent 
infestation with Demodex folliculorum as one hallmark diagnostic criterion in the vast majority 
of cases. These commensal mites flourish in hair follicles deep in the dermis of rosacea and are 
the base of deep inflammatory infiltrates. Bacillus oleronius has been identified as the principal 
bacterium harboured by D.folliculorum, and is thought to be shed by the mite following death of 
the obligate ecto-parasite. This reservoir for bacteria has been suggested to be a trigger for 
disease and antibiotics are routinely used in the treatment of rosacea. 
Microbe-associated molecular patterns are well described to induce antimicrobial 
peptides for controlling foreign agents. Cathelicidin antimicrobial peptide (CAMP) has been 
identified as one such antimicrobial agent induced in keratinocytes downstream of bacterial 
pattern recognition receptors such as TLR2, and undergoing proteolitic processing for activation. 
Enzyme processed forms of CAMP such as LL-37, FR-29, FA-29 and DI-27 have been 
identified in lesions of rosacea, but only LL-37 and FA-29 have been described to cause 
erythema in mice. LL-37 has been shown to be able to bind bacterial as well as human nucleic 
acids, to allow its condensation, and thus to be able to activate endosomal toll-like receptors- 
(TLR-) 7 and 9 in plasmacytoid dendritic cells (pDCs). Notably, pDCs produce vast amounts of 
type-I interferons and have been described to be implicated in the pathogenesis of other 
inflammatory skin diseases such as psoriasis. 
Recently, it has been reported that rosacea has a predominant TH1, TH17/22 cytokine 
signature with several chemokines expressed across different stages of rosacea. Flare-ups are 
thought to be triggered by external stimuli such as from bacteria, but little is known about the 
pathogenic mechanisms that subsequently drive inflammation during flare-ups. We report that 
type-I interferons are overexpressed selectively in acute flare-ups of rosacea, and that pDCs are 
required for this signature. In vivo blockade of either IFNAR signalling or pDC depletion result 
in a loss of the IL22 and TH17-related cytokine response induced by cathelicidin driven 
inflammation, as well as of select chemokine families. Among cathelicidin antimicrobial 
peptides identified in rosacea, we identify FR-29 as being able to activate pDCs to produce type-
I interferon more potently than LL-37, through increased nucleic acid binding and pDC 
internalisation capacity. Surface commensals are necessary for induction of type-I interferons, as 
topical antibiotics abolish the interferon signature. Finally, we find that killing of the rosacea-
associated bacterium B.oleronius by cathelicidins is sufficient to drive type-I interferon in vivo at 
the site of inflammation, providing a possible mechanism for initiation of the inflammatory 
events during acute flare-ups of rosacea. 
 
 
Results  
Type-I interferon overexpression correlates with pDC infiltration in flares of rosacea 
Cathelicidin peptides such as LL-37 were identified in lesional rosacea skin.(1, 2) As the 
peptide LL-37 has been described to be an inducer of type-I interferons during the pathogenesis 
of psoriasis,(3–7) we wondered whether there may also be a detectable interferon signature in 
rosacea. We obtained biopsies from lesions of 8 patients with rosacea during stabilised chronic 
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inflammation and from 16 others during acute flare-ups. The cathelicidin transcript hCAP18 was 
upregulated in all patients with rosacea as compared to healthy donours (Fig.1a), corroborating 
previous observations.(1) Type-I interferon genes are significantly upregulated selectively in 
patients with active flare-ups of rosacea as compared to healthy donours (IFNA2: p<0.0001, 
IFNB1: p<0.0001). Chronic lesions display low type-I interferon expression, similar to healthy 
skin, indicating a selective overexpression early during rosacea flare-ups. Interferon-response 
gene MX1 was significantly overexpressed as compared to healthy donours (p<0.0001), with no 
significant difference between sub-acute and acute flare-ups (p=0.6529), suggesting a previous 
interferon burst in stabilised lesions. 
Given the magnitude of expression of type-I interferons, we investigated the presence of 
pDCs in lesional skin of rosacea. Paraffin-embedded sections of the same biopsies from the 16 
patients taken during acute flare-ups, reveal pDC stainings in the dermis across all patients 
(Fig.1b) and samples were overlade with positive cells in relation to other infiltrates (Fig.1c). 
When plotting the percentages of CD123+ cells along with IFNA2 (Fig.1d) and IFNB1 (not 
shown) we found statistically significant (IFNA2: p=0.0011, IFNB1: p=0.0002) monotonic 
positive correlation between the two (IFNA2: r2=0.5422, IFNB1: r2=0.6322), indicating that 
pDCs may be the principal source of type-I interferons during flare-ups of rosacea. 
Innate and adaptive cytokines associated with TH1/17/22, but not TH2, are overexpressed in 
rosacea 
Because type-I interferon genes are strongly overexpressed exclusively and only during 
acute flare-ups of rosacea, we wondered whether other pro-inflammatory cytokines might be 
differentially expressed. We assessed conventional pathogenic innate and adaptive cytokine 
expression. We find a strong TH1 signature with significant overexpression of TNF, IFNG, 
IL12B (Fig.2a and b). There is no detectable expression of the TH2 cytokine IL4 and no 
overexpression of IL13. In contrast, TH17 and TH22 cytokines IL17A, IL17F and IL22 were 
significantly overexpressed as were cytokines known to be required for their induction including 
IL6, IL23A, IL1B but not the IL1-family IL36B. Among cytokines tested, only TNF is 
significantly underexpressed in acute rosacea flare-ups as compared to stable rosacea (Fig. 2c), 
in stark distinction to IFNα and β. Other than type-I interferons, only IL10 displays significant 
overexpression in acute rosacea flare-ups compared to stabilised lesions (Fig. 2c). 
Type-I interferon expression is critically dependent on pDCs in a mouse model of rosacea 
The positive correlation between pDCs and type-I interferon expression suggests that 
pDCs may be responsible for the observed overexpression. To determine whether pDCs might be 
directly responsible for interferon production during flare-ups of rosacea, we sought to verify if 
the pDC-IFN axis is relevant in a previously described in vivo model of rosacea.(1) We find in 
situ pDC recruitment (Fig.3a) and accumulation over time (Fig.3b), which correlate (r2=0.992) 
significantly (p=0.004) for both IFNα and β genes (Pearson correlation). Type-I interferon genes 
are induced and increase over time, concurrently with pDC infiltration (Fig.3c). Antibody-
mediated cell depletion of pDCs negates most induction of interferon α and severely diminishes 
interferon β gene expression (Fig.3d). Downstream interferon stimulated genes ISG15 and IRF7 
are largely abolished, with a significant reduction of MX2 and IFI202b. Similar results were 
achieved using a different pDC depletion system, the BDCA2-DTR transgenic mouse (Suppl. 
Fig.1). Type-I interferon signalling blockade leads to complete loss of all interferon-response 
genes, as expected.  
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Type-I interferon blockade and pDC depletion abolishes select Th1/22 signatures, and CXCR3 
and CCR1/5-family chemokines 
To understand the contribution of type-I interferon genes and pDCs to inflammatory 
cytokines, we investigated in situ expression of cytokines found overexpressed in rosacea. 
Inflammation brought on by LL-37 induces strong innate inflammatory cytokines including Th1-
polarising cytokines IL12A and TNF, Th17/22-polarising cytokines IL1B, IL23A, IL36B, and IL6, 
and IL10 (Fig.4a). Of these, TNF, IL1B, IL23A, and IL6 were significantly dependent on pDCs 
and type-I interferon signalling, whereas IL12A was selectively dependent on pDCs. IL36B and 
IL10 were induced independently of type-I interferons and pDCs. Adaptive cytokines of the 
TH17/22 family IL17A, IL17F and IL22 were induced by the cathelicidin LL-37 in situ, as were 
TH2 cytokines IL4 and IL13, and Th1 cytokine IFNG (Fig. 4b). Among these, only IL22, and to a 
lesser extent IL17F, were highly dependent on pDCs and type-I interferon signalling. 
Furthermore, several chemokines shown to be overexpressed in rosacea are strictly dependent on 
IFNAR signalling and pDCs, such as the CXCR3-family chemokines CXCL9, 10 and 11 and to 
some degree chemokines of the CCR-family CCL2 and CCL5 (Fig.4c). Unexpectedly, CXCL1 is 
also significantly reduced upon loss of type-I interferon signalling, but not the IL-8 functional 
homologs in the mouse CXCL2 and CXCL15. Other chemokines described to be upregulated in 
rosacea do not appear to be dependent on type-I interferon such as CXCL12, CXCL13, CCL19 
and CCL20. Strikingly, interferon α/β genes were also abrogated upon IFNAR blockade 
(Fig.3d), suggesting that interferon requires a self-propagating loop to achieve its full breadth of 
expression. Moreover, IFNAR blockade led to a significant reduction of pDC infiltration (Suppl. 
Fig. 2) in line with loss of type-I interferon gene expression. Put together, these results indicate 
that, during skin innate inflammation induced by cathelicidin LL-37, pDCs are required for type-
I interferon expression, and that the latter is necessary for interferon feed-forward mechanisms. 
Blockade of the IFNAR pathway, both by depletion of pDCs or direct blockade, did not 
influence by a noticeable degree the observable erythema (Suppl. Fig. 3). Put together, these data 
suggest that type-I interferon derived from pDCs is an important inducer of IL22 and of known 
TH17-polarising cytokines in the skin, potentially via targeted recruitment of specialised cell 
types, yet this does not considerably affect erythema using concentrations found in chronic 
disease. 
FR-29 induces type-I interferons by strongly binding and complexing DNA more potently than 
other cathelicidins found in rosacea 
It is widely established that LL-37 is able to activate pDCs to produce large amounts of 
type-I interferons by internalising extracellular nucleic acids. Because cathelicidin is processed 
into several C-terminal peptides, among which LL-37, FR-29, FA-29 and DI-27 directly 
identified in rosacea lesions, we wondered whether these had a differential ability to activate 
pDCs. To address this, we isolated human pDCs which we stimulated with DNA-cathelicidin 
derived peptide complexes. For the same molar concentration, FR-29 activates pDCs to produce 
IFNα more potently than LL-37, but only in the presence of DNA (Fig.5a). FA-29 and DI-27 are 
unable to stimulate detectable amounts of IFNα from pDCs in vitro. When reducing the 
concentration of peptides bellow the stimulatory capability of LL-37 to 3μM, FR-29 still retains, 
albeit drastically reduced, stimulatory capacity. Concurrently, in vivo intradermal injection of 
FR-29 induces more potent interferon α gene expression than LL-37, for the same molar 
concentration (Fig. 5b). In contrast, in vivo pDC infiltration was similar between FR-29 and LL-
37 suggesting that difference is due to differential activatory capacity of the cathelicidin peptides 
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(Fig. 5c). We assessed the DNA-binding capacity by picogreen fluorescence quenching, and 
found that for the same concentration of DNA, FR-29 binds DNA more potently than LL-37 
(Fig.5d). Conversely, FA-29 has greatly reduced and DI-27 has almost indiscernible DNA 
binding activity. To assess the capacity of FR-29 and LL-37 to condense and internalise DNA 
into pDCs, we fluorescently tagged purified, undigested DNA, and complexed it with the 
cathelicidin peptides LL-37 and FR-29. Whereas the proportion of pDCs that could uptake 
fluorescently labelled DNA in the absence of cathelicidin peptides was near null, LL-37 and FR-
29 both allow the uptake in ca. 10% of cells (Fig.5e). However, the relative uptake of DNA was 
more pronounced when complexed with FR-29 than with LL-37. Taken together, these data 
indicate that several fragments found in rosacea such as FA-29 and DI-27 cathelicidin peptides 
cannot activate pDCs, whereas others such as FR-29 have a more potent effect than LL-37 due to 
an increased affinity to nucleic acids. 
Cathelicidin peptides kill bacteria associated with rosacea leading to activation of pDCs 
To better elucidate the role of pDCs and antimicrobial cathelicidins in the pathogenesis of 
rosacea, we wanted to address whether there may be a context-specific source of nucleic acids. 
Rosacea is known to have an altered microbiome and to be infested particularly with bacteria 
such as Bacillus oleronius and Staphylococcus epidermidis. Among cathelicidin peptides tested, 
we find that FR-29 is most potent for killing of skin-associated bacteria B.oleronius and 
S.epidermidis, followed by LL-37 and to a lesser extent FA-29 (Fig.6a). FR-29 is less or equally 
efficient as LL-37 in the bacterial killing of other bacteria often associated to the gut and the lung 
such as E.coli, P.aeruginosa, and K.pneumoniae (Fig.6b). DI-27 is mostly unable to impair 
bacterial growth in all conditions tested. Intriguingly, among bacteria tested, B.oleronius is most 
sensitive to cathelicidin-mediated killing, followed by S.epidermidis and P.acnes (Fig.6c). pDCs 
are described to be responsive to antimicrobial peptide-killed bacteria,(8) we wondered whether 
LL-37-killed B.oleronius could activate pDCs. For this, we isolated human pDCs from multiple 
donours and put them in culture with live bacteria with or without LL-37. Whereas intact 
B.oleronius alone is not able to activate pDCs, the addition of LL-37 allows for potent activation 
of pDCs leading to important production of IFNα (Fig.6d). Concurrently with previous results, 
FR-29 is able to activate pDCs more potently than LL-37 when in the presence of B.oleronius. 
To understand whether B.oleronius is able to induce type-I interferon in the context of aberrant 
overexpression of LL-37 such as is the case in rosacea, we compare LL-37 alone, B.oleronius 
alone, and B.oleronius in the presence of LL-37 in vivo. Whereas B.oleronius alone is not able to 
induce type-I interferon expression, we find that B.oleronius pre-incubated with LL-37 induces 
significantly more type-I interferon expression (Fig. 6e), suggesting that bacterial load alone is 
not sufficient to engage the type-I interferon pathway. To elucidate whether commensal bacteria 
are necessary for induction of type-I interferons by exogenous LL-37, we treated mice with 
Neosporin® containing wide-spectrum antibiotics for 48h, followed by the standard cathelicidin 
LL-37 mediated inflammation. We find that type-I interferon expression is significantly reduced 
upon antibiotic treatment of the skin (Fig. 6f). Interestingly, antibiotic treatment followed by 
injection of B.oleronius pre-incubated with LL-37 leads to strong induction of type-I interferons. 
Taken together, these data suggest that cathelicidin peptides LL-37 and FR-29 found in rosacea, 
are able to induce type-I interferons potently in a pDC-reliant manner. B.oleronius, found in the 
lesions of rosacea is a potential source of nucleic acids for pDC activation. Moreover, 
commensal bacteria are required, and B.oleronius is sufficient for type-I interferon induction by 
cathelicidins. 
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Discussion 
We find that type-I interferons are selectively and uniformly upregulated in patients with rosacea 
specifically during active flare-ups. Intriguingly, downstream interferon-response genes, which 
are longer lived than type-I interferons, are found upregulated also in stabilised lesions. This 
suggests previous interferon induction, thus pointing to the cyclical nature of type-I interferon 
bursting during the progression of the disease. Fuelled by this observation, we set out to 
investigate the role and origin of the type-I interferon pathway in rosacea flares. We find that 
pDCs are actively recruited to the site of inflammation and that they are critically required for 
type-I interferon expression, and of downstream interferon-response genes. We describe a 
mechanism by which type-I interferons control Th22 and Th17-polarising cytokine expression in 
situ following cathelicidin LL37-mediated inflammation. Moreover, cathelicidins specifically 
described in rosacea have differential capacities to activate pDCs in vitro and in vivo, suggesting 
that the imbalance of cathelicidin processing can have pathogenic repercussions. Finally, we find 
that commensal bacteria are necessary to induce LL37-mediated type-I interferon induction, and 
that bacteria found in rosacea, in the presence of cathelicidin peptides, are sufficient to drive the 
type-I interferon pathway. 
Our data indicate a primary role of pDCs in the production of type-I interferons during acute 
flare-ups of rosacea. Recent elegant studies demonstrate that, during chronic inflammation, 
keratinocytes can be an important source of IFNβ in the skin.(9) Intriguingly, we find that, unlike 
IFNα, IFNβ expression is not entirely abolished upon pDC depletion. Furthermore, certain 
interferon response genes such as MX2, which are known to be strongly expressed particularly 
within the epidermis following interferon stimulation, are significantly reduced but not abolished 
in their entirety. This may indicate that keratinocytes could be a potential source of IFNβ also 
upon acute inflammation. 
Commensal bacteria are known to populate normal skin, but also to often be deregulated in 
cutaneous disorders. It is well regarded that rosacea has a strong microbial component associated 
to the disease, in particular as to infestation with demodex mites which harbour commensal 
bacteria such as B.oleronius and S.epidermidis. We find that among cathelicidins tested, FR-29 is 
vastly superior to LL-37 and other cathelicidin fragments in killing of certain bacteria, in 
particular B.oleronius and S.epidermidis, but not of other bacteria. This differential killing 
capacity of cathelicidin peptides may reflect an attempt to control the increase in microbial 
burden observed in rosacea, providing broad-spectrum antimicrobial specificity. It remains to be 
determined whether there is a specific microbial detection signal which influences protease 
activity to generate specific fragments, or whether this is stochastic effect dependent on 
microbial burden. 
We and others have observed a pathogenic role for pDCs that gain access to the skin, for diseases 
such as psoriasis,(3, 7) lupus,(10) and scleroderma.(11) These skin associated disorders share a 
major common feature which usually is overt autoimmunity. Rosacea is not generally regarded 
as an autoimmune disease, and for now only few studies have focused on the genetics of the 
disease.(12, 13) Herein, we propose a mechanism by which the pDC-IFN axis is engaged during 
flare-ups of disease and can induce innate inflammation which can become self-sustained in 
predisposed individuals. There is increasing molecular evidence for a progression between stages 
of rosacea(14), and therefore continuous flare-ups of disease may prime a constantly aggravated 
inflammatory response. As such, targeting type-I interferon signalling during flare-ups may be a 
viable target for the treatment of rosacea. Though targeting IFNα has not proven to be successful 
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in the treatment of chronic plaque-type psoriasis,(15) it is now postulated to play a role in the 
acute rather than chronic phases of psoriasis.(16) Furthermore, the difficulty of targeting all type-
I interferons might also be responsible for the failure of the trial, with IFNβ not being directly 
targeted. There is considerable success from trials in lupus, both for selective inhibition of 
IFNα(17, 18) and for indiscriminate IFNα/β blockade through the inhibition of the receptor.(15, 
19) Additionally, newer biologics are currently being trialled, targeting specifically pDCs 
(NCT02847598), and these may provide wider type-I interferon inhibition without affecting local 
antiviral immunity. Our data indicate that pDC blockade is sufficient to inhibit Th17-related 
cytokines and IL22 induction in situ, at the site of inflammation, thus making such approaches 
relevant for the treatment of rosacea. 
Several key questions remain to be addressed as to the similarities and potential differences 
between rosacea, lupus and psoriasis. For one, it is intriguing that similar mechanisms are 
involved in diseases with rather different histo-pathological outcome. Genetics may define key 
differences between these, yet whereas there has been considerable focus on the genetics of 
psoriasis(20–22), little success has been achieved in capitalising novel landmark discoveries for 
rosacea.(12) It is suggested that association with polymorphisms in intergenic HLA-DRA, B, 
DQA and DQB regions may be in connection with presentation of antigens from extracellular 
sources, providing a potential link with microbes. Fundamental differences between psoriasis 
and rosacea might be related to the composition of the microbial flora, which is well known to 
influence inflammatory processes. We provide evidence that, in the right circumstances, 
antimicrobial peptides such as FR-29 in conjunction to infestation with hyper-susceptible 
bacteria, will lead to potent type-I interferon induction. The presence of B.oleronius in the 
demodex mite likely provides it with protection, allowing it to thrive beyond control out of the 
reach of the immune system. Its shedding following the normal life-cycle of the mites, or 
environmental stresses such as UV light, could initiate release of the bacterium, thus provide the 
nucleic acid content required for the triggering of type-I interferons and flare-ups of disease.  
In summary, we find that during flare-ups of rosacea, type-I interferons are robustly 
overexpressed and derived from pDCs. Using a mouse model of rosacea, we identify that both 
type-I interferon signalling and pDCs maintain a Th17-favourable environment at the site of 
inflammation. Aberrantly processed antimicrobial cathelicidins display differential bacterial 
killing and nucleic acid binding capacities, which dictate increased activation of pDCs both in 
vitro and in vivo. Finally, we find that among bacteria tested, B.oleronius is many fold more 
susceptible to cathelicidin-mediated killing, and coupled with its increased numbers in lesions of 
rosacea, this suggests that it may be the source of nucleic acids for pDC activation during flare-
ups of disease. Commensal bacteria are needed for induction of type-I interferon, and 
B.oleronius coupled with cathelicidin is sufficient to restore type-I interferon at the site of 
inflammation. 
 
 
 
Materials and Methods 
Human samples. Studies were approved by the local institutional review board of Lausanne, 
Switzerland (ethical approval number 265/12) and Dusseldorf, Germany (ethical approval 
number 2048). After dermatopathological assessment, punch-biopsies were taken with informed 
consent from acute flare-ups or stabilised rosacea lesions. Samples were selected where a 
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Cutaneous Lupus Erythematous diagnosis was unequivocally ruled out by immunopathological 
assessment. Biopsies from healthy individuals were obtained with informed consent from 
residual skin from aesthetic surgery of healthy individuals. Buffy coats from healthy donours 
were obtained from the local transfusion centre and blood bank, with ethical approval from 
cantonal authorities. 
Mouse experimentation. Animal experiments were performed according to institutional and the 
Swiss Federal Animal Protection Act and cantonal laws on animal protection. Consent was 
received from the Swiss Federal Food Safety and Veterinary Office. Balb/cByJ (JAX mouse 
strain) mice were purchased from Charles River Laboratories France and experiments performed 
on age- and sex-matched animals. Intradermal injections of LL-37 were performed as previously 
described unless stated otherwise. Briefly, a 50µL volume of sterile saline, or 250µM of LL-37 
or FR-29 (Proteogenix, France) was injected intradermally 4 times every 12h and mice 
euthanized and biopsied at 48h. Antibodies anti-IFNAR (MAR1-5A3, BioXCell) and anti-
PDCA1 (BX444, BioXCell) were each injected (200µg) 24h prior to intradermal LL-37 
injections. Erythema was scored according to intensity and area of visible redness. B.oleronius 
(104 CFU after overnight culture) was incubated for 12h with 250µM of LL-37, or saline, and 
injected intradermally in a 50µL final volume at 0h and +12h. 
Immunohistochemistry. For immunohistochemistry of human skin, samples were fixed in 4% 
paraformaldehyde and paraffin-embedded. Stainings were performed using anti-CD123 (7G3, 
BD Pharmingen) followed by visualisation using the horseradish peroxidase technique. The 
number of positive cells per high magnification field was normalized to the number non-stromal 
inflammatory cells using automated and standardized counting of round nuclei (ImageJ v1.50b). 
For immunohistochemistry of mouse skin, samples were snap-frozen in Tissue-Tek optimal 
cutting temperature compound (VWR) and cryosections stained using anti-CD34 (RAM34, 
eBiosciences) and visualized using the horseradish peroxidase technique. 
Gene expression analyses. For quantitative real-time PCR, samples were homogenized by 
mechanical disruption using Polytron PT1200E (Kinematica) in Trizol reagent (Invitrogen) and 
total RNA obtained using phenol/chloroform extraction, and isopropanol followed by ethanol 
precipitation methods. RNA was reverse transcribed using SuperScript II reverse transcriptase kit 
(#18064014, Invitrogen). Relative gene expression was determined using TaqMan probes along 
with TaqMan Gene Expression Mix (Lifetechnologies). Values are expressed as 2Δ-ΔCt x 104 
relative to the endogenous control GAPDH and for human samples these were normalized to 
healthy donour expression. 
Flow cytometry. Biopsies of 0.6cm in diameter were taken of the injection site, and skin was 
mechanically disrupted using a sterile scalpel in PBS containing 2mM EDTA. The resulting cell 
suspension was stained in 0.5% FBS/PBS 2mM EDTA using anti-B220 (RA3-6B2, BD 
Pharmingen), anti-CD11c (N418, eBiosciences), anti-CD45 (30-F11, BD Pharmingen), anti-
PDCA1 (927, Biolegend), anti-Siglec-H (eBio440c, eBiosciences). 
pDC stimulations. pDCs were isolated using the Diamond Plasmacytoid Dendritic Cell Isolation 
Kit II (Miltenyi), and cultured 5x104 cells/200µL in RPMI 1640 supplemented with 10% FBS 
and 1% penicillin/streptomycin. Stimulations were performed using 5µg/mL human DNA and 10 
µM or 3 µM of the indicated peptides. Live B.oleronius was added at 105 CFU/mL alone or in 
combination with 5µM of LL-37. IFNα production was measured by ELISA after 24h of 
stimulation using the human pan specific IFN-α development kit (Mabtech). 
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DNA-cathelicidin peptide complex uptake. Isolated pDCs were incubated with 3 µg/mL of Alexa 
Fluor 488-labeled DNA alone or in combination with 1 µM of the indicated peptide at 37C for 
3h in RPMI 1640 (Gibco) supplemented with 10% FBS. 
DNA binding. DNA binding and condensation activity of the cathelicidin peptides was 
determined using a picogreen (Invitrogen) dye fluorescence quenching technique. Peptides were 
added to 2ug of purified human genomic DNA at the indicated final concentrations for 30 
minutes, and picogreen dye added to the samples. Sample fluorescence was determined using 
480nm excitation and measured at 520nm using a spectrofluorometer as indicated by the 
manufacturer. When there is strong peptide-DNA binding, condensed DNA molecules are 
rendered inaccessible to the dye. 
Bacterial killing. Bacterial strains Bacillus oleronius (ATCC 700005), Staphylococcus 
epidermidis (ATCC 14990), Propionibacterium acnes (ATCC 6919), Klebsiella pneumoniae 
(O1:K2), Pseudomonas aeruginosa (ATCC 27853) Escherichia coli (O18:K1:H7) were prepared 
at the indicated working concentrations and incubated with the indicated peptide at working 
concentrations ranging 0.2-10 µM for 5h in PBS, plated and CFU were counted after overnight 
incubation at 37°C, except for P.acnes which was incubated under anaerobic conditions. Values 
are expressed as percentage of survival. Killing potency against human cells was assessed by 
incubating 105 PBMCs in PBS with the indicated peptides and concentrations ranging 0.2-50 
µM, and determined using SYTO13/SYTOX staining and expressed as percentage of surviving 
cells. 
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Fig.1: Type-I interferon expression correlates with pDC infiltration in acute flares of 
rosacea. (A) Gene expression of indicated genes from acute flare-ups (•) and stabilised lesions 
(○) as compared to healthy skin. P-values of two-tailed Mann-Whitney nonparametric unpaired 
t-test are depicted. (B) Rosacea flare-up and healthy skin sections stained for CD123+ pDCs. (C) 
Percentages of CD123+ pDCs were determined in relation to non-stromal inflammatory cells per 
high magnification field as mean of triplicate measurements per patient sample. (D) Percentage 
CD123+ pDCs pictured in (C) plotted against IFNA2 expression from lesions during flare-ups 
pictured in (A). Non-linear regression with least-squares fit is depicted, with corresponding p-
value. 
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Fig.2: Inflammatory cytokine profile in acute flare-ups and stabilised lesions of rosacea. (A) 
Gene expression of innate and (B) adaptive inflammatory genes from acute flare-ups (•) and 
stabilised lesions (○) as compared to healthy skin. (C) TNF and IL10 expression comparison 
between flare-ups and stabilised lesions. P-values of two-tailed Mann-Whitney nonparametric 
unpaired t-test are depicted.  
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Fig. 3: Type-I interferon and downstream response gene expression require pDCs in vivo. 
(A) Dotplots from mouse skin biopsies of LL-37 intradermal injections, pre-gated on CD45+ 
lymphocytes at the indicated timepoints. (B) Quantification of pDC infiltration and (C) IFNA1 
and IFNB1 expression, values expressed as means ± SD of 5 mice per group. (D) Gene 
expression from biopsies following LL-37 intradermal injection in mice depleted of pDCs or 
blockaded of type-I interferon signalling 24h prior to injection. (E) Dotplots and quantification 
from skin biopsies of LL-37 intradermally injected mice, with or without prior antibody-
mediated IFNAR blockade. P-values of two-tailed Mann-Whitney nonparametric unpaired t-test 
are depicted (*: p<0.05; **: p<0.01; ***: p<0.005; ****: p<0.001). 
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Fig. 4: Type-I interferon and pDC contribute to Th1 and Th22, but not Th2, inflammatory 
cytokine expression in situ. (A) Innate and (B) adaptive cytokine, and (C) chemokine 
expression in biopsies obtained from intradermally injected mice with corresponding pre-
treatments. P-values of two-tailed Mann-Whitney nonparametric unpaired t-test are depicted (*: 
p<0.05; **: p<0.01; ***: p<0.005; ****: p<0.001). 
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Fig. 5: Cathelicidin peptide FR-29 activates pDCs more potently than LL-37 by binding 
DNA with more affinity, resulting in more potent internalisation of nucleic acids. (A) 
Isolated human pDCs were stimulated the indicated cathelicidin peptides complexed with DNA, 
and IFNα was measured from supernatants after a 24h stimulation. (B) LL-37, or FR-29, or 
vehicle control (saline) were injected intradermally twice over a 24h period into wild-type Balb/c 
mice, and biopsies taken for gene expression analysis and (C) pDC quantification by flow 
cytometry. (D) DNA-binding efficacy of the indicated cathelicidin peptides as measured by 
picogreen assay. (E) DNA was labelled with Alexa488 according to manufacturer’s instructions, 
incubated with the indicated cathelicidin peptide, and put in culture with isolated human pDCs 
for 3h before measuring the fluorescence by flow cytometry. 
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Fig. 6: Cathelicidin-mediated killing of rosacea-associated bacteria activates pDCs to 
produce IFNα. (A) Skin- and (B) gut- and respiratory tract-associated bacteria killing assay by 
indicated cathelicidins. Bacteria CFU counts were determined after 18h culture in their 
appropriate culture conditions and the corresponding 104-105 CFUs were incubated with the 
indicated peptides at the indicated concentration for 2h, followed by plating and culturing for 
18h. CFUs were counted and calculated as relative percentage of control cultures. (C) Bacteria at 
the indicated CFU were incubated with FR-29 at a constant 10µM concentration for 3h, and 
subsequently CFUs were counted after 18h culture in their appropriate culture conditions. (D) 
Plasmacytoid dendritic cells were isolated from human blood and stimulated with live 
B.oleronius, or B.oleronius pre-incubated with either LL-37 or FR-29, or left unstimulated 
(dotted line) for 24h, and IFNα production was assessed by ELISA. Results are pooled from a 
total of 7 donours. (E) IFNα gene expression from biopsies collected mice injected with LL-37, 
heat-killed B.oleronius, or heat-killed B.oleronius pre-incubated with LL-37, (F) in either 
neosporin treated mice or untreated controls. P-values of two-tailed Mann-Whitney 
nonparametric unpaired t-test are depicted (ns: not significant; *: p<0.05; **: p<0.01). 
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Supplementary Materials: 
 
Fig. S1: pDC depletion in BDCA2-DTR mice leads to loss of type-I interferon and 
downstream response genes during LL37-mediated inflammation. (A) In situ gene 
expression of type-I interferon genes and of (B) downstream interferon-response genes. Mice 
were treated with DT or control injections 24h prior to intradermal LL37 injections. Following 4 
intradermal injections over 48h, biopsies were taken and gene expression analyses performed. P-
values of two-tailed Mann-Whitney nonparametric unpaired t-test are depicted (*: p<0.05; **: 
p<0.01). 
 
Fig. S2: Neither IFNAR blockade nor pDC depletion lead to differential erythema score in 
the LL-37 injection model. (A) Mice were treated with either anti-IFNAR or depleted of pDCs 
using anti-PDCA1 antibodies 24h prior to start of intradermal LL-37 injections. Images are 
representative of each individual group. Erythema scores are defined as mean of two parameters 
which include shade of redness and size of the area affected around the injection site. Data 
depicted are of five mice per group, mean ±SD. 
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Interleukin 23–Helper T Cell 17 Axis as a Treatment Target
for Pityriasis Rubra Pilaris
Laurence Feldmeyer, MD, PhD; Alessio Mylonas, MSc; Olivier Demaria, PhD; AnnaMennella, MSc;
Nikhil Yawalkar, MD; Emmanuel Laffitte, MD; Daniel Hohl, MD; Michel Gilliet, MD; Curdin Conrad, MD
IMPORTANCE Treatment of pityriasis rubra pilaris (PRP) is solely based on its resemblance to
psoriasis rather than any knowledge of its pathomechanism. Insight into pathogenic
mediators of inflammation is essential for targeted and valid treatment options that could
replace previous serendipitous therapeutic approaches in refractory PRP.
OBJECTIVE To determine whether blockade of the interleukin 23–helper T cell 17 (IL-23–TH17)
pathway with ustekinumab represents an efficacious and, based on its proinflammatory
cytokine profile, targeted treatment option in PRP.
DESIGN, SETTING, AND PARTICIPANTS In this case report, a patient with PRP received
outpatient treatment at a university hospital department of dermatology with ustekinumab
according to the dosing regimen approved for psoriasis. Lesional skin biopsy samples were
taken from this patient and 2 others with refractory PRP. Messenger RNA (mRNA) expression
of proinflammatory innate and T-cell–derived cytokines were measured and compared with
skin samples from patients with psoriasis and healthy donors. From 1 patient, lesional skin
samples were taken before ustekinumab treatment and 4 and 28weeks after treatment
initiation. Follow-up was completed after 6months.
INTERVENTION Subcutaneous ustekinumab, 45mg, at weeks 0 and 4 and quarterly
thereafter.
MAIN OUTCOMES ANDMEASURES The primary outcomewas to determine the changes in
expression of proinflammatory innate and T-cell–derived cytokines during ustekinumab
therapy. The secondary objective was to evaluate the clinical and histopathologic phenotype
in relation to themRNA expression profile of proinflammatory cytokines.
RESULTS In lesional PRP skin samples from a single patient, upregulated expression levels
were found for most proinflammatory innate cytokines, including tumor necrosis factor
(TNF), IL-6, IL-12, IL-23, and IL-1β. Among adaptive T-cell cytokines, an increase of TH1
cytokines and, in particular, TH17 cytokines IL-17A, IL-17F, and IL-22 was seen in PRP. The
patient with PRPwho received ustekinumab showed regression of skin lesions after 2 weeks
and almost complete resolution after 1 month. Clinical and histopathologic improvement
paralleled the expression levels of TH17 cytokines but not of interferon-γ and TNF, which
lagged behind the amelioration.
CONCLUSIONS AND RELEVANCE In this case report, a role of the IL-23–TH17-axis in PRPwas
identified, suggesting a shared pathogenic inflammatory pathway with psoriasis, despite
evident clinical and histopathologic differences. In addition, this report provides a rationale
for targeting the IL-23–TH17-pathway as a treatment option for refractory PRP.
JAMA Dermatol. 2017;153(4):304-308. doi:10.1001/jamadermatol.2016.5384
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P ityriasis rubra pilaris (PRP) is a chronic inflammatoryskin disease that typically appears sporadically and isacquired inmost cases.1 Pityriasis rubra pilaris is clini-
cally characterizedby follicularhyperkeratosisonanerythem-
atousbase.Thesepapulesshowatendencytocoalesce, thereby
forming large orange-red plaques with classic demarcated is-
landsof sparing. Pityriasis rubrapilaris frequently involves the
palms and soles, leading to palmoplantar orange-red waxy
keratoderma. Themajor clinical differential diagnosis is pso-
riasis. However, in its most common form, type 1 PRP is typi-
cally self-limited and resolves within 3 years in 80%of cases.
Basedon reported associationswithvarious autoimmunedis-
eases, such as myasthenia gravis, arthritis, and myositis, a
pathogenesisdrivenbyanaberrant immuneresponsehasbeen
suggested. However, the pathogenesis of PRP remains elu-
sive. Thus, treatment of PRP is mainly empirical and, owing
to its resemblance to psoriasis, classic treatments for psoria-
Figure 1. Expression of Helper T Cell 17 (TH17) and TH22 Cytokines in Skin Lesions of Pityriasis Rubra Pilaris (PRP)
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A, Clinical image of a patient in his 40s with PRP shows typical orange-red
follicular papules with scaly centers progressing to a widespread
suberythroderma with islands of normal skin. B, Histopathologic evaluation of
lesional skin with PRP shows a psoriasiform acanthosis (thickening of the
epidermis), irregular hyperkeratosis (thickening of the corneal layer) with
alternating vertical and horizontal orthokeratosis and parakeratosis
(characteristic checkerboard pattern), and keratin plugs in the follicles
(hematoxylin-eosin, bar indicates 100 μm). C, Relative messenger RNA (mRNA)
expression of innate cytokines and adaptive T-cell–derived cytokines in lesional
PRP skin compared with healthy skin shows particularly an upregulation of TH17
cytokines in PRP. Error bars represent range of duplicates. HS indicates healthy
skin; IFN-γ, interferon-γ; IL, interleukin; mRNA, messenger RNA; and TNF,
tumor necrosis factor.
Key Points
Question Does targeting the interleukin 23–helper T cell 17
pathway represent a targeted treatment option for pityriasis rubra
pilaris?
Findings In this case report, gene expression analyses of lesional
skin samples taken from 3 patients with pityriasis rubra pilaris
revealed a preferential helper T cell 17 expression profile. Analyses
of samples from 1 patient performed before and during
anti–interleukins 12 and 23 treatment with ustekinumab showed
that expression levels of helper T cell 17 cytokines, but not of
tumor necrosis factor or interferon-γ, paralleled clinical and
histologic improvements.
Meaning This report identifies a role of the interleukin 23–helper
T cell 17 axis in pityriasis rubra pilaris and provides a rationale for
targeting this pathway as a treatment option for refractory
pityriasis rubra pilaris.
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sis areused.Topical corticosteroids, vitaminDanalogues,pho-
totherapy, systemic retinoids,methotrexate disodium, cyclo-
sporine, and more recently anti–tumor necrosis factor (TNF)
agents have been described.1 In addition, isolated cases of ef-
fective treatment with combined anti–interleukins 12 and 23
(IL-12, IL-23) (ustekinumab) have been published.2,3 None of
these treatments was based on a pathophysiological ratio-
nale, but solely on the resemblance of PRP to psoriasis.
Hereinwereport that thecytokineexpression inPRPshows
a helper T cell 17 (TH17) and TH1 profile and that clinical im-
provement parallels the decrease in lesional TH17 cytokines
during effective anti–IL-12/IL-23 therapy. These findings sug-
gest a role for TH17 cytokines in PRP and provide basis for a
targeted treatment in blocking the IL-23–TH17 axis.
Methods
Skinbiopsy sampleswereobtained from3patientswithPRPat
specified time points. Skin sampleswere fixed using 4%para-
formaldehyde for histopathologic analysis or snap frozen and
storedat−80°C for reverse transcription–polymerase chain re-
actionanalysis (RT-PCR).Paraffin-embeddedskinsectionswere
deparaffinizedandstainedusingastandardhematoxylin-eosin
stainingprotocol.ForquantitativeRT-PCR,complementaryDNA
was synthesized using reverse transcriptase (SuperScript II;
Invitrogen), and relative geneexpressionwasquantifiedusing
specificprobes(TaqMan;LifeTechnologies)andcalculatedusing
the comparative CTmethod,where 2Δ-ΔCt describes the differ-
ence inCTvaluesbetween the target geneandnormalizer gene
[(CT geneof interest − CT internal control) sampleA − (CTgene
ofinterest − CTinternalcontrol)sampleB)]usingglyceraldehyde-
3-phosphate dehydrogenase (GAPDH) as an endogenous con-
trol. Analyseswere performed in duplicates, andmeanvalues
ormean values plus the range of duplicates are depicted. This
studywas performed in accordancewith the guidelines of the
DeclarationofHelsinki4 andwasapprovedby thecantonal eth-
ics committeeofVaud,Switzerland.All patientsprovidedwrit-
ten informed consent.
Report of a Case
Aman inhis 40swith PRPpresentedwithpainful palmoplan-
tar hyperkeratosis, erythema of the face and scalp, and char-
acteristic confluent red to orange follicular papules progress-
ing to suberythroderma (Figure 1A). Diagnosiswas confirmed
by results of histopathologic analysis showing a psoriasiform
dermatitiswith irregular hyperkeratosis and the typical alter-
nating vertical and horizontal orthokeratosis and parakerato-
sis (checkerboard pattern), keratin plugs in the follicles, and a
sparse lymphohistiocytic, perivascular dermal infiltrate
(Figure 1B). Because PRP shares common features with pso-
riasis, we analyzedmessenger RNA (mRNA) expression of in-
nate and adaptive cytokines involved in psoriasis pathogen-
esis.We found upregulatedmRNA expression levels formost
proinflammatory innate cytokines, includingTNF, IL-6, IL-12,
IL-23, and IL-1β in the lesional skin sample of the patientwith
PRP comparedwith normal skin (Figure 1C). Among adaptive
T-cell cytokines, we found a particular increase of TH17 cyto-
kines IL-17A, IL-17F, and IL-22 inPRP comparedwith basal ex-
pression innormal skin, suggesting that these cytokinesmight
play a pathogenic role in PRP similar to that in psoriasis. Pref-
erential overexpression of TH17 cytokineswas confirmed in 2
additional patients with PRP, showing a similar profile
(Figure 2). Furthermore, cytokines of the IL-23–TH17 axis
showed comparable mRNA expression levels in all 3 patients
with PRP and in psoriasis.
Figure 2. Preferential Expression of Helper T Cell 17 and 22 (TH17 and TH22) Cytokines in Skin Lesions of Pityriasis Rubra Pilaris (PRP)
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Messenger RNA (mRNA) expression of innate cytokines and adaptive
T-cell–derived cytokines in the lesional skin samples of 3 patients (the patient in
Figure 1 and 2 additional patients) with PRP compared with healthy skin (HS)
confirms upregulation of proinflammatory innate cytokines and TH17 cytokines
in PRP. Triangles represent individual donor with HS; dots, individual patients
with PRP (open symbol corresponds to the patient in Figure 1). Horizontal bar
denotes themean value. IFN-γ indicates interferon-γ; IL, interleukin; and TNF,
tumor necrosis factor.
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In ourpatient, topical therapies remained insufficient; his
PRP was further aggravated despite 4 months of treatment.
Worsening of the dermatosis on sun exposure prevented us
fromusingphototherapy.Acitretinandmethotrexatewerecon-
traindicatedowing toahistoryofadrug-inducedhepatitiswith
ongoingelevationof liver enzyme levels.Because IL-23 is criti-
cal for the differentiation and expansion of TH17 cells,5,6 and
becausewe found a preferential overexpression of TH17 cyto-
kines, we opted for ustekinumab (Stelara), a human anti–
IL-12/IL-23 antibody approved for severe psoriasis.7
Subcutaneous ustekinumab, 45mg,was given atweeks 0
and4 andquarterly thereafter, according to the psoriasis dose
regimen. The lesions showed regression after 2 weeks and al-
most complete resolution after 1 month (Figure 3A). After 6
months,thetreatmentwasinterruptedandthepatientremained
in remission. The clinical improvement as reflected by the
4-pointPhysicianGlobalAssessment(ameasureofthemeanred-
ness, thickness,andscalingof the lesions,eachgradedonascale
of0-4,withhigher scores indicating increased severity) nicely
paralleled the mRNA expression of IL-17A and IL-17F and, to
somedegree,expressionof IL-22(Figure3B).Ontheotherhand,
although theexpressionofTNFand IFN-γdeclinedeventually,
theirdecreasemarkedlylaggedbehindtheclinical improvement,
whereas IL-1βandIL-10mRNAexpressionremainedunchanged
after6monthsoftreatment.Furthermore,theexpressionofTH17
cytokines also paralleled the improvement of histopathologic
findings, suchasnormalizationof theepidermal thickeningand
the corneal layer and attenuation of the cellular infiltrate
(Figure3C).This findingsuggestsa role forTH17cytokines in the
pathogenesis of PRP and in driving its skin phenotype.
Discussion
Studies of PRP treatment are hampered by the unclear patho-
genesis and the low incidence of the disease; therefore PRP
therapy is based on the results of small case series and case
reports.8,9 Consequently, the therapy for PRP remains largely
Figure 3. Change in Helper T Cell 17 (TH17) Cytokines in Pityriasis Rubra Pilaris (PRP) During TreatmentWith Ustekinumab
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A, Clinical image of the patient with PRP before (week 0) and week 4 after
initiation of anti–interleukins 12 and 23 (IL-12/IL-23) treatment (ustekinumab
[Stelara]) shows rapid improvement. B, Relative messenger RNA (mRNA)
expression of tumor necrosis factor (TNF), interferon-γ (IFN-γ), IL-10, IL-17A,
IL-17F, and IL-22 within the skin at weeks 0, 4, and 28. The different cytokines
are shown overlapped to the Physician Global Assessment (PGA) score to
analyze potential correlation of gene expressions with clinical improvement.
PGA scores range from0 to 4, with higher scores indicating greater severity.
Error bars represent range of duplicates. C, Histopathologic images of lesional
skin samples with PRP at weeks 0, 4, and 28 show reduction of acanthosis,
normalization of hyperkeratosis and parakeratosis toward orthokeratosis, and
disappearance of the dermal inflammatory infiltrate (hematoxylin-eosin).
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empirical and, owing to its clinical and histopathologic simi-
larities topsoriasis, classicpsoriasis treatments arebeingused.
In psoriasis, epidermal hyperplasia is driven by IL-23 and
mediated by IL-17 and IL-22, with IL-22 directly inducing ke-
ratinocyte hyperproliferation.10,11 Furthermore, the block-
ade of IL-12/IL-23, IL-23 specifically, and IL-17 have all been
proven effective in psoriasis.7,12,13 Epidermal thickening, hy-
perproliferationandaltereddifferentiationofkeratinocytesare
alsohallmarksofPRP, renderingTH17cells an interesting thera-
peutic target in PRP. Indeed, we found an increased TH17 ex-
pression profile in skin lesions of 3 patients with PRP and
showed that the expression levels of TH17 cytokines, but not
of TNFor the TH1 cytokine IFN-γ, paralleled clinical improve-
ment during anti–IL-12/IL-23 treatment. Pityriasis rubra pila-
ris is often self-limiting, but theprogressivedisease coursebe-
fore treatment and the rapid response after a single injection
strongly suggest that disease resolution was not spontane-
ous. Furthermore, previous reports in PRP described equally
rapid efficacy on initiation of ustekinumab treatment.3 Suc-
cessful anti–IL-17 treatment of a patient with refractory PRP
was also recently reported, which further supports an effi-
cacy of the IL-23–TH17 blockade in PRP.14
This study indicates a shared inflammatory pathway in
psoriasis and PRP. Interestingly, mutations in the caspase re-
cruitment domain family member 14 gene (CARD14 [HGNC
16446]) havebeen identified in bothdiseases, raising thepos-
sibility that CARD14 is upstream of the IL-23–TH17 pathway.
However, our patient did not display any CARD14 mutation
known in familial15 or sporadic16 PRP.Whether the efficacy of
blocking the IL-23–TH17 pathway is linked to a specific geno-
type and/or clinical subtype remains to be shown.
Despite pathogenic commonalities betweenpsoriasis and
PRP, obvious distinctions remain, such as orange-red waxy
keratoderma, follicular hyperkeratosis, and absence of neu-
trophils in PRP. Future studies should identify pathologic
mechanismsunderlying thesedifferences. Another feature of
PRP is its spontaneous resolution. Interestingly, we found
higher levels of IL-10 in PRP compared with psoriasis, which
persisted on treatment, suggesting a potential anti-
inflammatory pathway in PRP.
Limitations
This study has some limitations owing to the restricted num-
ber of patients included. Additional studies will need to fur-
ther corroborate our findings by treating larger cohorts of
patientswithPRPusingustekinumab,andanti–IL-17–andanti–
IL-23–specific antibodies.
Conclusions
This study identifies a role of the IL-23–TH17-axis in PRP,
suggesting a shared pathogenic inflammatory pathway with
psoriasis. The findings provide a rationale for targeting the
IL-23–TH17 axis as a treatment option for refractory PRP that
could replace previous serendipitous therapeutic approaches.
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Appendix 4 - Targeting CD8 T-cells prevents
psoriasis development1Targeting CD81 T cells prevents
psoriasis development
abundantly present in the psoriatic epidermis and potentiall
recognize peptide antigens presented on MHC class I molecule
such as HLACw6, which is the strongest psoriasis susceptibilitr-
tTo the Editor:
In psoriasis, intraepidermal T cells are predoy
is
.6
1
R
c
n
d
n
l
f
t
xminantly CD81
and represent key effector cells. Here, we show that these
T cells produce pathogenic IL-17 and that neutralization of
CD81 T cells effectively prevents psoriasis development
in vivo.
Psoriasis is a common inflammatory skin disease, resulting
from the interaction of genetic and environmental triggers,
leading to dysregulated immune response of innate and adaptive
immune cells.1,2 T lymphocytes infiltrating psoriasis skin lesions
play key effector roles by driving disease development and
maintenance. Traditionally, CD41 TH cells producing proinflam-
matory cytokines, such as IL-17A, IL-22, and IFN-g, are re-
garded as the main pathogenic T-cell subpopulation. However,
CD81 T cells, which are present in healthy skin as tissue resi-
dent memory T cells (TRM),
3 have been shown to produce a
similar profile of proinflammatory cytokines4; they are
A dermal CD30
5
10
15
20
25
0
20
40
60
80
100
120
N
um
be
rs
of
C
D
3+
T
ce
lls
dermal CD3
epidermal CD3
Ki67
0
5
10
15
20
25
1.0
1.5
2.0
2.5
3.0
3.5
4.0
N
um
be
rs
of
C
D
3+
T
ce
lls epidermal CD3
Papillomatosis
B
day 0 day 7 day 21 day 35
day 0 day 7 day 21 day 35
FIG 1. Expansion of epidermal T cells induces epi
phenotype. Quantification of T-cell numbers during p
0, 7, 21, and 35): dermal (dashed black line, A and B) a
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Table E1 in this article’s Online Repository at www.ja
 2015 The Authors. Published by Elsevier, Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-
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274allele.5 Furthermore, we have previously shown that intraepide
mal T cells represent key effector cells in psoriasis developmen
and that impeding the entry of T cells into the epidermis, b
blocking a1b1-integrin, prevents the development of psorias
in the clinically relevant AGR mouse model of psoriasis
Thus, we set out to explore the pathogenic relevance of CD8
T cells in psoriasis.
We first performed a time course experiment using the AG
mouse model. AGR mice are grafted with noninvolved skin from
patients with psoriasis, which spontaneously develops a psoriati
phenotype after 4 to 6 weeks.6 Thus, at days 0, 7, 21, and 35, ski
transplants were harvested and processed for histological an
immunohistochemical assessment as described previously.6 I
line with earlier findings, while the proliferation of derma
T cells preceded epidermal changes, the numerical expansion o
the epidermal T-cell pool temporally coincided with the onse
of the psoriatic phenotype, as shown by the papillomatosis inde
C Ki67, day 0N
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bers
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keratinoctes
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index
Ki67, day 35
dermal hyperproliferation and onset of a psoriatic
soriasis development in the AGR mouse model (days
nd epidermal (solid black line, A and B) T-cell counts
d number of Ki67-positive keratinocytes per 100 basal
ent. Microscopic view of nonlesional psoriatic skin
tation onto AGR mice and after development of fully
nd tomean values and reflect 1 representative exper-
2 donors (n 5 3-4 transplanted mice for every time
for each parameter and time point are depicted in
cionline.org.
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(Fig 1,A andC, and Conrad et al6).Moreover, the accumulation of
epidermal T cells paralleled the increase in proliferating keratino-
In keeping with the classical distribution of CD41 and CD81
T cells in human psoriatic lesions, intraepidermal T cells in
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FIG 2. Epidermal CD81 T cells are highly pathogenic and their blockade prevents the development of pso-
riasis. Relative frequency (A) and representative zebra plot (B) of CD31CD81 T cells among live CD451 cells
isolated from the epidermis and the dermis of 5 patients with psoriasis, with each patient denoted by a con-
necting line. Functional characterization of epidermal and dermal CD31CD81 T cells as IL-17A1 (C), with
representative zebra plot in (D) IL-17A1IFN-g1 and IL-17A1IL-221 (E) obtained by intracellular cytokine
staining after phorbol 12-myristate 13-acetate/ionomycin stimulation. Each line connects epidermal and
dermal CD81 T cells from the same patient. F,Microscopic changes of nonlesional psoriatic skin quantified
using the papillomatosis index 35 days after transplantation onto AGR mice treated with isotype control
mAb (mean6 SEM, 4.076 0.72), mAb to CD8 (2.176 0.22), or anti-TNFmAb (2.176 0.08).G, Representative
microscopic views of nonlesional psoriatic skin 35 days after transplantation onto AGR mice treated with
isotype control mAb, mAb to CD8, or anti-TNF mAb. B and D, Zebra plot shown is representative of 1 of
5 patients. F, Data shown represent pooled results from 2 independent experiments with skin of 2 patients.
Each symbol represents a transplanted mouse (n 5 5-7). Statistical analyses in A, C, and E were performed
by paired t test and in F with ANOVA followed by Bonferroni correction. All testing was 2-sided, and a P
value of less than .05 was considered to indicate statistical significance.
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Appendix 4 - Targeting CD8 T-cells prevents
psoriasis development2cytes as identified by positive Ki67-staining (Fig 1, B and C).
Importantly, in the absence of T-cell expansion upon transplanta-
tion, which did not occur in one of the experiments we performed,
we did not observe any epidermal pathology, in terms of both pap-
illomatosis and frequency of proliferating keratinocytes (see Fig
E1 in this article’s Online Repository at www.jacionline.org).
Thus, the accumulation of epidermal T cells induces both kerati-
nocyte hyperproliferation and onset of papillomatosis, 2 hall-
marks of psoriasis, thereby further confirming the role of
intraepidermal T cells as key effectors in psoriasis.skin grafts 35 days posttransplant were predominantly CD8
T cells (see Fig E2 in this article’s Online Repository at www
jacionline.org). Psoriatic CD81 T cells have been previousl
characterized in terms of their cytokine production; however, li
tle distinction has beenmade between those residing in the derm
and the epidermis in the absence of post-isolation in vitro culture
Thus, to obtain a faithful functional characterization of psoriati
CD81 T cells, we isolated T cells from the epidermis and th
dermis of psoriasis lesions and performed intracellular cytokin
staining and fluorescence-activated cell sorting analyses. Amon
138
live CD451 immune cells, the frequency of CD31CD81 T cells
was significantly higher in the epidermis than in the dermis
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psoriasis development3(Fig 2, A and B). Interestingly, the frequency of epidermal
CD31CD81 T cells producing IL17A (Fig 2, C and D) or
double-producing both IFN-g and IL-17A or IL-22 and IL-17A,
respectively (Fig 2, E), significantly exceeded that of dermal
CD31CD81 T cells. No significant difference was found for
IFN-g1, IL-221, or IL-221IFN-g1 T cells between the dermis
and the epidermis (see Fig E3 in this article’s Online Repository
at www.jacionline.org). Thus, the main factor differentiating the
epidermal from the dermal CD81 T-cell population is an active
Tc17 phenotype.
On the basis of these findings, we sought to determine the
in vivo pathogenic relevance of CD81 T cells infiltrating psoriasis
lesions. Therefore, we treated xenotransplanted mice with either
1 mg mAb to human CD8 (M-T807) or the corresponding isotype
control mAb on days 0 and 14, or mAb to TNF (infliximab, 1 mg
intravenously on days 7 and 21 after transplantation). Isotype con-
trol antibody-treated skin grafts developed fully fledged psoriasis
over the course of 35 days (Fig 2, F and G). Injection of mAb to
CD8 resulted in a significantly reduced papillomatosis index and
complete blockade of psoriasis development. The effect was
equivalent to that obtainedwith TNF antagonists, a current bench-
mark in psoriasis treatment (Fig 2, F and G).
CD81 T cells and their role in psoriasis are currently under the
spotlight (see Fig E4 in this article’s Online Repository at www.
jacionline.org). CD81 T cells isolated from patients with psoria-
sis produce psoriasis-relevant cytokines, they are retained in the
epidermis as TRM after successful therapy,
7 and LL-37–specific
CD81 T cells expressing a1b1-integrin, a key molecule for traf-
ficking of T cells into psoriatic epidermis,6 have been identified in
psoriatic blood.8 The preferential anatomical location in the
epidermis makes CD81 T cells ideally located to engage in a
pathogenic cross talk with keratinocytes (Fig E4); a recent mouse
model of psoriasiform murine inflammation relying on keratino-
cyte genetic abnormalities identified CD81 T cells as critical
players.9 In addition, we show that the accumulation of epidermal
T cells, which mainly reflect CD81 T cells, correlates with the
onset of keratinocyte hyperproliferation and papillomatosis, 2
characteristic features of psoriasis. Epidermal CD81 T cells
display highly pathogenic features, and the significantly increased
frequency of those producing IL-17A, alone or in combination
with IL-22 and IFN-g, makes them a reasonable primary source
for this pivotal cytokine, whose clinical targeting is proving high-
ly successful.10 Finally, we show that blockade of CD81 T cells
via a neutralizing mAb prevents the development of psoriasis in
a clinically relevant xenotransplantation mouse model, thus un-
covering a critical role for them in driving pathology. These find-
ings may provide the basis for the design of new strategies
targeting CD81 T cells for the treatment of psoriasis.
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Humannasal epithelial cells derived
from multiple subjects exhibit dif-
ferential responses to H3N2 influ
enza virus infection in vitro
To the Editor:
Nasal epithelium is the first line of mechanical and immuno
logic defense in the upper respiratory tract.1 Upper respirator139
METHODS
Animal studies were approved by the Kantonale Veterinaeramt of Zurich.
Human studies, conducted according to the Declaration of Helsinki, were
approved by the institutional review boards of the University Hospital of Zurich
and Guy’s and St Thomas’ Hospital and informed patient consents were
obtained. Xenotransplantation of noninvolved psoriatic skin, obtained from 3
patients with psoriasis, was performed as previously described using AGR129
mice, which are deficient in type I (A) and type II (G) IFN receptors in addition
to being Rag22/2 (R). After 4 to 6 weeks, these skin grafts spontaneously
develop a psoriatic phenotype including thickening of the epidermis (acantho-
sis), elongation of the rete ridges (papillomatosis), and increased numbers of
dermal and epidermal T cells, closely reflecting the pathology of patient samp-
les.E1 For fluorescence-activated cell sorting analyses of skin T cells, we ob-
tained 4-mm full-thickness skin biopsies from 5 patients with psoriasis,
incubated them in 0.5mol/LEDTAat 378C for 3 hours to separate the epidermis
and the dermis, and then digested them separately in 0.8 mg/mL collagenase
type IV in RPMI 1 10%FCS 1 1%Pen/Strep (cRPMI) at 48C overnight.
EDTA treatment does not affect the expression of cell surface markers, such
as CD4, in contrast to thewidely used dispase treatment (data not shown). Sub-
sequently, digested tissue was stimulated with phorbol 12-myristate 13-acetate
(50 ng/mL) and ionomicin (1mg/mL) in the presence of brefeldinA (3mM)and
monensin (3mM) in cRPMI at 378C for 5 hours. Dead cells were excluded from
the analysis by staining with Live Dead Yellow (Life Technologies, Carlsbad,
Calif). Cells were stained for surface markers, fixed and permeabilized, and
stained for intracellular cytokines. The following antibodies were used: anti-
CD3 APC (SK7, BD Biosciences, Franklin Lakes, NJ), anti-CD4 BV650
(SK3, BD Biosciences), anti-CD8 PE-Texas Red (3B5, Invitrogen, Carlsbad,
Calif), anti-CD45 V500 (HI30, BD Biosciences), anti–IL-17A V450 (N49-
653, BD Biosciences), anti–IL-22 PerCP-eFluor710 (22URTI, eBiosciences,
San Diego, Calif), and anti–IFN-g A700 (B27, BD Biosciences).
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FIG E1. Absence of epidermal pathology after failed T-cell expansion. Quantification of T cells present in
skin samples upon transplantation in the AGR mouse model (days 0, 7, 21, and 35): dermal (dashed black
line) and epidermal (solid black line) T-cell counts compared with papillomatosis index (solid green line,
A) and Ki-67 postive keratinocytes (solid red line, B) during psoriasis development. Microscopic view of
nonlesional psoriatic skin stained with an mAb to Ki-67 on the day of transplantation onto AGR mice and
on day 35 (C). Data in A and B reflect 1 experiment with skin from a single donor not showing any relevant
T-cell proliferation upon transplantation (n 5 2 for every time point).
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FIG E2. As in classical human psoriasis, intraepidermal T cells in the AGR mouse model represent mostly
CD81 T cells. Microscopic view of representative CD3, CD4, and CD8 immunostaining of nonlesional
psoriatic skin upon development of fully fledged psoriasis, 35 days after engraftment onto AGR mice.
Arrowheads depict intraepidermal CD81 T cells, and arrows depict dermal CD41 T cells.
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FIG E3. No differences in IL-22 and IFN-g production between epidermal
and dermal CD81 T cells. Functional characterization of epidermal and
dermal CD31 CD81 T cells isolated from the epidermis and the dermis of
5 patients with psoriasis. Percentages of IL-221, IFN-g1, and IL-221 IFN-g1
CD81 T cells, as obtained by intracellular cytokine staining upon phorbol
12-myristate 13-acetate/ionomycin stimulation, show no differences be-
tween dermal and epidermal CD81 T cells. Each line connects epidermal
and dermal CD81 T cells from the same patient.
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FIG E4. The role of CD81 T cells in psoriasis immunopathogenesis. Environmental triggers (eg, skin injury,
known as Koebner phenomenon) induce the expression of LL37 by keratinocytes, which forms complexes
with self-DNA/RNA released by dying cells. These complexes activate skin-infiltrating plasmacytoid den-
dritic cells (pDCs) to produce IFN-a, which in turn—together with LL37-RNA complexes—promotes matura-
tion and activation of conventional dendritic cells producing IL-23. This leads to expansion and activation of
autoreactive CD81 T cells, as well as CD41 T cells, in the dermis. Although CD41 T cells remain principally
within the dermis, activated CD81 T cells acquire expression of very late antigen (VLA)-1 and migrate into
the epidermis. Subsequently, potentially upon recognition of autoantigens on keratinocytes via MHC-I, in-
traepidermal CD81 T cells release IL-17, which is critically involved in psoriatic inflammation and its
pathogenesis.
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TABLE E1. Cellular and histologic changes over time during psoriasis development
Experiment depicted in Fig 1 Day 0 Day 7 Day 21 Day 35
Dermal T cells 3.22 (0.71) 16.08 (3.51) 22.30 (8.66) 6.65 (2.11)
Epidermal T cells 0.23 (0.08) 0.33 (0.24) 10.50 (1.62) 16.32 (1.68)
Papillomatosis index 1.507 (0.06) 1.598 (0.04) 2.529 (0.28) 2.978 (0.32)
Ki-67 16.67 (3.83) 11.67 (1.70) 56.39 (9.91) 72.78 (29.51)
Mean and SEM values of experimental data depicted in Fig 1, A and B. Mean (6 SEM) values of dermal and epidermal T cells, papillomatosis index, and Ki-67 positive
keratinocytes in skin samples upon xenotransplantation in the AGR mouse model at indicated time points. Values correspond to the data depicted in Fig 1, A and B.
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